Anello Photonics (Santa Clara, CA; $250K SBIR, founded 2018) which [former Intel researcher] Mario Paniccia founded, is using photonics technology to send or collect data — to make chip-based gyroscopes. Its chip is designed to replace fiber-optic gyroscopes in vehicles, drones and consumer electronics devices. Anello got an affirmation of its approach when it announced it had closed a $28 million Series A round, [Cromwell Schubarth, BayAreaInno, October 21, 2021]
Galera Therapeutics (Malvern, PA; $1.1M SBIR) down 70% [Oct 19, 21] announced results from the Phase 3 ROMAN trial of avasopasem manganese (avasopasem) for severe oral mucositis (SOM) in patients with locally advanced head and neck cancer (HNC) undergoing standard-of-care radiotherapy. The trial did not meet its primary endpoint of reduction in the incidence of SOM. [company press release, Oct 19, 21]
Omeros down 26%, [Oct 18, 21] announced that the company received a Complete Response Letter (CRL) from the U.S. Food and Drug Administration (FDA) regarding its Biologics License Application (BLA) for narsoplimab in the treatment of hematopoietic stem cell transplant-associated thrombotic microangiopathy (HSCT-TMA). [company press release, Oct 18, 21]
ESS Tech (Wilsonville, OR; $2.8M SBIR] down 20% [Oct 13, 21] began trading ... ESS manufacturer of long-duration batteries for commercial and utility-scale energy storage applications, and ACON S2 Acquisition a publicly traded special purpose acquisition company, today announced the completion of their previously announced business combination (the "Business Combination"), resulting in ESS becoming a publicly listed company. [joint companies press release, Oct 11, 21]
ChemoCentryx ($100K SBIR 20 years ago) up 96% [Oct 8, 21] had slipped 68.3% this year, while the broader S&P 500 SPX, 0.14% is up 16.1%. [yahoonews, Oct 8, 21]
Semba Biosciences (Madison, WI; $1.6M SBIR) has been bought by Tosoh Bioscience LLC, one of its investors and a Pennsylvania-based subsidiary of Tokyo chemical company Tosoh Corp. [Wisconsin Inno, Oct 7, 2021]
[present] therapies are not as effective at attacking cancer cells that lack the antigen they are designed to target. Yale University spinout Cybrexa Therapeutics (New Haven, CT; $1.2M SBIR) is reporting promising early evidence indicating it may have a solution to that shortcoming. Cybrexa has developed a peptide-drug conjugate (PDC) which, instead of aiming for a specific antigen, targets the acidic environment of cancer cells to deliver a toxic payload. [Angus Liu, Fierce Biotech, Oct 7, 2021]
REGENXBIO down 20% [Oct 4, 21]
Biomerica up 38% [Oct 1, 21] announced that it has entered into a General Merchandise Supplier Agreement with Walmart for the sale of the Company's EZ Detect(TM) colorectal disease screening test within the Walmart retail system. [company press release, Oct 1, 21]
Omeros (Seattle, WA; $5M SBIR) down 38% [Oct 1, 21] announced that [FDA] notified the company that, as part of FDA's ongoing review of the company's Biologics License Application (BLA) for narsoplimab in the treatment of hematopoietic stem cell transplant associated thrombotic microangiopathy (HSCT-TMA), FDA has identified deficiencies that preclude discussion of labeling and post-marketing requirements/commitments at this time. FDA stated that the notification does not reflect a final decision on the information under review. [company press release, Oct 1, 21]
Kytopen (Cambridge, MA; $1M SBIR) a biotechnology company spun out of MIT offering a scalable technology for engineered cell therapies, today announced it has raised $30 million in an oversubscribed Series A funding. The new capital will be used to commercialize Kytopen’s Flowfect® Tx for cGMP-compliant cell therapy manufacturing and move towards treating the first human patient with Flowfect® engineered cells. [company press release, Sep 28, 21]
SAB Biotherapeutics (Sioux Falls, SD; $3M SBIR) snared another $60.5 million from the U.S. Department of Defense (DOD) to fund an antibody program to treat COVID-19. This brings the total funding SAB's received from the Biomedical Advanced Research Development Authority and the DOD to $200 million to support development of treatments for the deadly respiratory disease, according to the company’s Wednesday press release. [Annalee Armstrong, Sep 22, 2021, Fierce Bjotech]
early-stage startup Spartina Biotechnologies (Santa Fe, NM; no SBIR), uses what are called exosomes to deliver genetic material and proteins to cells in the body. This helps to combat infection. Spartina Biotechnologies' technology packages RNA, a type of genetic molecule, into exosomes. ... currently attempting to raise an investment round of $1.5 million, which will allow the company to work through pre-clinical trials. [ Collin Krabbe, New Mexico INNO, Sep 27, 21]
Zalgen Labs (Germantown, MD; $2.8M SBIR) has inked a contract with the Coalition for Epidemic Preparedness Innovations, a foundation that invests in vaccine development for emerging infectious diseases including Covid-19, to run a clinical trial in West Africa. There, it will study Lassa fever. ... CEPI plans to buy more than $750K of diagnostics from Zalgen “in the short term,” to get the trial going, [Sara Gilgore, DCInno, Sep 23, 21]
When we look to government’s role, it’s clear that driving into the future based on the realities we knew in the pre-pandemic age is like steering down a highway at 85 mph by looking in the rear-view mirror. [Donald Kettl, Government Executive, Sep 27, 2021] The Republicans representing industry management will have to side with treating labor, any labor, as a mere commodity.
NanoViricides (no SBIR) up 63% [Sep 21, 21]
NeuroMetrix up 27% [Sep 21, 21]
Competition down-under. Phillips 66 announced that it had agreed to take a 16% stake [for $150 million] in Novonix Ltd., a Brisbane, Australia-based battery materials and technology company. . [Chris Mathews, Houston Inno, Aug 9, 21]
CTI (McLean, VA) announces it has been awarded a $188M GSA FEDSIM SBIR Phase III contract: "Multi-Domain Analysis, Evaluation, and Software for Tactical and Remote Operations (MAESTRO)." MAESTRO is a multi-sponsor, combined effort for engineering services and software development to integrate SBIR technologies into existing manned and unmanned vehicles and cloud solutions, leveraging CTI's Small Business Innovative Research (SBIR) developed technology. [company press release, Sep 21, 21] Well, only post-SBIR. GSA doesn't have an SBIR program, and Phase III is not SBIR money. SBIR law does encourage post-SBIR investment by giving the federal agency some sole-source authority.
Macrogenics (Rockville, MD; $2.6M SBIR) down 24% [Sep 16, 21] announced results from Cohort A Part 1 of the Phase 2/3 MAHOGANY clinical trial of margetuximab. MARGENZA(R) (margetuximab-cmkb) is approved in HER2+ metastatic breast cancer and is being investigated as a potential first-line treatment for patients with HER2+ gastric cancer (GC) or gastroesophageal junction (GEJ) cancer in combination with a checkpoint inhibitor, with or without chemotherapy. [company press release, Sep 16, 21]
Lexeo Therapeutics (New York, NY; $3M SBIR) has raised $100 million to advance a pipeline of treatments for genetic cardiovascular and central nervous system conditions. The series B fundraising comes barely two months after Lexeo snapped up three heart disease programs through the acquisition of Stelios Therapeutics. [ Annalee Armstrong, Fierce Biotech; Sep 9, 21]
The organ-on-a-chip developer Emulate (Boston, MA; one SBIR), a leading provider of next generation in vitro models, announced the close of an $82 million Series E financing round [company press release, Sep 7, 21]
[US Navy] awarded RE2 Robotics a $9.5 million defense contract to enhance the development of RE2's Maritime Mine Neutralization System (M2NS), an autonomous underwater robotic arm and computer system capable of disabling mines or other improvised explosive devices found in deep seas or oceans. [Nate Doughty, Pittsburgh Business Jounal, September 14, 2021]
Albany Molecular Research (Albany, NY; $800K SBIR), a leading global contract research, development and manufacturing organization serving the pharmaceutical and biopharmaceutical industries, today announced that it is changing its name to Curia, effective July 12, 2021. The new name reinforces the company’s strategic positioning as an end-to-end global CDMO, applying its scientific expertise and extensive capabilities from research and development (R&D) through to commercial manufacturing to enable its pharmaceutical and biotechnology customers to advance important new products that improve lives. [company press release, Jul 12, 21] .... announced it has entered into a definitive agreement to acquire LakePharma biologics drug discovery, clinical research, development and manufacturing organization with operations in California, Massachusetts, and Texas. [company press release July 14, 2021]
Paradromics (Austin, TX; $800K SBIR), a company Bloomberg identified as a competitor to Elon Musk's Neuralink, announced it had raised $20 million in seed funding. The company makes high data rate brain-computer interfaces. [AustinInno, Jul 22, 21]
Committees have marked up their drafts for the $3.5 trillion reconciliation bill, and the proposals include multiple, significant investments that could strengthen regional innovation economies. This article identifies more than $85 billion in potential innovation-focused spending without including much of the legislation’s potential R&D investments. [SSTI, Sep 16, 2021] Sounds good to the polticians, can't do much harm, but most likely to go to companies that cannot compete in capital markets because their innovations don't look like economic winners. For a discussion of industrial policy, see https://bostonreview.net/law-justice/mariana-mazzucato-rainer-kattel-josh-ryan-collins-industrial-policy-comeback-forum?utm_source=Boston+Review+Email+Subscribers&utm_campaign=915c8ac6d6-MC_Newsletter_9_16_21&utm_medium=email&utm_term=0_2cb428c5ad-915c8ac6d6-41080549&mc_cid=915c8ac6d6&mc_eid=d232e07603
Impel NeuroPharma (Seatle, WA; $3.8M SBIR) down 24% [Sep 10, 21] announced the pricing of its underwritten public offering to raise $45M [company press release, Sep 9, 21]
Gevo (Englewood CO; ($1.6M SBIR)up 37% [Sep 9, 21] Chevron and Gevo, announced a letter of intent to jointly invest in building and operating one or more new facilities that would process inedible corn to produce sustainable aviation fuel, which can lower the lifecycle carbon intensity of fuels used in the aviation industry. The new facilities would also produce proteins and corn oil.[joint companies press release, Sep 9, 21]
INmune Bio down 22% [Sep 8, 21]
CorMedix (Berkeley Heights, NJ; $300K SBIR) down 22% Sep 7, 21] provided an update with respect t its resubmission timeline for the DefenCath New Drug [company press release, Sep 7, 21]
Impel NeuroPharma (Seattle, WA; $3.9M SBIR) down 19% [Sep 3, 21] announced that the [FDA] approved TRUDHESA(TM) (dihydroergotamine mesylate) nasal spray (0.725 mg per spray) for the acute treatment of migraine with or without aura in adults. TRUDHESA was previously known as INP104. [company press release, Sep 3, 21]
American Superconductor (Ayer, MA; $24M SBIR) up 21% [ug 31, 21] ComEd, one of the nation's largest electric utilities and AMSC, a leading system provider of megawatt-scale power resiliency solutions that orchestrate the rhythm and harmony of power on the grid(TM), today announced the successful integration of AMSC's REG system, which utilizes high-temperature superconductor wire to enhance the reliability, resiliency and performance of the electric power grid. [joint companies press release, Aug 31, 21]
NeuroMetrix (Woburn, MA; $600K SBIR in the 1980s) down 14% [Aug 31, 21]
startup Psyonic (Champaign, IL; $1.2M SBIR) that's creating a more affordable bionic hand that lets wearers "feel" what they're touching has officially made its product available to the public. ... , developed out of the University of Illinois by founder Aadeel Akhtar, is a high-tech prothesis that provides sensory feedback to its users. The device uses sensors that are embedded in the fingertips of the hand, so when a user touches an object, the skin is stimulated electrically, giving off a tingling or vibration sensation. The device has been in development since 2015 and this week officially became available to users and clinicians across the country. [Jim Dallke, ChicagoInno, Sep 2, 2021]
Watching the last American military plane go wheels up and out of the Afghanistan War reminded me of an old saying: History often repeats itself, but a lot of us would rather not pay attention. [Clarence Page, Chicago Tribune, Sep 1, 21]
Liberty. 47% of undereducated gullible Americans believe they have a constitutional right to act irresponsibly and selfishly -in the name of their perceived freedom- to go and expose others to sickness and death. [commenter, NY Times, Sep 1, 2021]
You don’t need to believe that a never-ending cycle of deficit-funded spending, offset by monetary intervention, is sustainable in order to believe that the scale of spending generally contemplated to deal with an existential threat like climate change, or a societal threat like poverty, is woefully inadequate. You can just believe we need to pay for it. [Robert Rubin reviewing Adam Tooze's SHUTDOWN How Covid Shook the World’s Economy, NY Times Sep 4, 2021]
NeuroMetrix (Woburn, MA; $600K SBIR in the 1980s) down 16% [Aug 30, 21]
NeuroMetrix (Woburn, MA; $600K SBIR in the 1980s) up 66% [Aug 27, 21]
Everspin Technologies (Chandler AZ; $700K SBIR) up 18% Aug 26, 21] reported quarterly financial results
Agenus Pharma (Lexington, MA; 9$1.6M SBIR) is now in the closing stretch of its multidecade effort to bring a drug to market. With the FDA set to decide whether to approve PD-1 drug balstilimab in December, Agenus has published the phase 2 data it hopes will secure authorization in cervical cancer. [Nick Paul Taylor, Fierce Biotech, Aug 27, 21]
BioCryst was ready for the public markets, but after shares sank 14% in the wake of the announcement, ... has withdrawn a proposed $200 million public offering after deciding “current market conditions are not conducive to an offering on terms that would be in the best interests of our current stockholders.” [Fierce Biotech, Nick Paul Taylor, Aug 11, 2021]
Great Duchenne muscular dystrophy (DMD) therapies are just not getting enough medicine into the cells, and PepGen (Alameda, CA; $2.3M SBIR) hopes to change that thanks to a $112.5 million raise that will advance a new candidate into the clinic early next year. [Nick Paul Taylor, Fierce Biotech, Aug 5, 2021]
The same Republican Party that led the establishment of a multitrillion-dollar security state after September 11 doesn’t even want to investigate what happened on January 6. [Ben Rhodes, Foreign Affairs, S/O21]
Suono Bio (Cambridge, MA; one SBIR) raised $12.2M as part of an equity offering worth approximately $15.2M. [BostInno, Aug 2, 221]
Surmodics (Eden Prairie, MN; $23M SBIR) medical device manufacturer, announced that it has acquired privately held Vetex Medical Limited. The Galway, Ireland based medical device developer and manufacturer has focused exclusively on venous clot removal solutions. The transaction expands Surmodics’ thrombectomy portfolio with a second (FDA) 510(k)-cleared device, the ReVene™ Thrombectomy Catheter. [company press release, Jul 6, 21]
II-VI Introduces Heated Ion Implantation Foundry Services for 150 mm Silicon Carbide Wafers [company press release, Jun 15, 21]
Sinking confidence. Less than 40% of small firms say they expect economic conditions to improve; ‘It seems like it is just a bust’ [Ruth Simon, Wall Street Journal, Aug 14, 21]
countless articles report that the U.S. innovation system is lagging behind other nations. However, fewer accounts emphasize the extreme lack of diversity among those who receive funding. ... the innovation budget has systematically disenfranchised hundreds of communities and millions of potential innovators while weakening U.S. innovation outcomes, [Brookings, Aug 12, 21] Hello, "fair share" SBIR was invented forty years ago to fix that problem. Of course, human nature and federal procurement rules defeated that purpose. The "fair-share money went to the best proposers wherever they lived. And they mostly lived where private capital was investing in R&D. Biden's [olitical plan to half of the $40 billion it proposes for upgrades of “research infrastructure” for HBCUs and other MSIs will simply lower the new innovation from its highest potential.
NexImmune (Gaithersburg, MD; #300K SBIR) up 18% [Aug 10, 21] reported quarterly financial resuts
Impel NeuroPharma (Seattle, WA; $3.6M SBIR) down 26% [Aug 10, 21] announced that its pivotal Phase 3, open-label study, STOP 301, was published in the August 7, 2021 edition of Headache: The Journal of Head and Face Pain, the official journal of the American Headache Society [company press release, Aug 9, 21]
bluebird bio down 27% [Aug 9, 21] after the company announced new safety issues, and the suspension of its European commercial operations. [Josh Nathan-Kazis, Barron's, Aug 9, 21]
AVROBIO down 20% [Aug 9, 21]
Dicerna Pharmaceuticals (Lexington, MA; $5.7M SBIR) down 28% [Aug 6, 21] announced positive top-line results from the Company's PHYOX(TM)2 pivotal clinical trial of nedosiran, which is in development as a once-monthly treatment for primary hyperoxaluria (PH), a family of ultra-rare, life-threatening genetic disorders that initially manifest with complications in the kidneys. [company press release, Aug 5, 21]
Novavax dwon 20% [Aug 6, 21] after it delays emergency use submission to FDA of COVID-19 vaccine [MarketWatch, Aug 6, 21]
Everybody gets a say. The democratization of authority spurred by the digital revolution has flattened cognitive hierarchies along with other hierarchies, and political decision-making is now driven by often weaponized babble. [Francis Fukuyama, Foreign Affairs, J/A2020]
Turn about, fair play. The same Republicans who cheered Trump's $2Tr debt increase tax cuts for the rich in 2017 now declare horror as Democrats do the same thing for their concept of government.
Novavax up 19% [Aug 4, 21]
Kopin (Taunton, MA; $9M SBIR) down 19% [Aug 3, 21]
Annovis Bio up 20% [Aug 2, 21] said it is pleased by the positive interim results released on July 28 from Phase II clinical trials of its lead compound, ANVS401 (Posiphen). [company press release, Jul 30, 21]
In essence Biden is defending liberal democracy and the notion that you can’t govern a nation based on the premise that the other half of the country is irredeemably awful. [David Brooks, NY Times, Aug 5, 21]
Six years of Donald J. Trump largely blocking out all other voices in his party have left Republicans without a credible messenger to push vaccines, even if they wanted to. [Reid J. Epstein, NYTimes, Jul 31, 2021]
A simple plan to end America’s vaccine hesitancy: Serve it deep-fried on a stick [Rex Huppke, Chicago Tribune, Aug 5, 21]
INmune (Boca Raton, FL; $700K SBIR) down 23% [Jul 26, 21] announced the design of its upcoming Phase 2 clinical trial of XPro(TM) in patients diagnosed with mild Alzheimer's disease (AD). The announcement is accompanied by the release of additional biomarker data from the Phase 1b AD trial that shows improvement in white matter (myelinated axons) that degenerate in AD patients. [company press release, Jul 26, 21]
Chembio Diagnostics down 29% [Jul 23, 21]
NeuroMetrix (Woburn, MA; $600K SBIR) up 19% [Jul 21, 21]
NeuroMetrix (Woburn, MA; $600K SBIR) up 107% [Jul 21, 21]
Chembio Diagnostics (Hauppauge NY; $7M SBIR) up 159% [Jul 21, 21] announced receipt of a $28.3 million purchase order from Bio-Manguinhos for the purchase of Chembio's DPP SARS-CoV-2 Antigen tests for delivery during 2021 to support the urgent needs of Brazil's Ministry of Health in addressing the COVID-19 pandemic [company press release, Jul 20, 21]
NeuroMetrix (Woburn, MA; $600K SBIR) up 208% [Jul 20, 21] announced that its Quell(R) d evice has received Breakthrough Designation from the U.S. Food and Drug Administration (FDA) for treating the symptoms of fibromyalgia in adults. [company press release, Jul 20, 21]
PLx Pharma up 18% [Jul 20, 21]
Cytokinetics (Sount San Francisco, CA; $500K SBIR) up 40% [Jul 19, 21] announced positive topline results from Cohorts 1 and 2 of REDWOOD-HCM (Randomized Evaluation of Dosing With CK-274 in Obstructive Outflow Disease in HCM), the Phase 2 clinical trial of CK-3773274 (CK-274), an investigational next-generation cardiac myosin inhibitor in development for the potential treatment of hypertrophic cardiomyopathy (HCM). [company press release, Jul 19, 21]
FibroGen down 42% [Jul 16, 21] announced that [FDA] voted to recommend not approving roxadustat, an oral hypoxia-inducible factor prolyl hydroxylase (HIF-PH) inhibitor, for the treatment of anemia due to chronic kidney disease (CKD) in adult patients. [company press release, Jul 15, 21]
Glaukos (San Clemente, CA; $200K SBIR) down 21% [Jul 14, 21]
PLx Pharma up 27% [Jul 13, 21] announced that three stock-keeping units ("SKUs") of VAZALORE, the first and only U.S. Food and Drug Administration ("FDA") approved liquid-filled aspirin capsules, will be available in over 4,500 Walmart stores across the United States in mid-August. [company press release, Jul 13, 21]
Meridian Bioscience (Cincinnati, OH; $600K SBIR) down 23% [Jul 13, 21] provided preliminary revenue results for its third quarter
Gliknik (Baltimre, MD; 41.6M SBIR) an immunology company dedicated to patients with cancer and autoimmune disorders, today announced that it has successfully completed an $11.5 million Series C Preferred Stock financing. [company press release, Jun 24, 21]
Surmodics (EDEN PRAIRIE, MN; $26M SBIR) announced today that it has acquired privately held Vetex Medical Limited. The Galway, Ireland based medical device developer and manufacturer has focused exclusively on venous clot removal solutions. The transaction expands Surmodics’ thrombectomy portfolio with a second U.S. Food and Drug Administration (FDA) 510(k)-cleared device, the ReVene™ Thrombectomy Catheter. [Surmodics press release, Jul 7, 21]
Sirnaomics (Gaithersburg, MD; $1.2M SBIR) announced that it has sealed $105 million in a Series E financing. [company release, Jul 1, 21]
Celldex Thera (Hmpton, NJ; $600K SBIR) up 25% [Jul 12, 21] announced updated data from the Company's ongoing, open label Phase 1b clinical trial of CDX-0159 in patients with antihistamine refractory cold urticaria and symptomatic dermographism, the two most common forms of chronic inducible urticaria. [company press release, Jul 9, 21]
Selux Diagnostics (Cambridge, MA; $2.3M SBIR) an antimicrobial therapy company for Infectious Diseases, has been awarded $14.6M in funding from the Biomedical Advanced Research and Development Authority [BostInno, Jul 1, 21]
II‐VI, a leading provider of wafer-level diffractive optics, announced the introduction of high-efficiency multifunctional metalenses based on a II-VI proprietary platform that enables ultracompact optical sensors for a broad set of applications, [company press release, Jun 23, 21]
Editas Medicine up 23% [Jun 30, 21]
CEL-SCI down 32% [Jun 30, 21]
Kiromic Biopharma down 28% [Jun 30, 21]
Antheia (Palo Alto, CA; $1.6M SBIR) a startup using synthetic biology to produce medicines currently sourced from plants, has raised $73 million in new venture-capital financing. [Brian Gormley, Wall Street Journal, Jun 30, 21]
Kiromac Biopharma (Houston, TX; $1.3M SBIR) down 17%, [Jun 29, 21]
CEL-SCI down 45% [Jun 28, 21]
Kiromac Biopharma (Houston, TX; $1.3M SBIR) down 20%, [Jun 28, 21] announced We intend to use our AI target, Mesothelin isoform 2, in the upcoming first-in-human dosing for solid tumors in 3Q-2021. [company press release, Jun 28, 21]
When labels matter “It’s [infrastructure bailout] full of stuff that isn’t a tax increase and isn’t a spending cut and is just wishful and fanciful.” [Yuval Rosenberg and Michael Rainey, Fiscal Times, Jun 29, 21] If Congress wants to rely on pixie dust to pay for its spending, it has the ultimate power to do so.
When governments act. “But a pandemic is not about mere anxiety [Islam,immigration], it’s about fear for your health and life: You’re not interested in someone confirming your anxiety, you need someone to perform swiftly, and mainstream parties were seen as doing that, while the populist opposition argued against action,” Mr. Krastev said. [Bojan Pancevski, WSJ, Jun 30, 21]
The developer of a line of advanced rotary diesel and multi-fuel internal combustion engines is expanding into the renewable energy game. LiquidPiston's X-Engine, which we've covered previously and is helping the Air Force develop vertical takeoff and landing concepts, can now run on hydrogen gas. [Greg Nichols for Robotics, ZDNet, June 25, 2021]
Cyteir Therapeutics (Cambridge, MA; $2.2M SBIR) up 20% [Jun 25, 21] announced the closing of its [IPO] with gross proceeds $133 million [company press release, Jun 22, 21]
Miromatrix Medical down 16% [Jun 25, 21]
Vision Quest Biomedical (Albuquerque, NM; $1.2M SBIR, founded 2007) awarded a $2M grant from the National Institutes of Health’s National Institute of Allergy and Infectious Diseases to commercialize ASPIRE, a device that uses AI for cerebral malaria diagnosis. [company press release, Jun 12, 21]
Miromatrix Medical (Eden Prairie, MN; $2.6M SBIR) up 69% [Jun 24, 21] announced the pricing of its upsized [IPO] to raise $43M ... pioneering a novel technology for bioengineering fully transplantable human organs to help save and improve patients' lives. The Company has developed a proprietary perfusion technology platform for bioengineering organs that it believes will efficiently scale to address the shortage of available human organs. [company press release, Jun 24, 21]
Because of development delays, Novavax should expect little uptake for its COVID-19 vaccine in the United States. But there's still a ready market globally, which the shot is well equipped to serve, GlobalData analysts report. [Kevin Dunleavy, Fierce Life Sciences, Jun 24, 21]
Zai Lab (China) will pay MacroGenics (Rockville, MD; $2.6M SBIR) $25 million upfront and make an equity investment of $30 million in common stock. Those are small numbers compared to the up to $1.4 billion that MacroGenics could receive in biobucks for [four CD3- or CD47-based bispecific antibodies for immuno-oncology] as well as additional royalties on annual net sales if the products make it to market. [Kyle LaHucik, Fierce Biotech, Jun 16, 2021[
Synaptogenix (Newark, NJ; $1M SBIR) up 25% [Jun 17, 21]
Anavex Life Sciences up 21% [Jun 16, 21]
PDS Biotechnology down 28% [Jun 15, 21] announced that it has commenced an underwritten public offering of shares of its common stock. [company press release, Jun 14, 21]
Anavex Life Sciences down 17% [Jun 15, 21]
Solid Power (Longmont,CO; $4.6M SBIR) is latest electric-vehicle business to announce plans to go public via a special-purpose acquisition company. ... Decarbonization Plus Acquisition Corporation III DCRC said it would buy Solid Power for $1.2 billion. ... Solid-state batteries promise to replace the [flammable lithium] liquid with a solid. [Steven Wilmot, WSJ, Jun 16, 21]
Anavex Life Sciences up 35% [Jun 14, 21] reported that ANAVEX(R) 2-73 (blarcamesine) and ANAVEX(R) 3-71 (AF710B) are featured in a new peer-reviewed publication in the journal of Expert Opinion on Therapeutic Targets, titled "The emerging role of the sigma-1 receptor in autophagy: Hand-in-hand targets for the treatment of Alzheimer's".
AXT up 20% [Jun 14, 21]
Novan up 18% [Jun 14, 21]
NanoGraf (Chicago, IL; no SBIR) advanced battery material startup, announced a breakthrough in its lithium-ion battery that enables it to be longer-lasting, lighter weight, and have a shortened charge cycle. The company said its battery now has the highest energy density 18650 cylindrical lithium-ion cell in the world, providing a 28% longer run time than traditional cell chemistries. [Jim Dallke, ChicagoInno, Jun 14, 21]
Venture Firm Seeks $50 Million to Back Civilian, National-Security Tech. Newly formed J2 Ventures says it can offer expertise to young health and tech startups on landing Defense Department contracts [Brian Gormley, WSJ, June 14, 21]
After decades of slowing entrepreneurial dynamism, 4.4 million new businesses were started in 2020, by far a modern record. During the first quarter of this year U.S. start-ups raised $69 billion, 41 percent more than the previous record, set in 2018. [David Brooks, New York Times, Jun 17, 21]
Novan (Morrisville, NC; $8M SBIR) up 62% [Jun 11, 21] announced positive topline efficacy and safety results for the B-SIMPLE4 pivotal Phase 3 clinical study of SB206, a topical antiviral gel, for the treatment of molluscum contagiosum ("molluscum"). Molluscum is a common, contagious skin infection caused by the molluscipoxvirus, affecting approximately six million people in the U.S. annually, with the greatest incidence in children aged one to 14 years. [company press release, Jun 11, 21]
Vaxart up 22% [Jun 11, 21]
Heat Biologics down 22% [Jun 11, 21]
Acumen Pharmaceuticals (Livermore, CA; $800K SBIR) is filing for a $100 million [IPO] hot on the heels of the FDA’s conditional approval of Biogen's controversial Alzheimer's disease drug Aduhelm (aducanumab). [Kyle LaHucik, Jun 10, 2021, Fierce Biotech]
ViaCyte (San Diego, CA; $1.7M SBIR) More than two and a half years after raising an $80 million series D, ViaCyte has expanded the round with a $45 million financing tranche. The San Diego-based clinical stage biotech is developing multiple programs aimed at treating type 1 diabetes. [Kyle LaHucik, Fierce Biotech, Jun 9, 2021]
The FDA has lifted a clinical hold placed on bluebird bio’s sickle cell gene therapy in February, making way for the company to get a phase 1/2 trial and phase 3 study of the treatment back on track. [ Amirah Al Idrus, Fierce Biotech, Jun 7, 2021 ]
Some estimate that by 2040, the world's computer chips will demand more electricity than is expected to be produced globally [Max Kozlov reviewing The Ascent of Information: Books, Bits, Genes, Machines, and Life's Unending Algorithm by Caleb Scharf, Science, Jun 4, 2]
Heat Biologics (Morrisville NC; $300K SBIR) up 40% [Jun 10, 21]
Aethlon Medical (San Diego, CA; $2.7M SBIR) down 26% [Jun 10, 21] announced that it has entered into a definitive agreement with a single institutional investor for the purchase in a registered direct offering of 1,380,555 shares of its common stock, [comapny oress release, Jun 10, 21]
Aethlon Medical (San Diego, CA; $2.7M SBIR) up 388% [Jun 9, 21] after major news emerged from the company last week regarding the fight against the novel coronavirus. [Nick Clarkson, Investor Place, Jun 9, 21]
First Solar (Tempe, AZ; $1.6M SBIR) The biggest American-owned solar-panel maker announced plans to invest $680 million in a new Ohio factory, in one of the largest bets on domestic solar manufacturing since China began dominating the industry a decade ago. .... said it plans to begin construction after necessary permits and local incentives have been secured and is aiming to open the plant early in 2023. [Bob Davis, Wall Street Journal, Jun 0, 21]
INmune Bio (La Jolla, CA; $700K SBIR) up 19% [Jun 7, 21]
PDS Biotech (Lawrenceburg, IN; $1.7M SBIR) down 26% [Jun 7, 21]
The Senate approved a bipartisan, $250 billion bill boosting government spending on technology research and development amid rising competition from China and other nations. [Wall Street Journal, Jun 9, 21] big new tech money likely after House passes its version. Then will come the challenge of hiring innovative govenment investors. SBIR history says federal agencies not up to it; only DARPA has succeeded.
Daxor (Oak Ridge, TN; $700K SBIR) up 38% [Jun 4, 21]
American Superconductor up 37% [Jun 4, 21] announced over $19 million of new energy power system orders. [company press release, Jun 2, 21]
Chicago tech hub mHUB is expanding its accelerator program offerings with a new initiative focused on med-tech. mHUB announced it's launching an accelerator program for medical device startups that have "the potential to transform health care." The program expects to launch in the fourth quarter of this year, with applications opening this summer. [Jim Dallke, Chicago Inno, Jun 4, 21]
Ford and BMW are investing $130 million in auto battery maker Solid Power (Louisville, CO; $4.6M SBIR) [Nick Greenhalgh, WiscInno, Jun 4, 21]
ColdQuanta (Boulder, CO; $9M SBIR) has brought on $20 million to help commercialize its quantum computing technology. ... brings ColdQuanta’s total funding to $74 million [Nick Greenhalgh, Colorado Inno, May 13, 2021]
43North (Buffalo, NY) is calling for startups to apply to their seventh competition. The competition, which ultimately selects eight companies, offers founders a chance to secure up to $1 million in funding and land a spot in 43North’s accelerator program. Investments are made in exchange for five percent equity. [43North, Jun 2, 21]
Stellanova Therapeutics (Houston, TX, no SBIR) announced raising $15.5 million in Series A funding ... is developing an antibody that targets fiber blast cells, which protect cancer cells against treatment and promote cancer cell growth. [Chris Mathews, Houston Inno, Jun 6, 21]
Bivacor (Houston, TX; $3M SBIR) raised $22 million through a Series B capital raise and a grant award .. to support the first human studies using its artificial heart device. [Chris Mathews, Houston Inno, May 19, 21]
Grove Biopharma (Chicago, IL; no SBIR), a startup that's creating a novel class of “protein-like polymers” to make drugs that could treat Parkinson's, Alzheimer's, Multiple Sclerosis and other difficult to treat conditions, raised $4 million [Chicago Inno, May 10, 21]
CincyTech, based in the University of Cincinnati’s 1819 Innovation Hub in Avondale, raised $19.7 million for its fifth investment fund. ... to invest in seed-stage startups, as it has done for the past 15 years. [Steve Watkins, CincyInno, May 19, 21]
[Samuel Hammond of the Niskanen Centre] believes that government agencies that fund research have become sclerotic: he sees a “compliance culture” resulting from a risk-averse leadership wary of heavy-handed congressional oversight. That is a problem, says Benjamin Reinhardt, an independent researcher who has studied DARPA, because big wins come from taking risks. “All the value,” he says, “is in the long tail.” ... On paper, the approach is straightforward. Take enormous, reckless gambles on things so beneficial that only a handful need work to make the whole venture a success. [The Economist, Jun 5, 21] SBIR could have done that for the last forty years, but it was invented instead as a fair-share program for uncompetititve R&D companies with only one absolute rule -- spend the money.
Annovis Bio (Berwyn, PA; $900K SBIR) up 27% [Jun 1, 21] announced the notable finding that in a test that measures speed, AD and PD patients both respond with a statistically significant increase in correctly coded fields after 25 days of treatment with ANVS401. The test was part of the Company's ongoing Phase 2a study in AD and PD patients. [comapany press release, Jun 1, 21]
C2N Diagnostics (St Louis, MO; $3.M SBIR) which offers the PrecivityAD™ blood test that can help detect if certain markers for Alzheimer’s disease are in the brain, now has its results available for review. The study appears in Clinica Chimica Acta, the official peer-reviewed journal of the International Federation of Clinical Chemistry and Laboratory Medicine. [company press release, May 27, 21]
San Francisco-based MetaVC Partners is raising $100 million for its first fund, and has already received capital from Bill Gates, co-founder of Microsoft Corp. and an anchor investor in the fund, and Nathan Myhrvold, formerly chief technology officer at Microsoft who runs intellectual-property firm Intellectual Ventures. .... to invest in startups commercializing metamaterials, a budding area of materials science that could improve the performance and reduce the size and weight of devices such as lenses and sensors ... Messrs. Alliegro and Burke estimate that about $1 billion has been invested in metamaterials startups to date. [Yuliya Chernova, Wall Street Journal, Jun 3, 21] An innovation enterprise unlikely to get bogged down in predictable incremental improvements for the mission of a government agency.
miRecule (Rockville, MD; $1.7M SBIR) raised $5.7M in fresh funding investments to take its RNA therapies for drug-resistant cancers to the clinic, CEO Anthony Saleh [said] positioning the company to start human testing for its lead candidate to treat head and neck cancer. [DCInno. May 27, 21]
Dynetics (lots of SBIR), a wholly owned subsidiary of Leidos , has secured a potential $90 million contract to build a laser-based technology to measure the temperature, pressure, carbon dioxide and oxygen within the Orion spacecraft during NASA's planned human missions to the moon. [govconwire.com, Jun 1, 21]
Annovis Bio (Berwyn, PA; $900K SBIR) up 127% [May 21, 21] announced new results from a double-blind, placebo-controlled study of ANVS401, its lead drug candidate for the treatment of AD and PD. Patients treated with ANVS401 for 25 days showed statistically significant cognitive improvement as measured by the Alzheimer's Disease Assessment Scale-Cognitive Subscale 11 (ADAS-Cog11). The 11-part test is one of the most frequently used tests to measure impaired cognition in clinical trials for AD. [company press release, May 21, 21]
Ultralife up 23% [May 18, 21]
Bivacor (Houston, TX; $2M SBIR) recently closed a series B funding round for a total of $19 million, ... also received another $3 million from the National Institutes of Health, in the form of a small business grant from the National Heart, Lung and Blood Institute. [Andrea Park, Fierce Biotech, May 20, 21]
In conflict zones around the world today, impunity is on the march. [Ed Milliband, Foreign Affairs, J/J 21] Impunity brings on war and disease to naturally reduce world population.
“Right now in Washington, D.C, it would be hard to get members of Congress to agree on the proper way to butter toast", Sen. Ron Wyden (D-OR), the committee chair, said.
New political math. US Representtive from Texas says not a single Covid death in Texas from March 2 ending of mask mandate. Texas health department says 3600 such deaths. Does 3600=0?
CEL-SCI (Vienna, VA; $2.6M SBIR, founded 2007) down 15% [May 17, 21]
ColdQuanta (Boulder, CO; no SBIR) announced it raised $20 million to continue commercializing cold atom quantum technology and accelerate hiring initiatives. ...has developed technology that allows engineers to cool atoms to a few millionths of a degree above zero and use lasers to manipulate the make-up of the atom. By altering their atomic composition, ColdQuanta is able to manufacture components for computing, radio frequency sensing, timekeeping and communications. [Cassidy Ritter, bulletincolorado.com, May 12, 21]
Interline Therapeutics (San Francisco, CA; no SBIR), which launches out of Foresite Capital’s incubator with $92 million to develop drugs that alter protein communities to treat disease. [Amirah Al Idrus, Fierce Biotech, May 13, 21]
Whatever the progress, Business leaders are confident that they can stop almost all of President Biden’s proposed tax hikes by pressuring moderate congressional Democrats, Politico’s Ben White reports. [Yuval Rosenberg and Michael Rainey, Fiscal Times, May 18, 21], someone else should pay for it.
“I cannot believe that we used to celebrate birthdays by eating a cake that someone has blown all over,” said Brian Labus, an epidemiologist at the University of Nevada, Las Vegas.
Second Sight Medical Products up 28% [May 12, 21] announced two-year results of its Early Feasibility Study (Study) of the Orion Visual Cortical Prosthesis (Orion). The Study is a single arm six subject study at UCLA and Baylor College of Medicine. The Study was paused due to the COVID-19 pandemic, but is now resumed at both centers. [company press release, May 12, 21]
Bren-Tronics (Commack, NY; $1M SBIR), Inventus Power (no SBIR), Navitas Systems (Woodridge, IL; $1.6M SBIR) government solutions group and Ultralife (Newark, NY; $200K SBIR) have secured spots on a potential nine-year, $1.25 billion contract for a lightweight wearable battery being developed under the Army's Tactical Power Generation Program [Christine Thropp, govconwire.ccom. May 13, 21]
Plug Power up 18% [May 11, 21]
Fluidigm up 18% [May 11, 21]
Dynaxax Tech down 19% [May 10, 21]
The pandemic has shown how hard it can be to change the minds of ideologically driven politicians and hardened vaccine sceptics or to beat back disinformation on Twitter. [Helen Pearson, Nature, May 12, 21]
ChemoCentryx down 62% [May 7, 21]
The most recent annual report from the (SBA) concludes that a majority of participating federal agencies did not comply with the mandated minimum spending requirements for the (SBIR/STTR) programs. [SSTI, May 6, 21] The only thing Congress really cares about, and is easy to understand, for SBIR is getting the money to their constituents. Whether SBIR is worth the bother is too hard to judge witout some deep economics.
BioCryst Pharma up 21% [May 6, 21] reported quarterly earnings
COnovate (Milwaukee, WI; $1.4M SBIR) startup developing a novel anode material for lithium-ion batteries, announced the successful completion of its initial round of financing. The COPHITE material is a patented 2D material that is the first solid form of carbon monoxide that exists at room temperature and pressure. It was discovered by Dr. Hirschmugl and her co-founder Dr. Marija Gajdardziska-Josifovska at the University of Wisconsin-Milwaukee. [company press release, May 4, 21]
OnLume (Madison,WI; $3.4M SBIR, founded 2015) announced the completion of its [$7M] Series A funding to assist its plans for commercial launch. [company press release, Apr 30, 21]
RNAimmune, a biopharmaceutical company specializing in discovery and development of mRNA-based therapeutics and vaccines, announced execution of definitive agreements for a seed round financing of $10 million. RNAimmune is a spin- off entity from Sirnaomics (Gaithersburg; $1.2M SBIR), a biopharmaceutical company engaged in the discovery and development of RNAi therapeutics against cancer and fibrotic diseases. [company press release, Apr 21, 21]
CryoLife up 24% [Apr 30, 21] reported quarterly financials
Vaxart up 17% [Apr 30, 21]
Novel Microdevices (Baltimore, MD; $1.3M SBIR) a developer of an innovative molecular diagnostics platform, announced today that CARB-X has awarded it up to $13.8 million in non-dilutive funding to develop its next-generation rapid molecular test for the diagnosis of sexually transmitted bacterial infections, including Chlamydia trachomatis and Neisseria gonorrhoeae. [company press release, Apr 6, 21]
Galera Therapeutics (Malvern, PA; $900K SBIR) up 20% [Apr 29, 21] announced "The data from this trial continue to impress, showing consistent and durable benefits across multiple measures, including the most important for the patient, overall survival," said [CEO] Mel Sorensen, [company press release, Apr 28, 21]
Arcadia Biosciences (Davis, CA; $5M SBIR) announced it has acquired the assets of Agrasys SA, a food ingredients company based in Barcelona, Spain. The transaction includes the physical and intellectual property assets to enable Arcadia to commercialize Tritordeum, a proprietary cereal grain that was developed at the Instituto de Agricultura Sostenible — Consejo Superior de Investigaciones Científicas, (IAS-CSIC) the largest public institution dedicated to agricultural research in Spain [company press release, Apr 19, 21]
[Biden’s plans] represent the most dramatic shift in federal economic and social welfare policy since Ronald Reagan was elected 40 years ago. Reagan’s small-government philosophy resulted in a decades-long squeeze on the federal government, especially domestic spending, and on tax policies that mainly benefited the wealthiest Americans. [Dan Balz, WashPo, Apr 28, 21] The otherwise eloquent Republican response conveniently omitted the facts that Reagan’s trickle-down supply side economics has disproportionately further enriched the already rich. But Biden’s grand plan will be met by a hailstorm of objection by anyone who is called upon to pay for the many benefits. After all, it's American democracy to want more than you're willing to pay for.
“Humanity is running an ecological Ponzi scheme in which society robs nature and future generations to pay for short-term economic enhancement today.” “Most economies operate on the basis that counteraction now is too costly to be politically palatable. Combined with disinformation campaigns to protect short-term profits it is doubtful that the scale of changes we need will be made in time” Professor Ehrlich says. [Flinders University (Australia), Apr 25, 21] The readiness to borrow trillions for the pandemic bailout will eventually repeat with any climate "solution."
Inovio Pharma down 25% [Apr 23, 21] said early Friday that the U.S. government had decided to pull funding for a Phase 3 trial of the company’s experimental Covid-19 vaccine, given the “broad availability” of Covid-19 vaccines in the U.S. Inovio (ticker: INO) said it now plans to run a Phase 3 trial largely outside of the U.S. That would likely impact its ability to get the vaccine approved by the Food and Drug Administration. [Josh Nathan-Kazis, Barron's, Apr 23, 21]
CEL-SCI up 22% [Apr 22, 21]
INmune Bio (up 18% [Apr 21, 21]
Dynavax Technologies (Berkeley, CA; $6.5M SBIR) down 18% [Apr, 20, 21]
INmune Bio (La Jolla, CA; $700K SBIR) down 17% [Apr 19, 21]
Volexion (Wilmette, IL; $200K SBIR) landed $1.1M to improve the performance of lithium-ion batteries just landed funding from a pair of climate-focused VC firms. [Jim Dallke, ChicagoInno, Apr 8, 21]
this country sent us to the front lines with none of the equipment needed for the battle [Sharon Griswold, an emergency room doctor in Pennsylvania, quoted by WashPo, Apr 22, 2012] The medics see a country objecting to a simple, cheap anti-virus defense - a nose and mouth mask that would have made life safer and more tolerable for medics. ‘You don’t have to set yourself on fire to keep other people warm.’ [Mona Masood, a psychiatrist who has counseled dozens of doctors in mental crisis in recent months]
Trump’s $27m-a-mile border wall being scaled with $5 ladders [The Guardian, Apr 24, 21] Trump's generals may well have told him that an unguarded wall is little barrier to crossing. But the wall was only ever an expensive poltical symbol. Arizona governor Janet Napolitano pronounced long ago "Show me a 50-foot wall, and I'll show you a 51-foot ladder."
Recursion Pharmaceuticals (Salt Lake City, UT; $3.5M SBIR) up 74% [Apr 16, 21] announced its [IPO] pricing to raise $436M [company press release, Apr 16, 21]
Akoya Biosciences (San Francisco, CA; $150K SBIR) up 30% [Apr 16, 21]
INmune Bio (La Jolla, CA; $700K SBIR) up 26% [Apr 16, 21]
Cleveland BioLabs up 20% [Apr 13, 21]
What researchers hope for is the unexpected. What funders prefer is to know the outcome in advance. [Andrew Crumey reviewing Genesis by Guido Tonelli, WSJ, Apr 17, 21] Safe SBIR by government agencies and experienced conpanies won't make for much innovation, even though both company and agency declare SBIR success.
FLIR Systems announced it has won a [DARPA] contract to rapidly develop novel fabrics with embedded catalysts and chemistries that can fight and reduce chemical and biological threats upon contact. The revolutionary fabrics will be incorporated into protective suits and other equipment such as boots, gloves, and eye protection that can be worn by troops on the battlefield, medical experts, healthcare workers, and more. FLIR received $11.2 million in initial funding for the potential five-year effort worth up to $20.5 million, including options. [company press release, Apr 12, 21]
Magic economics. The U.S. budget deficit grew to a record $1.7 trillion in the first half of the fiscal year [John McCormick, WSJ, Apr 13, 21] And nobody has (wants) to pay more taxes for the extra spending. Meanwhile, the lightly taxed profits from that spending flow upward to the wealthiest few percent of the population. And the share of the national wealth held by the richest keeps growing. At the bottom part of the economy, jobs are disappearing and pay barely keeps up with cost of living for decades. Yet the people keep electing friends of the wealthy to Congress and state legislatures. Is that not magic? And now more magic: Republicans have taken to calling themselves the party of the working class... shattering traditional conservative economic positions. [Gerald Seib, WSJ, Apr 13, 21]
Volexion (Chicago, IL; $200K STTR, founded 2018) materials startup developing a graphene coating for lithium-ion batteries to improve the performance ... just landed $1.1 million part of a $2.2 million round from a pair of climate-focused VC firms. ... founded by Northwestern professor Mark Hersam, [Jim Dallke, ChicagoInno, Apr 9, 21]
ValenzaBio (Bethesda, MD; no SBIR) reeled in a $70 million series A round that will propel a pair of monoclonal antibody programs toward the clinic. Those include a treatment for an autoimmune kidney disease, which is poised to start a phase 1b/2a study in the second quarter of this year, and a treatment for thyroid eye disease (TED) licensed from Pierre Fabre Medicament. [Amirah Al Idrus, Fierce Biotech, Apr 8, 21]
Traditional skepticism about government’s economic role is rooted in the belief that private markets, driven by the profit motive, are efficient, while governments are wasteful. But the excesses of private markets in recent decades – the rise of monopolies, the follies of private finance, extreme concentration of income, and rising economic insecurity – have taken the shine off the private sector. [Dani Rodrik, Project Syndicate, Apr 3, 21] Warning: good ideas must withstand political grandstanding.
Fibrogen (South San Francisco, CA; $1.3M SBIR) down 43% [Apr 7, 21]
China is increasing its strategic R&D as a share of its economy, as a share of whatever metric you want to use in a way that we have let deteriorate. And so the thing that has changed is that we’ve lived through a decade where China has been meticulously thinking about making those investments, marshaling those investments — not all successful, but all with a deliberate focus on trying to build its own industrial base and its own intellectual and innovation base. And we have, for the better part of a decade, ignored or derogated and undermined those levers. [Brian Deese, Presidential economic advisor, Apr 8, 21]
Our self-government experiment struggles as 75% approve of the President's pandemic management while resisting any enforceable ccommands to act responsibly. The acts of a teenager groping for independence. Meanwhile our politicians hustle to get in front of the crowd they profess to lead. The bad news: there is probably no better altenative as famously expeessed by Winston Churchill
Second Sight Medical Products up 27% [Apr 6, 21]
Molecular Templates (Austin, TX; one SBIR) down 23% [Apr 5, 21] announced that, following discussion with its co-development partner Takeda, MTEM will assume full rights to TAK-169 including taking control of clinical development from Takeda. In addition, MTEM announced the decision to discontinue development of MT-3724, MTEM's only first-generation ETB. [company press release, Apr 5, 21]
ACADIA Pharmaceuticals down 17% [Apr 5, 21]
By 2050 output of cobalt, graphite and lithium, for instance, would have to be more than 450% higher than in 2018 to meet battery demand. [The Economist. Apr 3, 21]
Double standard. Apparently McConnell and these guys are decrying the influence of corporations but not their money? I don’t understand where the line is. They can pack your pockets with cash, but they can’t talk to you or try to persuade you? [Dick Harpootlian, state senator in SC, Apr 6, 21]
Rgenta Therapeutics (Cambridge,MA; $400K Phase 1 SBIR), focusing on developing RNA-targeting medicines for historically undruggable disease-relevant targets, raised $4M in equity in a $38M funding round, per an SEC filing. [Rowan Walrath, BostInno, Apr 2, 21]
NBD Nanotechnologies (Lexington, MA; $1.6M SBIR) which develops advanced liquid repellant surface coatings and additives, raised $1.4M in debt in a $1.5M funding round, per an SEC filing. [Rowan Walrath, BostInno, Apr 2, 21]
An accelerator program from U.S. Air Force Lab and MassChallenge, a two-year pilot, has its second cohort. The second group includes Atomic-6, BoatBox Technologies, CorePower Magnetics, Inergy, Kinnami Software, Measure Global, OxbyEl Technologies, Particle.One, Rhoman Aerospace and Sentenai. The group gets special mentorships and support from experts at MassChallenge and the Air Force. [BostInno, Apr, 1, 21] One company had one SBIR. Maybe SBIR's rigid structure, and SBIR mills with hundreds of awards over three decades, should be shrunk, and more flexible opportunities opened. SBIR was always a fair-share handout program that Congress focused only on the mandated money being spent with the small biz world.
Intevac (Santa Clara, CA; $5M SBIR) up 32% [Mar 31, 21]
Kopin up 17% [Mar 31, 21]
Emalex Biosciences (Chicago, IL; no SBIR) The biotech startup that's developing treatments for central nervous system movement disorders raised $35 million. The startup says there are currently three Phase 2 clinical trials underway for its medicine, which will evaluate the efficacy and safety of its drug. [Katherine Davis, Chicago Inno, Mar 31, 21]
fix 20,000 miles of roads and 10,000 bridges, while also addressing climate change and racial inequities and raising corporate taxes. ... plus $180 billion for research and development [Jim Tankersley, NY Times, Mar 31, 21] What's not to like? Paying for it by any living person. Don't tax you, don't tax me/ Tax that guy behinnd the tree. [late Sen Robert Byrd]
Annovis Bio (Radnor, PA; $900K SBIR) down 16% [Mar 29, 21]
Ecovative Design (Green Island, NY: $4.5M SBIR) raised $60M in Series D financing (Albany Business Review, Mar 30, 21]
The JobsOhio Capital Growth Initiative picks up where last year's JobsOhio innovation Fund [with $50M] to help young companies survive the pandemic and be ready to grow again left off. [Mary Vanac, Cleveland Business Journal, Mar 29, 21]
Bills are for bragging. the US House of Representatives Committee on Science, Space, and Technology introduced a bipartisan bill that outlines plans to more than double the National Science Foundation’s budget and create a new technology directorate. [Asher Jones, The Scientist, Mar 29, 2021] In a world of pandemic and unlimited government spending, it might even happen.
XOMA up 20% [Mar 26, 21]
Rubius Therapeutics down 20% [Mar 26, 21]
Vaxess Technologies (Cambridge, MA; $4.3M SBIR) which is behind a smart patch designed to slowly release vaccines and other treatments into the skin, raised $2M in debt, according to an SEC filing. [BostInno, Mar 29, 21]
Coherent announced that its board of directors has determined to accept the II-VI merger proposal for a value of $7B. [Coherent press release Mar 25, 21]
More fuel for the flame. Biden also reiterated his call for government investment in science and research as a way to compete with China. "Back in the ‘60s we used to invest a little over 2% of our entire GDP in pure research and investment in science. Today it’s 0.7%. I’m going to change that." [The Fiscal Times, Mar 25, 21]
It is difficult to know whether Mr Trump, a huckster raised on the all-American dictum that the best salesmen believe their own spiels, actually thinks the election was stolen from him. The con-man’s eternal excuse is that he says what the rubes want to hear. [The Economist reviewing Cass Sunstein's Liars, Mar 20, 21]
Second Sight Medical Products down 20% [Mar 24, 21]
Debt before taxes. Indeed, the whole idea of paying for government spending with new revenues is apparently so foreign to Republicans and their Senate leader Mitch McConnell that they think it’s some sort of devious trick: "The Trojan horse will be called infrastructure. Inside the Trojan horse will be all the tax increases," McConnell said. [Jonathan Bernstein, Bloomberg, Mar 24, 21] Tax cuts and understaffed IRS for the wealthy and unlimited military spending make the Republican core dogma that has kept them in effective control of lawmaking for four decades.
Ionis Pharma down 22% [Mar 23, 21] after the biotech firm announced the halt of a Phase 3 trial of an experimental Huntington’s disease treatment called tominersen. [Barron's Mar 23, 21]
Hydrogeologic (Herndon, VA; three Phase 1 SBIRs long ago] won a spot on a $240 million [Army] contract to help the military branch mitigate potentially hazardous munitions found at defense training and testing areas. [Matthew Nelson, govconwire, Mar 22, 21]
Inflammatix (Burlingame,CA; $1M SBIR) a pioneering molecular diagnostics company, announced the closing of a $102 million Series D round of financing to support development and commercialization of its novel immune response diagnostics portfolio. [company press release, Mar 16,21]
Solid Biosciences down 32% [Mar 16, 21] reported encouraging interim functional (NSAA, 6MWT and PFTs) and biomarker data, and patient reported outcome measures (PROMs) from six patients after treatment in the ongoing IGNITE DMD Phase I/II clinical trial of its lead gene therapy candidate, SGT-001. [company press release, Mar 15, 21]
Zynerba Pharma down 27% [Mar 16, 21]
Rubius Therapeutics (Cambridge, MA; no SBIR) up 84% [Mar 15, 21], a clinical-stage biopharmaceutical company that is genetically engineering red blood cells to create an entirely new class of cellular medicines called Red Cell Therapeutics(TM), announced initial clinical, pharmacodynamic and tumor trafficking data from its ongoing Phase 1/2 clinical trial of RTX-240 in patients with advanced solid tumors. [COMPANY PRESS RELEASE, Mar 15, 21]
Zynerba Pharma up 49% [Mar 15, 21]
the Air Force wants a shortcut to an unmanned electric vertical takeoff and landing (eVTOL) concept for urban transport. The secret sauce? Pairing emerging electric vehicle technology with an innovative rotary internal combustion engine to keep batteries charged and extend flight times. ... AF awarded an STTR contract to LiquidPiston (Bloomdfield, CT; $400K prior SBIR), a developer of an advanced rotary internal combustion engine called the X-Engine. Paired with a generator, the X-Engine can be configured to charge the eVTOL vehicle's battery and keep it charged during flight, significantly extending the range of an electric propulsion system. Alternatively, it can be configured in parallel with an electric drive, using the engine directly to produce thrust or lift. [Greg Nichols for Robotics, zdnet.com, Mar 15, 21]
Pluton Biosciences (St Louis, MO; no SBIR) signed a research agreement with global life sciences company Bayer AG to investigate the development of an all-natural, microbial-based carbon-capture soil amendment for growers. Collaborating with Bayer, Pluton will use its Micromining Innovation Engine to identify and develop microbes currently found in soil that can store carbon and nitrogen. [company press release, Mar 2, 21]
COnovate (Shorewood, WI; $1.3M SBIR) is receiving a $100,000 phase 2 state matching grant. developing materials designed to add battery capacity and charging speed to lithium ion batteries. [Nick Williams, WisconsinInno, Mar 11, 21]
Scienss Biotechnology (one SBIR) which makes recombinant proteins for use as therapeutics in the livestock industry is receiving a $100,000 phase 2 state matching grant [Nick Williams, WisconsinInnoInno, Mar 11, 21]
GoDx (Madison, WI; one SBIR) developing and commercializing low-cost, rapid diagnostics for infectious diseases. The company has developed a paper strip test that can detect the bugs that cause diarrheal diseases from stool, which will help treat the second leading cause of death in children under age 5 is receiving a $100,000 phase 2 state matching grant [Nick Williams, WisconsinInnoInno, Mar 11, 21]
Second Sight Medical Products up 36% [Mar 12, 21]
Novavax has linked its COVID-19 vaccine to 100% efficacy against severe disease in countries where variants of concern are prevalent. The final phase 3 data suggest NVX-CoV2373 may protect against the worst outcomes caused by the coronavirus variants, even though the mutations limit its efficacy. [Nick Paul Taylor, Fierce Biotech, Mar 12, 21]
Prometheus (Sharon, MA; $8M SBIR) has upsized its IPO, positioning it to reel in $190 million to bankroll clinical development of an anti-TL1A monoclonal antibody in IBD. [ Nick Paul Taylor, Fierce Biotech, Mar 12, 21 ]
PhaseBio Pharma (Malvern PA; $3.6M SBIR) is signing a manufacturing partner for its Brilinta reversal agent as it ushers the drug through phase 3 and, it hopes, FDA approval. [Amirah Al Idrus, Fierce Biotech, Mar 11, 21]
Grifols is dropping $80 million to acquire the outstanding shares of its partner, polyclonal antibody developer GigaGen (South San Francisco, CA; $10M SBIR) . [Amirah Al Idrus, Fierce Biotech, Mar 10, 21]
Vuzix up 21% [Mar 11, 21]
In this edition of SSTI Useful Stats, we attempt to go beyond these measures to estimate states’ untapped potential for capturing future SBIR awards. [SSTI, Mar 10, 21] Pure fair-share politics which explains part of SBIR's mediocre results after three decades.
Second Sight Medical Products down 25% [Mar 10, 21]
The traditional skepticism toward industrial policy is well deserved. Once Washington starts writing checks for semiconductors, other industries may get in line with the outcome determined more by political clout than economic merit. [Greg Ip, WSJ, Mar 10, 21] Meanwhile, Asia makes more and more chips - an unavoidably strategic commodity.
Northvolt (Sweden) announced the acquisition of Cuberg (Emeryville, CA; $1.4M SBIR) battery technology company delivering high-performance lithium metal cells produced on existing lithium-ion manufacturing lines for electromobility solutions. Cuberg spun out of Stanford University in 2015 with the goal of commercializing next-generation battery technology based on a groundbreaking liquid electrolyte combined with a lithium metal anode. [Northvolt press release, Mar 9, 21] terms not disclosed
Second Sight Medical Products (Sylmar, CA; $200K SBIR) up 32% [Mar 9, 21]
Fuel Cell Energy up 21% [Mar 9, 21]
Graybug Vision (Redwood City, CA; $700K SBIR) down 51% [Mar 9, 21] provided preliminary topline data from the 12-month treatment phase of its Phase 2b ALTISSIMO trial of GB-102 for the treatment of wet age-related macular degeneration (wet AMD), Graybug's proprietary microparticle depot formulation of sunitinib malate injected intravitreally. [company press release, Mar 8, 21]
ACADIA Pharmaceuticals down 45% [Mar 9, 21] with the news that the [FDA] had “identified deficiencies” in the company’s application to expand the label of its drug pimavanserin. [Josh Nathan-Kazis, Barron's, Mar 9, 21]
Second Sight Medical Products (Sylmar, CA; $200K SBIR) up 103% [Mar 8, 21] announced U.S. Food and Drug Administration (FDA) has approved the Argus 2s Retinal Prosthesis System, a redesigned set of external hardware (glasses and video processing unit) initially for use in combination with previously implanted Argus II systems for the treatment of retinitis pigmentosa (RP). [company press release, Mar 5, 21]
Vuzix down 14% [Mar 8, 21]
The USG announced on February 19th a plan for an Advanced Research and Invention Agency (ARIA), which is modelled on America’s Advanced Research Projects Agency. That is a promising start. ARIA’s purpose is to fund high-risk, high-reward research, probably by directly funding exceptional scientists. But money is not all that matters. The successful translation of life-science research into treatments during the pandemic (see article) suggests some inexpensive measures that can also make a difference. [The Economist, Feb 27, 21] It's easier to announce a new DARPA-like creature but hard to make one work like the original now several decades old.
Five Prime Therapeutics (no SBIR) up 79% [Mar 4, 21] Amgen and Five Prime Therapeutics, a clinical-stage biotechnology company focused on developing immuno-oncology and targeted cancer therapies, today announced an agreement under which Amgen will acquire Five Prime Therapeutics for an equity value of approximately $1.9 billion. This acquisition adds Five Prime's innovative pipeline to Amgen's leading oncology portfolio. [joint companies press release, Mar 4, 21]
Vuzix down 23% [Mar 4, 21]
Pushing the wet noodles. DARPA will start formalizing and expanding a pilot program that connects its research teams to business expertise to help take technologies out of the lab and into production. In a partnership with nonprofit venture capital firm In-Q-Tel, the Embedded Entrepreneurship Initiative will provide 150 DARPA research teams with funds to hire business executives to develop go-to-market strategies, commercialization mentors and engagement with a DARPA working group stacked with corporate investors over the next five years. [Mila Jasper, govconwire.com, Mar 5, 21] Although DARPA is the most imaginative DOD R&D program, it is still a government program limited by appropriation law to doing government R&D. Its last big push into commercialization died a horrible death with firing of the DARPA Director by the GHWBush administration. A proper use of its R&D is to select companies and technologies that have the best potential for attracting private capital after proof of the concept. One useful step is to require third party validation investment during R&D to pursue the post-development. Anyway it's unlikely that a government hired business advisor will have the inspiring vested interest in the technology and its owner. For further perspective, troll thru the Clinton adminstration files of the DARPA spin-off efforts. Been there, done that.
NanoViricides (Shelton, CT; no SBIR) up 58% [Mar 2, 21] reported on the strong pan-coronavirus effectiveness of its two COVID-19 clinical drug candidates for which the Company is preparing a pre-IND application. [company press release, Mar 2, 21]
Solid Biosciences up 26% [Mar 2, 21]
FibroGen (South San Francisco, CA; $1.3M SBIR) down 25% [Mar 2, 21] FibroGen and partner, AstraZeneca announced that the Cardiovascular and Renal Drugs Advisory Committee of [FDA] will hold an advisory committee (AdCom) meeting to review the new drug application for roxadustat in the U.S. [company press release, Mar 1, 21]
Pear Therapeutics (Boston, MA; $1.6M SBIR) prescription digital therapeutics company, raised an additional $20M in equity, per an SEC filing [BostInno, Mar 3, 21]
Fearing not the virus. Texas businesses will be able to operate at full capacity and state residents will no longer be required to wear masks to visit them beginning March 10, Gov. Abbott said. [Wall Street Journal, Mar 3, 21]
modern American politics can be reduced to a single question: How long can Paducah tell Seattle what to do? [Ronald Brownstein, Atlantic, Oct 30, 20]
Vuzix up 25% [Mar 1, 21] announced that the Company's M400 and M4000 Smart Glasses now support Microsoft Teams. [company press release, Mar 1, 21]
Iteris (Santa Ana, CA; $700K SBIR in 2012) up 23% [Mar 1, 21] the global leader in smart mobility infrastructure management, today announced that its Board of Directors has reviewed and unanimously rejected the non-binding, unsolicited proposal disclosed today by Rekor Systems to acquire Iteris for consideration consisting of approximately 17% cash and 83% Rekor shares at current stock prices. [company press release, Mar 1, 21]
Athenex down 55% [Mar 1, 21]
ChromaDex (Irvine, CA; $800K SBIR) down 26% [Feb 26, 21]
Applied Optoelectronics down 17% [Feb 26, 21]
Vigilance still needed. Taking the first hint of a downward trend as a reason to reopen is how you get to even higher numbers. aid Marc Lipsitch, an epidemiologist at the Harvard T.H. Chan School of Public Health. .... But Looking ahead to late March or April, the majority of scientists interviewed by The Times predicted a fourth wave of infections. [Apoorva Mandavilli, NY Times, Feb 27, 21]
Ideas that might once have been confined to a pamphlet are now easily available on the internet, a space where anyone can be an expert and where conspiracy theories can provide a splendid living for those who peddle them. [Andrew Stuttaford reviewing Michael Butter’s The Nature of Conspiracy Theories, WSJ Mar 1, 21] Alas, America has a large audience of gullible netizens.
ChromaDex (Irvine, CA; $800K SBIR) up 92% [Feb 25, 21] announced results from the study "Combined Metabolic Activators Accelerates Recovery in Mild-to-Moderate COVID-19" were published Feb. 20 on medRxiv, a preprint publication website. The Phase 3 study demonstrated that patients with mild-to-moderate COVID-19 receiving standard of care experienced a 3.5 day reduction in recovery time when receiving an added nutritional protocol. Aimed at improving mitochondrial function, the protocol included nicotinamide riboside (NR), L-serine, N-acetyl-L-cysteine (NAC), and L-carnitine tartrate. [company press release, Feb 24, 21]
Elixirgen Therapeutics (Baltimore, MD; one SBIR) is gearing up to launch a pair of clinical trials this year — one for its new drug that targets bone marrow failure syndromes, and another for its version of a Covid-19 vaccine. [newsbreak.com, Feb 25, 21]
Theradaptive (Frederick, MD; $1.1M SBIR) biotechnology company specializing in regenerative therapeutics, announced the closure of a $6.2 million Series A investment round ... brings the total investment to $17.4M to date [company press release, Jan 9, 2021]
Novavax has fully enrolled its late-stage clinical trial of its experimental Covid-19 vaccine with 30K participants at 118 sites across the U.S. and Mexico. The study population focuses on people across diverse populations in age, race and ethnicity, and co-morbidities most vulnerable to the virus. And it advances the candidate aiming to report data at the end of Q1 or in early Q2 — which, if positive, would pave the way for it to reach patients. The Gaithersburg vaccine maker also has a new MOU with Gavi, the Vaccine Alliance, to ultimately provide 1.1B doses of its vaccine to at-risk groups as part of an international initiative. [Sara Gilgore, DCInno, Feb 25, 21]
NexImmune (Gaithersburg, MD: $3300K SBIR) closed its IPO with $126.5M in gross proceeds for two product candidates, now in early-stage clinical trials for acute myeloid leukemia and multiple myeloma, and its preclinical pipeline, which includes candidates for solid tumor and autoimmune diseases. The funding would also fund manufacturing activities, further use of its tech platform, as well as working capital and general corporate purposes, the company said. [Sara Gilgore, DCInno, Feb 25, 21]
Immunome up 52% [Feb 24, 21]
Cancer Genetics up 22% [Feb 24, 21]
Aqua Metals (no SIR) up 18% [Feb 24, 21] announced it has filed a provisional patent for recovering high-value metals from recycled lithium-ion batteries. [company press release, Feb 24, 21]
Solid Biosciences up 42% [Feb 23, 21]
AeroVironment has acquired the intelligent systems group [ISG] of Progeny Systems (Manassas, VA; $130M SBIR) through a $30 million cash transaction as part of efforts to drive autonomy and artificial intelligence technology development work and expand robotic systems engineering support for defense and commercial clients. AeroVironment said it will merge ISG with its MacCready Works Advanced Solutions team and make an additional payment of up to $6 million to Progeny Systems over three years if the acquired group meets specific performance targets. ISG is headquartered in Manassas, Virginia, and has 40 employee [Jane Edwards, govconwire.com, Feb 25, 21]
Controlling the enemy's counter-attack. Moderna said it has made the initial batch of doses of a new Covid-19 vaccine designed to better protect people against a new strain of the coronavirus that has shown some resistance to the company’s original vaccine. .... said it shipped the new shots to the National Institutes of Health to conduct the first human study of the variant vaccine, which could start within weeks. The new vaccine, code-named mRNA-1273.351, is designed to better match the virus variant that was first identified in South Africa but has since spread elsewhere. [Peter Loftus, Wall Street Journal, Feb 24, 21]
You can't beat something with nothing. instead of looking to the U.S. for help, Latin America is so far relying on Washington’s global rivals: China and Russia. In Argentina and Bolivia, authorities have begun vaccinating with Russia’s Sputnik V, which will soon arrive in Mexico. Chile began inoculating this month with 4 million doses of China’s Sinovac vaccine. [Ryan Dube and Luciana Magalhaes, Wall Street Journal, Feb 25, 21] America Firsters will say so what.
Choose better parents. Thanks to advances in technology, the cost of sequencing an individual’s DNA has declined a million-fold since 2003—the equivalent, he says, of a Ferrari plummeting from $350,000 to less than 40 cents. At the level of DNA, humans are 99.9% identical. On the other hand from science, Your ZIP Code, it’s said, is often a better predictor of health than your genetic code. [David Shaywitz reviewing The Genome Odyssey By Euan Angus Ashley WSJ, Feb 25, 21]
ChromaDex (Irvine, CA; $800K SBIR) up 16% [Feb 22, 21] announced that it has entered into a securities purchase agreement for the sale of $25.0 million of its common stock in a private placement. [company press release, Feb 22, 21]
Immunome (Exton, PA; one SBIR) up 76% [Feb 18, 21] biopharmaceutical company that utilizes its human memory B cell platform to discover and develop first-in-class antibody therapeutics, announced its discovery engine has isolated potent antibodies capable of neutralizing several SARS-CoV-2 variants, including the South African Variant (B.1.351), in pseudovirus testing. [company press release, Feb 18, 21]
Regenerative tissue developer Humacyte (Durham, NC: $8M SBIR) is going public through a special purpose acquisition company, or SPAC, and raising $275 million. .... The company is also pursuing work with the Department of Defense to study the vessel’s use in battlefield trauma care. [Amirah Al Idrus, Fierc Biotech, Feb 17, 21 ]
Bristol Myers Squibb is putting down up to $1.3 billion on a next-gen engineered toxin body cancer platform from Molecular Templates (Georgetown, TX; one SBIR). [Ben Adams, Fierce Biotech, Feb 12, 21]
[Rush Limbaugh] was not trying to lead people through thought but simply to divine where his followers were going and rushing to the head of the line so he could look as if he was leading them. [Peggy Noonan, WSJ, Feb 18, 21] an idea from Ghandi
Applied Genetic Technologies up 31% [Feb 16, 21] announced financial results for the quarter
Kopin (Taunton, MA; $6.4M SBIR going back SBIR start) up 25% [Feb 16, 21]
bluebird bio down 38% [Feb 16, 21] said that it was suspending marketing of its gene therapy Zynteglo, which treats beta thalassemia, and suspending two trials of another gene therapy for sickle cell disease. The suspensions came after a patient who received the sickle cell gene therapy more than five years ago was diagnosed with acute myeloid leukemia. [Barron's Feb 16, 21]
Inhibrx down 30% [Feb 16, 21]
AVROBIO down 28% [Feb 16, 21]
Hachigian and her team launched ImmuneID in 2020 using Elledge's technology. (The two had worked together previously on the launch of TScan Therapeutics, a Waltham-based cancer drug developer that raised a $100M Series C round just last month.) Hachigian now heads up the startup as CEO, and on Wednesday, the company officially emerged from stealth with $17M in seed funding. [BostInno, Feb 17, 21]
NexImmune (Gaithersburg, MD; $300K SBIR) up 49% [Feb 12, 21] after $110M IPO ; developing a novel approach to immunotherapy designed to employ the body's own T cells to generate a specific, potent and durable immune response that mimics natural biology. [company press release, Feb 11, 21]
Immunogen up 30% [Feb 12, 21] reviewed recent progress in the business and reported financial results for the quarter
Vuzix up 27% [Feb 12, 21]
II-VI made a roughly $6.5 billion bid for Coherent, setting up a seldom-seen, three-way takeover battle for the laser maker. [Wall Street Journal, Feb 13, 21]
Cyteir Therapeutics (Lexington, MA; $2,2M SBIR), a leader in the discovery and development of next-generation synthetic lethal therapies for cancer, today announced the close of an oversubscribed $80 million Series C financing. The company will use the new funds to advance its lead compound, the first-in-class inhibitor of RAD51-mediated DNA repair, CYT-0851, into phase 2 monotherapy trials in hematologic cancers and solid tumors, to initiate trials combining CYT-0851 with other cancer therapies, and to expand preclinical research to identify and advance additional novel cancer therapies. [company press release, Feb 11, 21[
You're flying on your own as CDC says it is not recommending required point of departure testing for domestic travel [CDC press release, Feb 12, 21]
The world wasn’t ready for Covid-19. [and] for the next, inevitable pandemic? ... must start by understanding that the lessons from battling Covid-19 aren’t just about Covid-19. We will fail if we learn nothing more than how to fight the last war better. ... I suggest a goal of “7-1-7”: Every country should be able to identify any new suspected outbreak within seven days of emergence, start to investigate the event within one day and report it then, and mount an effective response—defined by clear, specific benchmarks for different pathogens—within seven days. [Tom Frieden, Wall Street Journal, Feb 12, 21]
We would be riding the tiger of rapid [technology driven] change. The economy would grow faster but millions of people would have trouble finding a place in it. Universal basic income would become a red-hot topic. [David Brooks, NYTimes, Feb 11, 21] A bigger economy with higher profits and higher concentrated wealth would make a world with huge wealth at one enad and huge poverty at the other end. On the inevitable road to that end, The Trumps will gloat on the economy and markets and the Democrats will represent the bottom end, Eventually the numbers of poor with voting rights wiil demand relief. But for now the Reagan trickle-down philosophy still reigns.
They’re fine with hell, so long as they’re re-elected. [Frank Bruni, NYT, Feb 14, 21]
Law or force? A survey conducted by the American Enterprise Institute this week found that 55 percent of Republicans back the use of force as a way to “arrest the decline of the traditional American way of life,” as compared with 35 percent of independents and 22 percent of Democrats. [Lisa Lerer, NY Times, Feb 13, 21] The Republicans favoring force seem not to have read about the rise and inadequacy of Mussolini.
Zynerba Pharmaceuticals down 30% [Feb 11, 21]
Fluidigm down 21% [Feb 11, 21]
Cancer Genetics down 18% [Feb 11, 21]
Thanks in part to public investment, clean energy innovation has been fast and plentiful. The price of solar modules has declined by 99.6 percent since 1976. [David Brooks, NYTimes, Feb 11, 21]
Friends, you are the elected representatives of a great nation. The template is supposed to be Atticus Finch standing up to the crowd, not Atticus Finch endlessly sharing his retrospective terror on YouTube. [Peggy Noonan, WSJ, Feb 11, 21]
Cancer Genetics up 50% [Feb 10, 21]
Zynerba Pharmaceuticals up 47% [Feb 10, 21]
TransEnterix up 38% [Feb 10, 21]
PLx Pharma up 27% [Feb 10, 21]
PhaseBio Pharmaceuticals up 22% [Feb 10, 21]
LinQuest (Los Angeles, CA; $1M SBIR around 2006) announced that it had received a five-year contract from the Space Force worth $500 million. Under the indefinite delivery, indefinite quantity contract, LinQuest will provide analytical support to the federal agency and the other defense firms it works with [Elijah Chiland, LA Business Journal, Feb 5, 21]
Marrone Bio Innovations, maker of biologically based products to replace farm chemicals, has filed a $90 million [SEC] shelf registration statement to be able to quickly move to sell securities over the next three years. [Mark Anderson, Sacramento Business Journal, Feb 8, 21]
PDS Biotechnology (New Brunswick, NJ; $1.8M SBIR) up 53% [Feb 9, 21]
Heat Biologics (Durham, NC; $300K SBIR) up 50% [Feb 9, 21] reported positive interim data of the Company's fully-enrolled Phase 2 trial of HS-110, in combination with Bristol-Myers Squibb's (BMS) OPDIVO(R) (nivolumab) in advanced non-small cell lung cancer (NSCLC). HS-110 is an "off-the-shelf" allogeneic cell-based therapy designed to activate patients' immune system against multiple cancer testis antigens to elicit a diverse and robust immune response against tumor cells. [company press release, Feb 9, 21]
Cancer Genetics down 20% [Feb 9, 21]
Vaxart up 24% [Feb 8, 21]
ReAlta Life Sciences (Norfolk, VA: one $900K SBIR) is exploring whether RLS-0071, its treatment for a severe birth complication, can also treat patients with lung damage from Covid-19. The Norfolk-based biotech company raised a $14 million Series A round of funding in April, and in July it received clearance to begin early medical trials for Covid-19 treatments [RichmondInno] announced that the European Medicines Agency (EMA) has granted Orphan Drug Designation to RLS-0071 (also known as PIC1-dPEG24) for the treatment of neonatal encephalopathy. [compny press release, Dec 3, 20]
What George Shultz [died at 100] Taught Us About Making Policy. Begin with a goal, focus on the long term, talk to the other side, and never make empty threats. [John F. Cogan and John B. Taylor,Wall Street Journal, Feb 10, 21] Meanwhile, the internet has smothered the long term in insta-blather.
In self-imposed exile, Trump watches with unhappiness. [WashPost, Feb 9, 21] An heroic patriot worthy of the office would stand before the tribunal under oath and defend his actions. Instead, his lawyers rattle on to create an excuse to justify the Trump-fearing senators' vote against removal and lifetime ban.
The first Fabry disease patient treated with Avrobio (no SBIR) ’s plato gene therapy platform in a phase 2 trial has experienced the complete clearance of Gb3. [Nick Paul Taylor, Fierce Biotech, Feb 8, 21]
In one of the top biopharma licensing deals of 2019, Neurocrine Biosciences (San Diego, CA; $10M SBIR) bet $165 million—and promised $1.7 billion more—on a gene therapy partnership with Voyager Therapeutics (no SBIR). Now, it’s pulling out of the Parkinson’s disease portion of the deal, thanks to safety issues that have led to an FDA clinical hold. [Amirah Al Idrus, Fierce Biotech, Feb 3, 21]
Evidence to bolster the Democratic case has already emerged in federal criminal cases filed against more than 185 people so far in the aftermath of the insurrection. [Rosalind S. Helderman, Rachel Weiner and Spencer S. Hsu, WashPost, Feb 8, 21] Meanwhile, their instigator is being excused by his political party.
You can’t use reason to convince anyone out of an argument that they didn’t use reason to get into. by the astrophysicist Neil deGrasse Tyson.
Death, taxes and Tom Brady in the Super Bowl [Oliver Connolly,The Guardian, Feb 8, 21]
engineering company Scientific Research Corp (Atlanta, GA; $16M SBIR twenty years ago, founded 1988) will provide operational support for the U.S. Air Force’s command-and-control and combat intelligence functions under a potential five-year, $95 million contract. [Brenda Marie Rivers, govconwire.com, Feb 5, 21]
CorMedix (Berkeley Heights, NJ; $300K SBIR, founded 2006) up 23% [Feb 3, 21]
Vaxart down 58% [Feb 3, 21] announced preliminary data from its Phase 1 study of VXA-CoV2-1 showing that its oral COVID-19 tablet vaccine candidate was generally well-tolerated, and immunogenic as measured by multiple markers of immune response to SARS-CoV-2 antigens. [comapny press release, Feb 3, 21] Lifted by a Short Squeeze, Vaxart Stock Sinks on Lackluster Vaccine News [Bill Alpert, Barron's, Feb. 3, 2021]
Vaxart up 50% [Feb 2, 21]
Immunome up 18% [Feb 2, 21]
CEL-SCI down 18% [Feb 29, 21]
Catabasis Pharmaceuticals (Boston, MA; one SBIR) acquired Quellis Biosciences (Boston, MA; no SBIR), a biopharmaceutical company focused on discovering new molecules to treat serious rare diseases. The private placement is expected to result in gross proceeds to Catabasis of approximately $110M before deducting placement agent and other offering expenses. [Rowan Walrath, BostInno, Feb 2, 21]
Ursa Major Technologies (Berthoud, CO; one SBIR), manufacturer of propulsion solutions for the space community, raised $15 million in equity funding, according to a Form D filing. [Nick Greenhalgh, ColoradoInno, Feb 1, 21]
Dynavax up 63% [Feb 1, 21] Clover Biopharmaceuticals (China), and Dynavax Technologies announced the plan to initiate a global Phase 2/3 efficacy trial with the S-Trimer COVID-19 vaccine candidate adjuvanted with CpG 1018 plus alum in the first half of 2021 with an interim analysis for vaccine efficacy potentially in the middle of 2021 [joint companies press release, Feb 1, 21]
BioCryst Pharmaceuticals up 39% [Feb 1, 21]
Inovio Pharma up 33% [Feb 1, 21]
Vaxart up 30% [Feb 1, 21]
It's not news: A new president with his hair on fire wants to spend $1.9 trillion (that's twelve zeros) which he hasn't got, on his urgently necessary project. The veteran members of Congress have heard this story before, back at least to Bill Clinton. The Democrats wanted to pay for projects and the Republicans wanted to lower the upper income taxes. What each party was born for. Eventually a deal will emerge, and four years later the economists will report that the program just didn't have the great effect that it promised.
Novavax up 65% [Jan 29, 21] posted data on its own Covid-19 vaccine trial night that was stronger than the Johnson & Johnson data [Barron's, Jan 29, 21]
Vaxart up 34% [Jan 29, 21]
CEL-SCI up 29% ,Jan 29, 21]
Immucell up 26% [Jan 29, 21]
[State] Senate Republicans voted to end the [Democrat] governor’s health emergency declaration, which would kill the mask mandate. Assembly Republicans were expected to follow suit but delayed a vote after learning that ending the emergency declaration would cost the state $49 million in federal food assistance. [AP, Jan 29, 21]
Cancer Genetics up 37% [Jan 28, 21]
iRobot down 24% [Jan 28,, 21]
Unpredictable America.“The world cannot unsee the Trump presidency,” Jonathan Kirshner writes in a new essay. “From now on, all countries, everywhere, must hedge their bets about the United States. ... Whatever promises are made and best behaviors followed over the next few years, a resurgence of knuckle-dragging America firstism will loom menacingly in the shadows.” [Jonathan Kirshner, Foreign Affairs, Jan 28, 21]
CEL-SCI (Vienna, VA; $2.6M SBIR) up 73% [Jan 27, 21] the company CEO Geert Kersten tweeted, ‘the story of how the shorts have devastated companies with novel ideas shows collaboration deep into the system.’ ‘After $GME, big changes are coming,’ he added, referring to the gaming retailer, GameStop [seekingalpha.com, Jan 27, 21]
Sorrento Thera (San Diego, CA; $4.8M SBIR) up 46% [Jan 27, 21] announced positive preliminary results from its Phase 1b study of human allogeneic adipose-derived mesenchymal stem cells (COVI-MSC(TM)) for patients suffering from COVID-19-induced acute respiratory distress (ARD) or acute respiratory distress syndrome (ARDS). [company press release, Jan 26, 21]
biotech Theradaptive (Frederick, MD; $1.2M SBIR) raised $6.2 million and is working its way toward clinical studies of its regenerative medicine technology. [Morgan Eichensehr, Baltimore Business Journal, Jan 14, 21]
Fuel Cell Energy up 20% [Jan 26, 21]
Capricor Therapeutics down 18% [Jan 26, 21]
Cree is changing its name to Wolfspeed [for] the firm’s “transformational journey” toward being a pure play global semiconductor power house. Wolfspeed is the name of Cree's semiconductor unit. [Lauren Ohnesorge,, Triangle Business Journal, Jan 27, 21]
Hearing the baying of the Trump base hounds, the GOP senators find a diversion - Constitutionality - which relieves them of messy voting on the merits of impeachment.
“Socialism for the rich and capitalism for the rest” — a variation on a theme popularized in the 1960s — happens, [Ruchir Sharma, chief global strategist at Morgan Stanley Investment Management], explained in a phone interview, when government intervention does more to stimulate the financial markets than the real economy. So, America’s richest 10 percent, who own more than 80 percent of U.S. stocks, have seen their wealth more than triple in 30 years, while the bottom 50 percent, relying on their day jobs in real markets to survive, had zero gains. [Thomas Friedman, NYT, Jan 26, 21]
Evidence to override loyalty. Biden signed the Presidential Memorandum on Scientific Integrity and Evidence-Based Policymaking, which will task each agency with designating a senior career employee as its scientific integrity officer. That person will oversee and improve policies that shield employees from political interference and that ensure relevant programs follow science-based approaches. A task force will review the scientific integrity policies at every agency. [Eric Katz, govexec.com, Jan 27, 21]
Connected. It was a punishment for Dostoyevsky’s characters to be tormented by all those voices, internal and external; now we call it being connected. [Parul Sehgal reviewing Lauren Oyler's Fake Accounts, NYT, Jan 26, 21]
Today's word - heteronormativity. used in Christian Nationalism in their book “Taking America Back for God”: It includes assumptions of nativism, white supremacy, patriarchy and heteronormativity, along with divine sanction for authoritarian control and militarism. It is as ethnic and political as it is religious. Understood in this light, Christian nationalism contends that America has been and should always be distinctively ‘Christian’ from top to bottom — in its self-identity, interpretations of its own history, sacred symbols, cherished values and public policies — and it aims to keep it this way. [Thomas B. Edsall, NY Times, Jan 28, 21] as in We invaded here first, 400 years ago, and so, we own it.
Vaxart up 41% [Jan 25, 21]
Capricor Therapeutics up 35% [Jan 25, 21]
Dynavax (Emeryville, CA; $6M SBIR) up 25% [Jan 25, 21] Medigen Vaccine Biologics (Taiwan), a biopharmaceutical company focusing on the development and production of vaccines and biologics, and Dynavax Technologies, a biopharma focused on developing and commercializing vaccines, announced that the first participant has been dosed in the Phase 2 clinical trial evaluating MVC's COVID-19 vaccine candidate, MVC-COV1901. [joint companies press release, Jan 25, 21]
Immunome up 22% [Jan 25, 21]
Vuzix up 20% [Jan 25, 21]
As Merck announced scrapping its Covid-19 vaccine candidate, it announced that One of the experimental [therapeutic] drugs Merck is working on would treat severe and critical Covid-19 patients. Merck acquired the drug via a $425 million acquisition of OncoImmune (Rockville, MD; $4.3M SBIR). Merck expects results from a late-stage study by the end of March. [Jared Hopkins, Wall Street Journal, Jan 25, 21]
Republicans are signaling a determination to protect their 2017 tax-cut law and prevent President Biden from making good on campaign pledges to partially undo the measure. [The Hill, Jan 26, 21] Good solid Anerican politics: whatever needs doing, someone else needs to pay for it. And invent their own economics to justify it.
Ocean Power Tech up 34% [Jan 22, 21]
Ionis Pharma antisense oligonucleotide technology forms the backbone of three drugs to treat rare diseases. Now, the company is applying the technology to the blood cancer multiple myeloma, and it has positive results in mouse models that it says support a recently launched phase 1 trial. [Fierce Biotech, Arlene Weintraub, Jan 20, 21 ]
biotech startup Vaxess Technologies (Cambridge, MA; $3.6M SBIR) was awarded a [NSF] grant up to $2M and a subcontract from DARPA to advance two separate projects aimed at developing mRNA-based vaccines and other medical countermeasures. [Rowan Walrath, BostInno, Jan 22, 21]
ReVivo Medical (Albany, NY; $200K SBIR) startup developing a titanium alloy vertebrae implant has closed on an equity offering of over $550,000. .... will enable the startup to kick off the early stages of a clinical trial, necessary for overcoming the next hurdle of FDA market clearance for its products. [Justin Dawes, Albany Business Review, Jan 12,21]
Global scope. as Congress moves closer to offering subsidies for U.S. semiconductor chip manufacturing, the leading U.S. player, Intel Corp., is planning to outsource some chip making while investing in Chinese chip startups. [Greg Ip, Wall Street Journal, Jan 23, 21]
New investments by overseas businesses into the U.S., which for decades held the No. 1 spot, fell 49% in 2020, according to U.N. figures. [Paul Hannon and Eun-Young Jeong, Wall Street Journal, Jan 25, 21]
Cancer Genetics (Rutherford NJ; no SBIR) down 27% [Jan 21, 21]
CytomX Therapeutics down 19% [Jan 21, 21]
INmune Bio down 19% [Jan 21, 21]
Gaithersburg’s NexImmune has filed for [IPO], developing immunotherapy treatments for cancer, will look to raise $86.25M [DCInno, Jan 21, 21]
NVE Corp (Eden Prairie, MN; $40+M SBIR) called A Rare Investment Opportunity Offering Growth And Stable Income ... revenue was the greatest in the past nine quarters as a result of its greatest product sales in the same period. It also generated the greatest profit margin in history. .. a leader in spintronics technology ... generaates the largest margins in the industry, etc, , etc. [Jenks Jumps, Seeking Alpha, Jan 21, 21] Note: Carl Nelson Consuting does not offer investment advice.
In troubled times [the masses of men] do not profess to know what is wise, but they do know what is right. It is his ability to interpret what is in the hearts of his fellow-men which invests the President’s leadership with its moral authority. [Robert Jackson [then USAG], Jan 19, 1941] Jackson later was SCOTUS justice and chief prosecutor at Nuremberg war crimes trial.
Cancer Genetics (Rutherford NJ; no SBIR) up 75% [Jan 20, 21]
Vuzix up 21% [Jan 20, 21]
Gevo (Englewood, CO; $1.6M SBIR) down 21% [Jan 20, 21]
Aclaris Therapeutics (Wayne, PA; no SBIR) up 220% [Jan 19, 21] , a clinical-stage biopharmaceutical company focused on developing novel drug candidates for immuno-inflammatory diseases, announced positive preliminary topline results from a 12-week, Phase 2a, multicenter, randomized, investigator and patient-blind, sponsor-unblinded, parallel group, placebo-controlled clinical trial to investigate the safety, tolerability, pharmacokinetics and pharmacodynamics of ATI-450, an investigational oral MK2 inhibitor, in subjects with moderate to severe rheumatoid arthritis (RA) (ATI-450-RA-201). ATI-450 was developed internally utilizing Aclaris' proprietary KINect(TM) drug discovery platform. [company press release, Jan 19, 21]
TransEnterix (Research Triangle Park, NC; no SBIR)up 62% [Jan 19, 21] a medical device company that is digitizing the interface between the surgeon and the patient to improve minimally invasive surgery, announced the Company received CE Mark approval for the Intelligent Surgical Unit(TM) (ISU(TM) ) that enables machine vision capabilities on the Senhance Surgical System. This approval will provide Senhance digital laparoscopic programs in Europe access to this new technology, ushering them to the forefront of surgical innovation utilizing augmented intelligence. [company press release, Jan 19, 21]
Calyxt up 34% Jan 19, 21]
Acorda Thera up 19% Jan 19, 21]
Immunomic Therapeutics (Rockville, MD; $600K SBIR) raised another $16M following a mammoth raise in the spring of 2020. [DCInno, Jan 19, 21]
Yield 10 Bioscience (Woburn, MA; no SBIR) up 77% [Jan 15, 21]
Applied DNA Sciences up 23% [Jan 15, 21]
Calyxt up 20% [Jan 15, 21] a plant-based technology company, announced it has contracted to sell all 2020 grain production of its high oleic soybean to ADM, a global leader in human and animal nutrition and the world's premier agricultural origination and processing company headquartered in Chicago. [company press release, Jan 14, 21]
AeroVironment up 30% [Jan 14, 21]
Marrone Bio Innovations announced that it recently received approval for Grandevo WDG Bioinsecticide for use in New Zealand and Chile. Grandevo WDG and Grandevo CG have also been approved for use on hemp by the U.S. Environmental Protection Agency (EPA). [company ress release, Jan 14, 21]
Spreading even faster. A highly transmissible coronavirus variant is spreading rapidly in the U.S. and is likely to become the dominant strain circulating domestically in March unless steps are taken to slow it, federal health authorities said. [Betsy McKay, Wall Street Journal, Jan 16, 21] Vaccination racing too slowly to blunt the threat.
“The vast knowledge of the experts reduced me to silence and I didn’t know how they knew what they knew.” [Moira Hodgson's review of Claire Wilcox's autobiography, WSJ, Jan 15, 21] Wilcox now is organizing blockbuster shows of designers such as Vivienne Westwood, Gianni Versace and Alexander McQueen for London's V&A Museum.
Joe Biden’s quiet humanity will confront a noisy nation where too many citizens have become so sour that they’ve found solace, and entertainment, in an alternative reality. It will not be easy to lure them away from their noxious fantasies, but fact-based truth is not negotiable. [Joe Klein reviewing James Comey's Saving Justice, NYT, Jan 11, 21]
Acorda Therapeutics (Ardsley, NY; $@.4M SBIR around 2005) up 44% [Jan 13, 21] announced that it has entered into a definitive agreement to sell its INBRIJA manufacturing operations to Catalent for $80 million in cash. In connection with the sale, Acorda and Catalent have entered into a long-term global supply agreement under which Catalent will manufacture and package INBRIJA for Acorda, ensuring an uninterrupted drug supply for Acorda's patients and continued adherence to best-in-class manufacturing quality and safety standards. [company press release, Jan 12, 21]
AeroVironment (Monrovia, CA; $30M SBIR) a global leader in unmanned aircraft systems, and Arcturus UAV, leading provider of Group 2 and 3 unmanned aircraft systems (UAS) and services, today announced that they have entered into a definitive agreement under which AeroVironment will acquire Arcturus UAV for a total purchase price of $405 million, including $355 million in cash and $50 million in AeroVironment stock [company press release, Jan 13, 21]
Novavax has locked in a deal with Australia to sell 51M doses of its experimental Covid-19 vaccine. It’s just the latest in a string of such deals as the candidate undergoes late-stage clinical trials, with data expected potentially this quarter. [Sara Gilgore, DCInno, Jan 13, 21]
Biomerica (Irvine, CA; no SBIR) up 27% [Jan 12, 21] announced it has received CE Mark for its new COVID-19 Rapid Antigen Test for detection of COVID-19 infection. The Company has already received its first European orders and plans to ship the first part of these orders in the coming weeks. [company press release, Jan 12, 21]
Plug Power up 22% [Jan 12, 21]
Fuel Cell Energy up 21% [Jan 12, 21]
NeuroFlow (Philadelphia, PA; $1M SBIR) said the company raised a $20 million Series B funding round led by a customer, an independent psychologist in Philadelphia who used its software with his patients. The deal brings the firm's total back to date to $31 million. [Michelle Caffrey, Philadelphia Business Journal, Jan 13, 21]
Giving back to a source. II-VI committed to providing the II-VI Foundation with $1 million in funding in 2021, according to a news release. The money will go toward scholarships and other financial aid for both graduate and undergraduate students entering into STEM fields, as well as toward other environmental and social initiatives. II-VI reported that since 2007 its foundation awarded more than $29 million in funding to STEM students. [Julia Mericle, Pittsburg Business Times, Jan 13, 21]
Applied DNA Sciences down 24% [Jan 11, 21] 3125732709 BofA Lopez
As single-cell analysis technologies continue their rapid development—promising a cell’s-eye view of protein interactions and signaling—IsoPlexis (Wilmington, DE; $12M SBIR) hopes to establish itself as a provider of next-generation biology tools with $135 million in new financing. [Conor Hale, Fierce Biotech, Jan 11, 21]
Three months after launch, precision medicine startup Scorpion Therapeutics (Boston, MA; who needs SBIR?) raises $162M [Rowan Walrath, BostInno, January 07, 21]
Lexeo Therapeutics (New York, NY; $1.8M SBIR) is coming out of stealth with $85 million and 18 gene therapy programs primarily developed at Weill Cornell Medicine. [Amirah Al Idrus, Fierce Biotech, Jan 7, 21] Stealth questionable since SBIR awards are publicly published.
Ribometrix (Durham, NC, $700K SBIR for its one employee) announced a strategic collaboration with Genentech, a member of the Roche Group, to discover and develop novel RNA-targeted small molecule therapeutics against several targets. ... Genentech will pay $25 million upfront, and in return will receive exclusive rights to several predefined targets including an exclusive global license for the development and commercialization of molecules under this collaboration. Ribometrix will also be eligible to receive potential milestone payments exceeding $1 billion as well as tiered royalties on future global net sales of products that result from the collaboration. [company press release, Jan 6, 21]
Trump tweeted that “trade wars are good, and easy to win” in 2018 as he began to impose tariffs on about $360 billion of imports from China. ... wrong on both counts. Even before the pandemic, Beijing was withstanding Trump’s salvos, and once China got the virus under control, demand for medical equipment expanded its [new record] trade surplus with the U.S. despite the levies [paid by American importers]. [Bloomberg Politics, Jan 12, 21] In America, profit rules over politics.
Applied DNA Sciences (Stony Brook, NY; $1.1M SBIR) up 105% [Jan 8, 21] a leader in Polymerase Chain Reaction (PCR)-based DNA manufacturing, announced that [FDA] published a safety communication (the "Communication") that identifies the Company's Linea(TM) COVID-19 Assay Kit (the "Assay Kit") as one of only two tests marketed under the FDA's Emergency Use Authorization (EUA) that are potentially able to identify certain SARS-CoV-2 mutations, including a mutation found in the U.K. variant of SARS-CoV-2 (B.1.1.7). [company press release, Jan 8, 21]
Chimerix up 69% [Jan 8, 21] announced that the Company has acquired Oncoceutics, (Phldelphia, PA; $4M SBIR), clinical-stage biotechnology company developing imipridones, a novel class of compounds. Oncoceutics' lead product candidate, ONC201, has been shown in clinical testing to selectively induce cell death in multiple cancer types. [company press release, Jan 8, 21]
Sarepta Thera down 51% [Jan 8, 21] announced top-line results from Part 1 of Study SRP-9001-102 (Study 102), an ongoing, randomized, double-blind, placebo-controlled clinical trial to evaluate the safety, efficacy and tolerability of a single dose of SRP-9001 (rAAVrh74.MHCK7.micro-dystrophin) ... however, the difference was not statistically significant (P=0.37) [company press release, Jan 7, 21]
Solid Biosciences down 21% [Jan 8, 2]
Abcuro (Newton, MA; one , a biotech firm focused on autoimmune diseases and cancer, closed a $42M Series A-1 round [BostInno, Jan 7, 21]
Bluebird Bio, biotech pioneer in the field of gene therapies, plans to split itself in two later this year, spinning off its cancer-drug unit into a new, publicly traded company so it can focus on rare diseases. [Joseph Walker, WSJ, Jan 11, 20]
Isn't debt wonderful. The US total market cap/GDP is 40% higher than the peak of the Y2K stock boom. [Adam Taggart via PeakProsperity.com, Jan 8, 20] How high can such a tree grow? Depends on how high a borrowed economic stimulus will pump the economy.
Unready and underfunded. Supply-chain experts attribute the [vaccine] delays in part to the burdens faced by often underfunded state and local health agencies already stretched to their limits by the coronavirus pandemic, along with communication problems including confusion over how many doses states were set to receive. [Jennifer Smith, WSJ, Jan 11, 21] As ever, the public wants more government than they are willing to pay for. The siren political call for tax cuts for the last four decades.
Plug Power (Latham, NY; no SBIR) up 35% [Jan 7, 21] a leading provider of hydrogen fuel cell and fueling solutions enabling e-mobility, and SK Group, one of the leading South Korean business groups, announced today that the companies intend to form a strategic partnership to accelerate hydrogen as an alternative energy source in Asian markets. [compny pess release, Jan 6, 21]
Fuel Cell Energy up 22% [Jan 7, 21]
Scopus BioPharma up 21% [Jan 7, 21]
Solid Biosciences up 20% [Jan 7, 21]
The CEO of a [Chicago] suburban tech company was among dozens who were arrested after pro-Trump protestors stormed the U.S. Capitol building [Chicago Inno, Jan 8, 21]
we’ll still need vaccine research, which tends to run out of cash when there’s no emergency. The answer to this, Aaron Brown writes, is vaccine bonds, which provide regular financing for the studies we’ll need to fight the next pandemic while it’s still just a gleam in a bat’s eye. [Bloomberg Opinion Today, Jan 5, 20]
“This is what happens when we subordinate our moral principles for what we perceive to be business interests,” said Darren Walker, the president of the Ford Foundation and a board member at Square and Ralph Lauren. “It is ultimately bad for business and bad for society.” [David Gelles, NY Ties, [Jan 7, 21] biz remorse after the riot
Teledyne Technologies has agreed to acquire FLIR Systems (Portland, OR; $1.6M SBIR in mid 1990s, founded 1978) [up 19%, Jan 4, 21] for approximately $8B in cash and stock. ... Teledyne will fund the acquisition and refinance existing debt through a $4.5B credit commitment. [Jane Edwards, govconwire.com, Jan 5. 21]
Having made a hash of things over the last several decades, our self-described Indispensable Nation is looking pretty dispensable, not to mention confused and adrift. So there is a pressing need to understand how things went wrong and how to make them right. .... I leave it to others to determine if the combined efforts of the Bush 43, Obama and Trump administrations qualify as a strategy. ... The overarching theme of United States policy since the beginning is American exceptionalism, which can indeed be malevolent, employed to justify either running the world or ignoring it. [Andrew Bacevich, NY Times, Updated Dec. 21, 20]
Novavax has officially started advanced clinical trials of its Covid-19 vaccine candidate in the U.S. and Mexico, after they were delayed from mid-October. These trials kick off alongside late-stage trials in the U.K. and other studies in South Africa and Australia. [DCInno, Dec 29, 20]
The incoming Biden administration is likely to increase contracting opportunities for small and minority-owned businesses. [Courtney Buble, govexec.com, Dec 29, 20] Yeah, sure, heard that before. If the federals try to micromanage sub-contracting, they undercut the prime contractor's effort to hire the best available companies.
we’re not going to make any bold predictions for 2021. But we’re pretty confident that Covid-19 has sowed the seeds of change that will be every bit as consequential over the long term as the plagues that spurred Europe’s passage from the Dark Ages to the Renaissance. In science and technology, not to mention the way we work and play, we’ve just entered a new age of discovery. [Andrew Brown, Bloomberg New Economy, Jan 2, 21]
[Healthcare workers] fear infecting themselves or their families. They suffer the moral injury of fighting the virus while others party, travel, and cry hoax. [Ed Yong, Atlantic, Dec 29, 20]
Gevo (Englewood, CO; $2.4M SBIR) up 30% [Dec 28, 20] focuses on the development and commercialization of renewable alternatives to petroleum-based products.
SQZ Biotechnologies ($5.3M SBIR) up 26% [ec 28, 20]
this year is closing out with a second demonstration of the lesson we should have learned in the spring: In times of crisis, government aid to people in distress is a good thing, not just for those getting help, but for the nation as a whole. Or to put it a bit differently, 2020 was the year Reaganism died. [Paul Krugman, NYTimes, Dec 28, 20] Reaganism= tax cuts for the wealthy and laissez faire for everyone else.
SomaLogic (Boulder, CO; $400K SBIR) global leader in proteomic discovery and applications transforming biomedical discovery and clinical diagnostics, announced it added $81M to its current funding round [company press release, Dec 22, 20]
Scopus BioPharma up 48% [Dec 23, 20]
Fuel Cell Energy up 25% [Dec 23, 20]
Organovo Holdings (San Diego, CA; $2.4M SBIR) up 26% [Dec 22, 20]
Vuzix up 19% [Dec 22, 20]
Sangamo Thera up 19% [Dec 22, 20]
Scopus BioPharma down 19% [Dec 22, 20]
Nanochon (Washington, DC; one SBIR) is aiming to close a $3.5M seed round in January to fund the first human study of its product, an alternative to joint replacement surgery. The new funding would position the med-tech company to start its first clinical trial in Q4 2021 of its tech — licensed from George Washington University — that replaces lost or damaged cartilage and will target a lower cost than existing options. [DCInno, Dec 22, 20]
MacroGenics (Rockville, MD; $2.7M SBIR) announced a research collaboration and global license agreement to develop a preclinical bispecific molecule with Janssen Biotech, Inc. The collaboration will incorporate MacroGenics' proprietary DART® platform to enable simultaneous targeting of two undisclosed targets in a therapeutic area outside oncology. [company press release, Dec 18, 20]
COnovate (formerly SafeLi, Shorewood, WI; $1.5M SBIR) developing materials for lithium ion batteries, is receiving $50,000 in a seed investment from BrightStar Wisconsin Foundation, the Milwaukee-based nonprofit and an early-stage investment organization. [WiscInno, Dec 22, 20]
Chicago-based Bunker Labs has selected 179 companies for its Veterans in Residence 2021A cohort, a six-month in-person and virtual business incubator that provides veteran and military family member entrepreneurs with business support and workspace. Startups from across the country are participating, and seven are based in Chicago. See the full list of participating startups. [ChicagoInno, Dec 23, 20]
one thing I learned covering the Middle East is that there is only one reliable thing about extremists — they don’t know when to stop. So, in the end, they almost always go over the cliff, taking a lot of people with them. [Thomas Friedman, NY Times, Dec 23, 20] postulating that the Republican party will split into serious principled and suicidal unprincipled parts.
Editas Medicine up 30% [Dec 21, 20]
Scopus BioPharma down 25% [Dec 21, 20] announced the closing of its initial public offering.
908 Devices (Boston, MA; no SBIR) up 145% [Dec 18 20] after $130M IPO
Vuzix (Rochester, NY; $250K SBIR) up 25% [Dec 18, 20] announced that Envirotainer, the global market leader in secure cold chain solutions for air transport of pharmaceuticals, has successfully deployed an AR smart glasses-based remote training program globally utilizing Vuzix M400 Smart Glasses to support their fleet of more than 6,000 active temperature-controlled containers which are being used today to ship COVID-19 vaccines, as well as other pharmaceuticals in need of a temperature-controlled environment. [company press release, Dec 17, 20]
Scopus BioPharma down 36% [DEC 18, 20]
Moderna’s Covid-19 Vaccine Is Cleared for American Use [Wall Street Journal, Dec 18, 20]
engineering firm Applied Technology Associates (Albuquerque,NM; lots of SBIR) now part of a larger company, continues to win large government contracts. On Dec. 3, the company won a $29 million cost-plus-fixed-fee contract with the U.S. Air Force. The contract provides for onboard spacecraft sensing, and autonomous operations capabilities for tactical and strategic missions, according to the Department of Defense. [Collin Krabbe, Albuquerque Business First, Dec 14, 2020]
Scopus BioPharma (New York, NY; no SBIR) up 474% [Dec 17, 20] Another IPO that is having a better second day than first day engages in the development of therapeutics targeting the endocannabinoid system, had its 500,000-share IPO price at $5.50 [MarketWatch, Dec 17, 20]
Solid Biosciences up 24% [Dec 17, 20]
BioCardia down 26% [Dec 17, 20] announced that the independent Data Safety Monitoring Board (DSMB) has completed its prespecified data review for the Phase III pivotal CardiAMP(TM) Heart Failure Trial. The DSMB based its review on all available data for the 86 patients enrolled in the trial, including 60 randomized patients who have reached their one-year follow-up. The DSMB performed a risk-benefit assessment, indicated no safety concerns, and recommended that the study continue as designed. [company press relese, Dec 17, 20]
BCD Bioscience (Davis, CA; no SBIR) biotech founded by professors at the [UC]Davis raised $4.8 million in equity investment to research new uses for carbohydrates for nutrition and immunology [to] develop proprietary techniques to transform food-grade substances into products at the cellular level which may have nutritional and immune benefits. [Mark Anderson, Sacramento Business Journal, Dec 3, 2020]
NewLeaf Symbiotics (St Louis, MO; no SBIR) announced that it recently completed the final close of its Series D [$22 million] financing as it broadens and accelerates product commercialization. [company press release, Dec 1, 20]
MacroGenics will be taking its first product to market. ... said [FDA] has approved Margenza as a treatment for patients with metastatic HER2-positive breast cancer in combination with chemotherapy. The company said it expects the therapeutic to be available in March 2021. [DCInno, Dec 17, 20]
In vitro diagnostic startup General Fluidics (Waltham,MA; one SBIR in 2014) raised $6.7M in a sale of securities and convertible debt, per an SEC filing. [BostInno, Dec 16, 20]
BioCardia (San Carlos, CA; $200K SBIR) up 50% [Dec 15, 20] announced it has entered into definitive agreements with investors for the purchase and sale of [$8.5M in common stock] [compsny press release, Dec 15, 20]
Solid Biosciences up 23% [Dec 15, 20]
Naveris (Natick, MA; no SBIR) which aims to detect virus-related cancers early, closed its expanded Series A round [BostInno, Dec 15, 20]
the biomedical library PubMed [now] lists more than 74,000 COVID-related scientific papers—more than twice as many as there are about polio, measles, cholera, dengue, or other diseases that have plagued humanity for centuries... partly because there are just more scientists: From 1960 to 2010, the number of biological or medical researchers in the U.S. increased sevenfold, from just 30,000 to more than 220,000. [Ed Yong, How Science Beat the Virus, Defense One, Dec 15, 20]
Science muffled. during the coronavirus pandemic this year in the C.D.C.’s leadership suite shook them: Washington’s dismissal of science, the White House’s slow suffocation of the agency’s voice, the meddling in its messages and the siphoning of its budget. [Noah Weiland, New York Times, Dec 16, 20]
Hyundai Motor Group and SoftBank Group agreed on main terms of the transaction pursuant to which Hyundai Motor Group will acquire a controlling interest in Boston Dynamics (Waltham, MA; $5.5M SBIR) in a deal that values the mobile robot firm at $1.1 billion. The deal came as Hyundai Motor Group envisions the transformation of human life by combining world-leading robotics technologies with its mobility expertise. Financial terms were not disclosed. [joint companies press release, Dec 11, 20]
Solid Biosciences up 52% [Dec 11, 20] announced that it has entered into a securities purchase agreement with a select group of institutional investors and accredited investors for a $90 million private placement [company press release, Dec 11, 20]
Boston drugmaker Catabasis Pharmaceuticals is laying off 16 employees, 48% of the company's workforce, as part of a restructuring. [BostInno, Dec 11, 20]
Don’t abandon the middle ground, which actually exists. We’re a big and varied country. Maine isn’t Mississippi. People can be ornery about their rights and slippery about their responsibilities. [Peggy Noonan decribing attitudes of former Maine Senator Margaret Chase Smith, WSJ, Dec 12, 20]
AstraZeneca and Alexion Pharmaceuticals (Boston, MA, originally 1992 of New Haven, CT; $1.6M SBIR in the 1990s) entered into a definitive agreement for AstraZeneca to acquire Alexion [for] total consideration to Alexion shareholders of $39bn. [joint companies press release, Dec 12, 20]
According to Refinitiv, a data provider, this year the world’s non-financial firms have raised an eye-popping $3.6trn in capital from public investors [The Economist, Dec 12, 20]
Sangamo Thera up 53% [Dec 10, 20]
TG Therapeutics (Brisbane, CA; no SBIR) up 33% [Dec 10, 20] announced positive topline results from two global, active-controlled, Phase 3 studies, called ULTIMATE I & II, evaluating ublituximab, the Company's investigational novel, glycoengineered anti-CD20 monoclonal antibody, compared to teriflunomide in patients with relapsing forms of multiple sclerosis (RMS). Both studies met their primary endpoint [company press release, Dec 10, 20]
Editas Medicine up 32% [Dec 10, 20] announced it submitted an Investigational New Drug (IND) application with [FDA] for the initiation of a Phase 1/2 clinical trial of EDIT-301, an experimental CRISPR/Cas12a gene editing medicine in development for the treatment of sickle cell disease. [company press release, Dec 9, 20]
Greenwich LifeSciences (Stafford, TX; no SBIR) up 998% [Dec 9, 20] a clinical-stage biopharmaceutical company focused on the development of GP2, an immunotherapy to prevent breast cancer recurrences in patients who have previously undergone surgery, today announced the publication of a poster for the GP2 Phase IIb clinical trial final efficacy analysis at the San Antonio Breast Cancer Symposium in a virtual format. [company press release, Dec 9, 20]
Cytokinetics up 23% [Dec 9, 20] announced the progression of REDWOOD-HCM following the conduct of an interim analysis of data from Cohort 1. REDWOOD-HCM (Randomized Evaluation of Dosing With CK-274 in Obstructive Outflow Disease in HCM) is an ongoing Phase 2 clinical trial of CK-3773274 (CK-274), a next-generation cardiac myosin inhibitor in development for the potential treatment of hypertrophic cardiomyopathy (HCM). [company press release, Dec 9, 20]
In a new report from venture capital database Pitchbook, Chicago once again leads the country as the best city for VC investor returns. It's a designation Chicago first earned in 2016 and has held onto in years since. The metric is based on "Median Multiple On Invested Capital," or MOIC. MOIC is calculated as the ratio of exit value to amount of capital raised. [Jim Dallke, Chicago Inno, Dec 10, 20]
Chimerix up 25% [Dec 7, 20] announced that [FDA] accepted the filing of a New Drug Application (NDA) for brincidofovir (BCV) as a medical countermeasure for smallpox. ... Brincidofovir, an investigational therapy, is a nucleotide analog lipid-conjugate that has demonstrated antiviral activity as a medical countermeasure against smallpox under the FDA's Animal Efficacy Rule, which allows for testing of investigational drugs in animal models to support effectiveness in diseases which are not ethical or feasible to study in humans. [company press release, Dec 7, 20]
Mercury Systems has agreed to purchase defense systems integrator Physical Optics (Torrance, CA; a three-decade top SBIR consumer of about $420M) for approximately $310M in cash to expand the former's global avionics and missions systems portfolio. [Brenda Marie Rivers, GovConWire, Dec 8, 20] POC founded and operated by a Polish couple w PhDs from Warsaw Univ.
Booming med school applications may have a lot to do with the fact that people look at Anthony Fauci, look at the doctors in their community and say, 'You know, that is amazing. This is a way for me to make a difference,'" said Kristen Goodell, associate dean of admissions at the school of medicine at BU. Medical school admissions officers have started calling this the Fauci Effect. [Jon Marcus, NPR, Dec 7, 20]
BioCryst Pharma up 19% [Dec 4, 20] announced that [FDA] has approved oral, once-daily ORLADEYO(TM) (berotralstat) for prophylaxis to prevent attacks of hereditary angioedema (HAE) in adults and pediatric patients 12 years and older. [company press release, Dec 3, 20]
MacroGenics (Rockville, MD; $2.6M SBIR) is weeks away from a potential regulatory approval for its first product — and preparing to hit the ground running on a launch. The clinical-stage biotech has teamed up with Milwaukee life sciences firm Eversana to commercialize its breast cancer therapy candidate in the U.S. if it receives approval from the[FDA]. That decision is expected to drop Dec. 18 [Sara Gilgore, DCInno, Dec 4, 20]
Precision Biosciences down 18% [Dec 4, 20] announced positive interim clinical results from its Phase 1/2a study of PBCAR0191, the Company's off-the-shelf allogeneic CAR T cell therapy investigational candidate targeting CD19. As of the November 16, 2020 cutoff, 27 patients including 16 patients with aggressive NHL and 11 patients with aggressive B-ALL were enrolled and evaluated. [company press release, Dec 4, 20]
U.S. companies are sitting on the largest pile of cash ever. Investors are trying to gauge how they are going to use it. ... a record $2.1 trillion at the end of June, according to a report from Moody’s Investors Service. That is up 30% from that time last year [Sebastian Pellejero and Paul J. Davies, Wall Street Journal, Dec 4, 20]
Most of the jobs that were added in the U.S. in November were in the transportation and warehousing industries—the ones that package, ship and deliver goods to consumers. [Josh Mitchell, Wall Street Journal, Dec 4, 20]
What's a government for? I don’t love big government, but government is supposed to step up in a crisis, and with the CARES Act, it did. ... But the core problem is that Republicans have applied a dogmatically ideological approach to a situation in which it is not germane and is in fact ruthlessly destructive. ... If we don’t see a Covid-19 relief measure pass in the next week or two, then our democracy is existentially broken. [David Brooks, NYTimes, Dec 3, 20]
Merrimack Pharmaceuticals up 59% [Dec 2, 20]
FuelCell Energy down 20% [Dec 2, 20]
Inhibrx (La Jolla, CA; $1.5M SBIR) up 38% [Dec 1, 20]
FLIR Systems announced that it has acquired Altavian (Gainesville, FL; no SBIR, founded 2011) manufacturer of small unmanned aerial systems (sUAS) for defense and public safety customers. Altavian’s airframes integrate multiple sensors, including FLIR thermal technology, to provide users with decision support and intelligence, surveillance, and reconnaissance (ISR) capability. [FLIR press release, Dec 2, 20]
Dimension Inx (Chicago, IL; no SBIR, founded 2017) a next-generation biofabricationcompany developing regenerative medical implants that repair tissues and organs, announced that it has raised $3.175M to close its Series Seed financing round, [to] support the commercial development and FDA approval of the company’s first therapeutic implants for facial reconstruction in patients followingtrauma as well as those with dentalma lformations due to congenital defects or aging. [company press release, Nov 10, 20]
A smart drug delivery system and an all-electric, self-driving lawnmower company were among 37 startups that received funding as part of the latest Colorado Advanced Industries Accelerator Grant Program. A total of $7,657,811 was approved for Proof-of-Concept and Early Stage Capital and Retention Grants to fuel the growth of Colorado’s advanced industries, which include things like advanced manufacturing, aerospace, bioscience and electronics. [Nick Greenhalgh, Colorado Inno November 30, 2020] included Agile RF Systems (Bertoud, CO; $3.2M SBIR, $250K; ClearSight (Aurora, CO; $1.8M SBIR, $250K; Menogenix (Aurora, CO; $900K SBIR, $108K
Ambiq Micro (Austin, TX; one SBIR), maker of low-power semiconductors that work in wearables, chip cards and IoT devices, reported raising $55.8M in new equity funding, per an SEC filing. [Brent Wistrom, Austin Inno Dec 2, 20]
G1 Thera up 28% [Nov 30, 20]
Moderna up 20% [Nov 30, 20] announced that Moderna plans to request an Emergency Use Authorization (EUA) from [FDA] and conditional approval from the European Medicines Agency (EMA). [company press release, Nov 30, 20]
C2N Diagnostics (St Louis, MO; $2.4M SBIR) announced it has started selling the first blood test to help diagnose Alzheimer’s disease, a leap for the field that could make it much easier for people to learn whether they have dementia. It also raises concern about the accuracy and impact of such life-altering news. [company announcement, Oct 29, 20]Subsidies hit again. Evidence keeps piling up that what was hailed by President Donald Trump as the “Eighth Wonder of the World” was a facade. ... the company has no plans to complete the project and hire the 13,000 workers it promised [Michael Farren and Matthew Mitchell, Chicago Tribune, Nov 30, 20] In case you had not noticed, SBIR is also a subsidy program that hands out money on non-binding promises of future economic success.
Novavax up 22% [Nov 27, 20]
Sorrento Thera up 18% [Nov 27, 20]
Novavax up 22% [Nov 27, 20]
RAPT Thera up 18% [Nov 27, 20]
Moderna up 16% [Nov 27, 20]
[Democrats] should understand that there was really no way to avoid disappointment. Three factors — the logic of partisan polarization, which inaccurate polling obscured; the strength of the juiced pre-Covid-19 economy; and the success of Mr. Trump’s denialist, open-everything-up nonresponse to the pandemic — mostly explain why Democrats didn’t fare better. [Will Wilkinson, NY Times, Nov 26, 20] A huge section of the public insists on its liberty to infect each other in groups that then spread the disease to the rest of the public to inundate the hospitals where they assume medical miracles are their due from the very people whose life mission is caring for others are on the verge of collective collapse. [Katherine J. Wu, NY Times, Nov 26, 20]
A frightening number. Only 3% of those who voted for President Trump consider Mr. Biden's election legitimate. (CNBC Nov 25, 20). Our nation's stability depends on the losers accepting the results and peacefully moving on toward winning the next election.
Fuel Tech (Warrenville, IL; no SBIR) up 114% [Nov 24, 20] more than week after it nearly doubled following earnings results that beat expectations. [Seeking Alpha, Nov 24, 20]
Early-stage biotech Elevian (Allston, MA; no SBIR) raised $15 million as it looks to target multiple age-related diseases. The company said the small raise would help its preclinical work toward the clinic to treat stroke and other age-related diseases. [Fierce Biotech, Nov 23, 20]
Fuel Cell Energy up 54% [Nov 23, 20]
Myomo up 23% [Nov 23, 20]
Bellerophon Therapeutics down 18% [Nov 23, 20]
Merck and OncoImmune (Rockville, MD; $4.3M SBIR) [which has reported positive results from a late-stage study of a coronavirus therapeutic candidate],announced that the companies have entered into a definitive agreement pursuant to which Merck, through a subsidiary, will acquire all outstanding shares of OncoImmune for an upfront payment of $425 million in cash. In addition, OncoImmune shareholders will be eligible to receive sales-based payments and payments contingent on the successful achievement of certain regulatory milestones. OncoImmune recently announced positive top-line findings from an interim efficacy analysis of a Phase 3 study evaluating its lead therapeutic candidate CD24Fc for the treatment of patients with severe and critical COVID-19. [joint companies press release, Nov 23, 20]
AVROBIO down 18% [Nov 20, 20] Announces Pricing of Underwritten Public Offering of $75 Million of Common Stock
Eli Lilly and Precision BioSciences (Durham, NC; $500K SBIR) announced a research collaboration and exclusive license agreement to utilize Precision's proprietary ARCUS® genome editing platform for the [R&D] of potential in vivo therapies for genetic disorders, with an initial focus on Duchenne muscular dystrophy (DMD) and two other undisclosed gene targets. [joint copanies press release, Nov 20, 20]
Eli Lilly and Incyte say the [FDA] issued an emergency use authorization for their baricitinib arthritis drug in combination with Gilead Sciences' remdesivir to treat hospitalized patients with COVID-19. "This is an important milestone for hospitalized patients on oxygen, as baricitinib may help speed their recovery," Eli Lilly Chairman and CEO David Ricks says. [Seeking Alpha, Nov 20, 20]
the results of a survey of over 1,000 institutional and corporate venture capitalists led by Paul Gompers of the Harvard Business School, suggests VCs have slowed their pace of investing by 29 percent this year and hope to be at 81 percent of normal next year. The VCs also said 38 percent of their portfolio companies had been negatively affected by the pandemic. (Note: the survey was conducted during the summer, before the larger, second wave of infections appeared.) [SSTI, Nov 18, 20]
A new AI model for summarizing scientific literature can now assist researchers in wading through and identifying the latest cutting-edge papers they want to read. The Allen Institute for Artificial Intelligence has rolled out the model onto its flagship product, Semantic Scholar, an AI-powered scientific paper search engine. It provides a one-sentence tl;dr (too long; didn’t read) summary under every computer science paper. [MIT Tech Review, Nov 19, 20]
Organize the Army. Under a forthcoming solicitation under the Army’s SBIR, the branch will be asking small businesses for “solutions leveraging data science and/or machine learning techniques that will revolutionize how the Army recruits, develops, selects, and distributes talent across the force.” The official opportunity will be released Nov. 24, with bids openings Dec. 8. The program office will accept questions from potential proposers from Nov. 24 to Dec.23. Proposals will be due by noon Jan. 12.
Olema Pharmaceuticals (San Francisco, CA; no SBIR) up 157% after IPO raises $290M [company presss release, Nov 18, 20]
SCYNEXIS up 17% [Nov 19, 20]
We told you a couple weeks ago that biotech Adaptive Phage Therapeutics (Gaithersburg, MD; no SBIR) had administered its therapy to select patients in Texas with antibiotic-resistant bacterial infections from Covid-19. Now, it’s armed with a game-changing allowance from regulators — clearing its expanded access investigational new drug application for coronavirus patients infected with certain types of bacteria that cause pneumonia, as well as bacteremia or septicemia, or bacteria in the bloodstream. [Sara Gilgore, DCInno, Nov 19, 20]
Tariffs fail. In the 1980s, it took 10 hours of work to produce a ton of steel; now it takes one hour. In fact, steel protection is a job-destroying policy. Economists at the Federal Reserve found that the steel and aluminum tariffs reduced overall employment in manufacturing by 75,000 workers. ... Many more workers are employed in steel-using industries than in the steel industry itself. [Douglas Irwin, Wall Street Journal, Nov 19, 20] But a gullible electrorate will fall for a political claim that a trade war will improve the nation's employment.
Fuel Cell Energy (Danbury, CT; $14M SBIR) up 24% [Nov 18, 20]
CVD Equipmwnt (Central Islip, NY; $100K SBIR in 1987) down 18% [Nov 18, 20]
ColdQuanta (Boulder, CO; $13M SBIR) announced it has raised $32M in Series A funding, with additional funding expected to close soon [company press release, Nov 5, 20]
Preventing death. Today’s IHME modeling shows that if 95% of U.S. residents were to wear masks when leaving home, we could prevent the deaths of tens of thousands of Americans over the winter months. [Christopher J.L. Murray, M.D., Director, Institute for Health Metrics and Evaluation,University of Washington Seattle, Nov 18, 20] Masks are at least painless.
AXT [formerly American Xtal, Fremont, CA; $2M SBIR) up 20% [Nov 17, 20] announced a strategic plan to access China's capital markets in order to enhance its ability to support at scale the strong, expected demand for strategic compound semiconductor materials and to continue to elevate its business and manufacturing operations in support of Tier-1 customer requirements, as well as to replenish its cash with minimal dilution and further strengthen its financial structure. [compaany press release, Nov 16, 20]
SQZ BioTech up 26% [Nov 16, 20]
RAPT Thera down 46% [Nov 16, 20] announced positive initial clinical data from its ongoing Phase 1/2 trial for FLX475 in multiple cancer indications.
Moderna announced its coronavirus vaccine was 94.5 percent effective, based on an early look at the results from its large, continuing study. Researchers said the results were better than they had dared to imagine. But the vaccine will not be widely available for months, probably not until spring. [NY Times, Nov 16, 20]
RE2 Robotics (Pittsburgh, PA; $20M prior SBIR) announced that it has received $1.1 million [Army] Phase II SBIR to develop a mobile robotic manipulation system that will allow combat medics to remotely assess and extract injured soldiers on the battlefield. The (ACE) program will utilize the Company’s dual-arm Highly Dexterous Manipulation System (HDMS) mounted to a FLIR [Systems] Kobra unmanned ground vehicle (UGV), provided by FLIR Systems,, to autonomously locate a casualty in the field. [comapny press release, Nov 1, 20]
X-COR Therapeutics (Allston, MA; no SBIR) developer of a novel extracorporeal carbon dioxide removal device, closed a $2.6M seed round [Rowan Walrath, BostInno, Nov 13, 20]
Having greatly empowered Republican politics, Mr. [Chrles] Koch said he has since come to regret his partisanship, which he says badly deepened divisions. “Boy, did we screw up!” he writes in his new book. “What a mess!” Mr. Koch is now trying to work together with Democrats and liberals on issues such as immigration, criminal-justice reform and limiting U.S. intervention abroad, where he thinks common ground can be found. [Douglas Belkin, Wall Street Journal, Nov 13, 20]
Tantrums work. “Fear has always worked for Trump. Tantrums have always paid dividends.” said Eric Dezenhall, a crisis management expert who worked in communications in Ronald Reagan’s White House. [Michael Tackett and Calvin Woodward, Associated Press, Nov 14, 20]
Five Pime Thera up 25% Nov 12, 20]
Vaxart up 15% Nov 12, 20]
Five Prime Thera up 237% [Nov 11, 20] announced positive topline results from the global, randomized, double-blind placebo-controlled Phase 2 FIGHT trial. The trial compared mFOLFOX6 chemotherapy in combination with bemarituzumab (bema, FPA144), a first-in-class targeted therapy, in patients with fibroblast growth factor receptor 2b-positive (FGFR2b+), non HER2 positive (non HER2+) front-line advanced gastric or gastroesophageal junction (GEJ) cancer. [company press release, Nov 10, 20] also announced that it plans to offer and sell, subject to market and other conditions, 5,000,000 shares of its common stock in an underwritten public offering.
Apic Bio (Cambridge, MA; no SBIR) which is developing cures for patients with genetic diseases, raised $12.1M in equity in a $46.1M funding round, per an SEC filing. [Rowan Walrath, BostInno, Nov 12, 20]
Nearly 100,000 small businesses are estimated to have gone under since the pandemic began in March. [Nick Martin, New Republic, Nov 12,]
Arcturus Therapeutics up 24% [Nov 11, 20]
Myomo up 19% [Nov 11, 20]
Vaxart up 19% [Nov 11, 20]
President-elect Joe Biden is stacking his transition team with policy academics and former Obama administration officials, a clear break from President Donald Trump's policy of choosing industry insiders. [Bloomberg, Nov 11, 20]
Biden carried only 477 of the 3,141 counties in the United States, but those counties account for 70 percent of the country’s economic output, according to new figures from the Metropolitan Policy Program at the Brookings Institution. The 2,497 counties that voted for President Trump account for just 29 percent of gross domestic product (GDP). [Reid Wilson, The Hill, 11/11/20] No surprise. Urban area counties large populations in millions and rural counties have small populations in tens of thousands.
Inovio Pharma up 35% [Nov 10, 20]
Aptevo Therapeutics up 35% [Nov 10, 20]
Luna Innovations up 17% [Nov 10, 20] Reports Strong Third-Quarter 2020 Results
Novavax (Gaithersburg, MD; one 2009 SBIR) has received a crucial status for its Covid-19 vaccine candidate as the pandemic drags on and coronavirus cases once again soar across the country. The Gaithersburg company has earned fast-track designation from the FDA for NVX-CoV2373, a coronavirus vaccine candidate in late-stage development. It means the biotech can submit parts of its application on a rolling basis for a speedier review by the agency, and gives Novavax more direct and frequent access to the FDA. [DCInno, Nov 10, 20]
lying is now such a growth industry it deserves its own G.D.P. line: “Auto sales and durables were each down 10 percent last quarter, but lying grew 30 percent and economists predict that the lying industry could double in 2021.” [Thomas Friedman, NY Times, Nov 11, 20]
Aptevo Therapeutics up 38% [Nov 9, 20]
Arcturus Therapeutics down 45% [Nov 9, 20]
Vaxart down 32% [Nov 9, 20]
Fluidigm down 21% [Nov 9, 20]
Inovio Pharma down 19% [Nov 9, 20]
iRobot down 15% [Nov 9, 20]
Free market success. FWIW: VP Mike Pence tried to take credit on Twitter this morning, citing the White House's Operation Warp Speed "public-private partnership." One big problem with that boast? "We were never part of the Warp Speed," Pfizer's head of vaccine development Dr. Kathrin Jansen told the New York Times. "We have never taken any money from the U.S. government, or from anyone." [DefenseOne, Nov 9, 20]
nLight up 25% [Nov 6, 20]
Liquidia Tech up 19% [Nov 6, 20]
Assembly Biosciences (South San Francisco, CA; no SBIR) down 69% [Nov 6, 20] reported disappointing scientific trial results
Global Blood Thera down 37% [Nov 6, 20]
Anavex Life Sciences down 35% [Nov 6, 20] announced additional details on and presented the results from the proof of concept Phase 2 controlled trial evaluating the safety, tolerability, and efficacy of ANAVEX(R) 2-73 (blarcamesine) in patients with Parkinson's disease dementia (PDD) [company press release, Nov 6, 20]
Epizyme down 24% [Nov 6, 20] announced that the company has entered into an amended and restated agreement with funds managed by Pharmakon Advisors, LP, an affiliate of Royalty Pharma, to expand its loan facility and plans to draw down $150 million. [company press release, Nov 6, 20]
Applied Optoelectronics down 23% [Nov 6, 20] reported quarterly financial results
Everspin Technologies down 23% [Nov 6, 20] reported quarterly financial results
Molecular Templates down 21% [Nov 6, 20] reported quarterly financial results
As the continuing controversy over this week’s U.S. elections demonstrates, faith in the fundamental fairness of democratic institutions is, for many, no longer a given amid a political polarization that often generates echo chambers of conspiracy theories. [Yaroslav Trofimov, Wall Street Journal, Nov 7, 20] Imagined conspiracies can yield endless and comforting delusion as a voting majority calls for soemthing more.
Aptevo Therapeutics up 25% [Nov 5, 20]
II-VI up 19% [Nov 5, 20]
bluebird bio down 17% [Nov 5, 20]
Dewpoint Therapeutics, a Boston-based molecular condensates company, raised $77.1M in equity, according to an SEC filing.
The system worked. If Trump had evidence of real problems or misconduct, he’d be parading it in front of the cameras — and, more important, in front of judges. That hasn’t happened. [Jonathan Bernstein, Bloomberg, Nov 6, 20]
Aptevo Therapeutics (Seattle, WA; no SBIR) up 51% [Nov 4, 20]
Cassava Sciences up 25% [Nov 4, 20]
Even if Trump ends up losing his reelection bid, Trumpism — an unapologetically coarse, swaggering and nasty brand of politics — has been vindicated. Forget competence. Forget dignity. Forget class. Even forget policy (remember Trump’s health care plan that was always just two weeks away from unveiling?). Tribalism is king. Fear clobbers hope. Truth is optional. Character doesn’t count. The guardrails are down. [Eric Zorn, Chicago Tribune, Nov 5, 20]
Aptevo Therapeutics (Seattle, WA; no SBIR) up 78% [Nov 3, 20] announce that, based on preliminary data, a patient in cohort 6 of the clinical trial has shown complete remission. [company press release, Nov 3, 20]
SQZ Biotech (Watertown, MA; $1.7M SBIR), raised $71 million in its NYSE [IPO] debut. [Amirah Al Idrus, Fierce Biotech, Oct 30, 20] We physically squeeze cells at high speeds through a microfluidic chip, temporarily opening the cell membrane and enabling biologic material of interest, or cargo, to diffuse into the cell before the membrane reseals. This technology allows us to create a broad pipeline of product candidates for different diseases. [company website]
Liquidia Tech down 28% [Nov 2, 20]
Applied Technology Associates (Albuquerque, NM; $39M SBIR) announced it's joining the formation of BlueHalo, a leading provider of advanced engineering solutions and technology to the national security community. BlueHalo was formed through the combination of AEgis Technologies (Albuquerque, NM; $22M SBIR), including its previously integrated acquisitions Excivity (Birmingham, AL; no SBIR) and EMRC Heli (no SBIR) , and its recently announced acquisition of Brilligent Solutions (Fairborn, OH; one SBIR). [ATA press release, Oct 29, 20]
Got no case. “There is no evidence that any election worker did anything outside of the law, policy, or procedures,” the judge wrote. Judge Wilson also said the plaintiffs didn’t have standing to bring the challenge because they didn’t show they were harmed. [Brent Kendall and Sara Randazzo, WSJ, Nov 3, 20] Wishful imagination doesn't sell as evidence.
Vedere Bio (Cambridge, MA; no SBIR) stealthy startup focused on restoring functional vision from blindness, was acquired by Novartis for $150M upfront. The startup will be eligible for up to $130M in milestone payments, for a total of $280M. [BostInno, Oct 30]
Now, there are so many cases, in so many places, that many people are coming to a frightening conclusion: They have no idea where the virus is spreading. [Sarah Mervosh and Lucy Tompkins, NY Times, Oct. 31, 20] Protect yourself: assume everyone you see is infectious. Any infection you contract has a non-zero probability of causing long term damage to your body. Don't beileve anything you hear from the White House.
Unk-unks. “We don’t know for sure what we don’t know,” said Dr. Edward Lifshitz, medical director of the Communicable Disease Service at the New J ersey Department of Health, which doesn’t publicly report antigen positive cases because the figure is incomplete. [Amy Schoenfeld Walker, Lisa Waananen Jones and Jugal K. Patel, NY Times, Nov. 1, 2020]
From gerrymandering to voter roll purges, we showed people around the world how the American system works. It didn’t go well. [video by Chai Dingari, Brendan Miller, Adam Westbrook and Emily Holzknecht, NY Times, Nov 2, 20] And Trump Backers Block Highways and Democratic buses, as the end justifies the means, which has been going on since the election of 1796.
Novavax expects to start its pivotal trial for its Covid-19 vaccine candidate in the U.S. and Mexico by the end of November, rather than mid-October as originally planned, after both “significant progress in large-scale manufacturing” and “delays experienced versus original timing estimates,” the Gaithersburg biotech said [DCInno, Oct 29, 20]
Micronic Technologies (Bristol, VA, $800K SBIR, founded 2008) announced $3 million seed round investment to develop a breakthrough Zero Liquid Discharge (ZLD) water purification technology that reduces wastewater volume by 95% and removes over 99% of contaminants in a sustainable and cost-effective way that hasn’t been achievable until now. [Virginia CIT press release, Oct 21, 20]
Targets of opportunity. Whatever happens during the U.S. election next week, the political party that loses the presidency is likely to lay the blame at least partly at the feet of the country’s social media giants—either for doing too much or not doing enough. That means scenes like Wednesday’s hearing battering the tech CEOs will remain a favored political pastime for the foreseeable future. [Sarah Frier, Bloomberg, Oct 29, 20] The workings of the Congress have depended on Republican fear of Trump's single-minded political base that cares not for an adult approach to serious questions of governance. The pending election will answer how acceptable that worship is to the other 70% of the electorate. VOTE safely and countably.
Exact Sciences up 23% [Oct 27, 20]
Catabasis Pharmaceuticals down 71% [Oct 27, 20]
Kala Pharmaceuticals (Watertowwn, MA; $400K SBIR) down 19%[Oct 27, 20] announced that the [FDA] approved EYSUVIS (loteprednol etabonate ophthalmic suspension) 0.25% for the short-term (up to two weeks) treatment of the signs and symptoms of dry eye disease. [company press release, Oct 27, 20]
Sirnaomics (Gaithersburg, MD; $1.2M SBIR) announced that it has sealed its USD$105 million Series D financing [to] to fund continued development of its novel RNAi therapeutics for treatment of diverse human disorders, including cancers, fibrosis diseases, metabolic diseases and viral infections. [company press release, Oct 22, 20]
Trump aides and allies increasingly acknowledge that anyone who is seriously concerned about the virus threat won’t vote for Trump anyway. [Politico, Oct 28, 20]
Bayer AG (Germany) said it would pay as much as $4 billion for U.S. biotech firm Asklepios BioPharmaceutical (Chapel Hill, NC; $3.4M SBIR) to strengthen the German company’s drugmaking arm... for which Bayer will pay $2 billion now and as much as a further $2 billion based on future success milestones—is a bet on cutting-edge gene therapy, in which a functional gene is inserted to counter the effects of a disease caused by a missing or faulty gene. [Bayer press release, Oct 27, 20]
Catabasis Pharmaceuticals said the Phase 3 PolarisDMD trial of edasalonexent in Duchenne muscular dystrophy did not meet the primary endpoint, which was a change from baseline in the North Star Ambulatory Assessment over one year. The secondary endpoint of timed function tests also did not show statistically significant improvements, the company said. Consequently, the company said it is stopping activities related to the development of edasalonexent, including the ongoing GalaxyDMD open-label extension trial. Catabasis also said it plans to work with external advisors to explore and evaluate strategic options going forward. [Yahoo Finance, Oct 27, 20]
Exact Sciences and Thrive Earlier Detection (Cambridge, MA; no SBIR), a healthcare company dedicated to incorporating earlier cancer detection into routine medical care, announced they have entered into a definitive agreement under which Exact Sciences will acquire Thrive for cash and stock consideration of up to $2.15 billion. [joint companies press release, Oct 27, 20]
XOMA up 14% [Oct 23, 20]
CyberOptics down 29% [Oct 23, 20] reported increased sales and a net profit [company press release, Oct 22, 20]
Credit card stretching. White House officials and House Speaker Pelosi are closing in on a nearly $2 trillion deal to provide another round of stimulus checks, reinstate extra weekly unemployment benefits and extend aid for small businesses, airlines and state and local governments. [Wall Street Journal, Oct 24, 20] How much credit card debt can this household afford to maintain its life syle? Would the answer be different if this were not a presidential election timer? Would you buy a federal bond at less than 1% interest to support this spending?
It sounded so good. President Trump’s trade war against China didn’t achieve the central objective of reversing a U.S. decline in manufacturing, economic data show, despite tariffs on hundreds of billions of dollars of Chinese goods to discourage imports. [Josh Zumbrun and Bob Davis, Wall Street Journal, Oct 26, 20] As always, be wary of politicians' economic claims supported by hand-picked advisors.
A federal health agency halted a public-service coronavirus advertising campaign funded by $250 million in taxpayer money after it offered a special vaccine deal to an unusual set of essential workers: Santa Claus performers. ... chairman of the Fraternal Order of Real Bearded Santas, called the news “extremely disappointing,” [Wall Street Journal, Oct 26, 20]
If leaders won't do it, why should we? Vice President Mike Pence plans to maintain an aggressive campaign schedule this week despite an apparent outbreak of the coronavirus among his senior aides, the White House says. [AP, Oct 26, 20] No wonder that ccntact tracing and quarantine isn't working in America, With the coronavirus spreading out of control in many parts of the United States and daily case counts setting records, [a 40 percent rise in the past month] health experts say it is only a matter of time before hospitals reach the breaking point. [New York Times, Oct 26, 20], it's downright inconvenient for people who love to gather.
Safety first. “You can’t just open the economy and expect everything to go back to pre-Covid levels,” said Michael Luca, a Harvard Business School economist who has studied the impact of restrictions during the pandemic. “If a market is not safe, people won’t participate in it.” [Ben Casselman and Jim Tankersley, NY Times, Oct 22, 20]
Organovo Holdings (Solana Beach, CA; $2.4M SBIR) up 30% [Oct 21, 20]
Coapt (Chicago, IL; $2.4M SBIR), a startup creating technology that turns prosthetic arms and hands into fully-functioning body parts, announced Wednesday that it received $2.3 million from the DoD to develop virtual reality and hardware-based therapies that help war vets with pain related to the loss of their arms or legs. [Jim Dallke, Chicago Inno, Oct 21, 20]
Peak Nanosystems subsidiary PolymerPlus (Valley View, OH; $2.5M SBIR), a military material R&D company that was acquired by Peak in April, landed a $5 million five-year contract from the U.S. Army to develop plastics that can be used in military armor and transportation, in a partnership with Case Western Reserve University and the Army Combat Capabilities Development Command’s Army Research Laboratory. [Kevin Cummings, North Texas Inno, Oct 1, 20]
SK hynix and Intel announced that they have signed an agreement under which SK hynix would acquire Intel’s NAND memory and storage business for US $9 billion. ... Intel intends to invest transaction proceeds to deliver leadership products and advance its long-term growth priorities, including artificial intelligence, 5G networking and the intelligent, autonomous edge. [joint companies press release, Oct 20, 20] A repeat of Intel's dumping the DRAM business three decades ago to Japan. Its new plan to focus on software abandons its historic success in hardware.
It’s the economy, stupid.[James Carville, 1992] Apparently not in 2020 where people like Trump's economy, as they ignore the debt growth, but plan to vote otherwise according to the polls. pollster Peter Hart, who helps oversee the Journal/NBC News poll, says that as Americans already are standing in long lines to cast ballots, 2020 is a year in which voters see the broader course of the country as the real issue. [Gerald F. Seib, WSJ, Oct 19, 20] The monetary pumping of the economy with liquidity and government debt may become the burning issue by the next big election in 2024.
As Trump made clear to his campaign staffers, his notion of freedom means the right to ignore rules meant for the common good. [David Knowles, YahooNews, Oct 19, 20]
Calyxt down 21% [Oct 16, 20]
Biomerica down 20% [Oct 16, 20]
Solarea Bio (Cambridge,MA; no SBIR) which is developing microbiome-based therapeutics, disclosed the investors in its $11.2M Series A round [BostInno, Oct 19, 20]
With all the disparate vaccine trials under way, we will eventually invent several vaccines, of varying effectiveness—just not in time to make a major difference in the primary course of the pandemic. But vaccine uptake may not be rapid or widespread, especially if its safety is in doubt. [Nicholas Christakis, WSJ, Oct 16, 20]
The frequency of the word “I” in American books, according to Putnam and Garrett, doubled between 1965 and 2008. [David Brooks, NY Times, Oct 16, 20]
Research at Boston University’s National Emerging Infectious Diseases Laboratories has shown the Klaran UVC LEDs made by Crystal IS (an Asahi Kasei company, Green Island, NY; $2.4M SBIR) can inactivate the SARS-CoV-2 virus, The Crystal IS product produces a type of ultraviolet light that inactivates viruses and bacteria. Its customers are companies that use the LEDs to make disinfecting products. [Justin Dawes, Albany Business Review, Oct 15, 20],/
“We are staring down the barrel of a blue tsunami,” [the Senator] added. [NY Times, Oct 15, 20] Remember that English, including mataphors, is a living language always in flux.
Vote now. A tenth of the expected electorate has already voted to avoid the probable mess on November 3. The shortage of election poll workers [election judges] and the Trump threatened trouble-making foretell a situation to avoid. Avoid rubbing up against strangers during a pandemic. Vote in person or file an absentee ballot either by mail or at an official ballot dropbox.
Oncorus (Cambridge, MA; $300K SBIR, IPO Oct 1, 20) up 24% [Oct 14, 20]
Protective nanocoating company actnano (Boston, MA; no SBIR, founded 2012) announced that it has raised $12M in a Series A funding round. ...is setting a new standard for electronics protection with its commercialized water and environmental resistant coating technology, Advanced nanoGuard™ (ANG). [company press release, Oct 13, 20] More nano-wonder products adding to a potential serious health hazard, although the company claims human-safe, non-toxic and environmentally sustainable.
ADVENT TECHNOLOGIES (Madison, AL; one SBIR) an eight-year-old startup developing fuel cell technology as alternative source of energy for transportation, aviation and off-grid power generation, plans to go public via a reverse merger. [Rowan Walrath, BostInno, Oct 14, 20]
After four years of parrying with President Donald Trump, the Chinese leader shows no intention of scaling back his ambitions to supplant the U.S. as the dominant tech power. [Bloomberg Politics, Oct 15, 20] The core question is do we have the political and industrial leadership to defend our economic security with any national strategy that requires teamwork in a bitterly polarized free-fire zone.
Liquidia Tech down 30% [Oct 13, 20]
Vaxart, a clinical-stage biotechnology company developing oral vaccines that are administered by tablet rather than by injection, announced that the first subject has been dosed in its Phase 1 study of VXA-CoV2-1, an oral tablet COVID-19 vaccine candidate. [company press release, Oct 13, 20]
Spoke out, thrown out. Dr. Rick Bright, ousted vaccine director turned whistleblower, told CNN on Thursday that Trump saying you shouldn’t be afraid of the coronavirus after he was released from Walter Reed National Military Medical Center was “probably the most reckless and deadly piece of information I have ever heard.” Earlier this week Bright resigned from his position at the National Institutes of Health where he had been reassigned following his whistleblower complaint. [govexec.com, Oct 13, 20] If you blow a whistle in .gov, be prepared for a lonely existence out of sight. Look up the long lonely second DOD career, with secretary, of A. Ernest Fitzgerald.
When McKinley defeated Bryan (1896), more than 40% of Americans worked on farms. Today, even though farm production and exports have soared, only 1.5% of the workforce is in agriculture. Manufacturing employment, which constituted more than 30% of the U.S. workforce in the 1950s, has declined to 8.8%, even as rising productivity allows industry to produce more with fewer workers. And despite Mr. Trump’s campaign promises, coal-mining jobs hit a new low in 2019. A new economy more focused on information and services is coming for reasons largely unrelated to public policy. [William Galston, WSJ, Oct 14, 20] The danger is growing for Trump's uneducated laborers who will be outvoted by the growing class of the educated who will reject Trump's lowball tactics and attitudes.
According to the Johns Hopkins coronavirus tracker, America has suffered 65.74 Covid deaths per 100,000 people, or about 216,000 total. China has lost 0.34 per 100,000, or about 4,750 people. Maybe China’s fibbing. OK — so quadruple its numbers — China still has been vastly better at protecting its people than the United States. [Thomas Friedman, NYT, Oct 14, 20]
StemPharm (Madison, WI; $1M SBIR) wins $100K award [from a combination of state and federal funds, to commercialize their [SBIR] innovations], leverages its expertise in biomaterials and cellular interactions to develop high-value applications of organoids (3D in vitro models) for drug discovery and cell-friendly coatings for the manufacture of cell-based therapies. [Brandon Anderegg, Milwaukee BizTimes, Sep 30, 2020]
If one is good, two is better. Novavax, developing next-generation vaccines for serious infectious diseases, announced the formation of a leadership team to advance NanoFlu to regulatory licensure and the promotion of Russell (Rip) Wilson, [to inter alia] the exploration of a combined influenza/COVID-19 vaccine that could be used in a post-pandemic setting. Novavax announced results of its successful NanoFlu pivotal Phase 3 clinical trial earlier this year and intends to seek regulatory approval from the U.S. Food and Drug Administration (FDA) under the accelerated approval pathway previously granted to the company. [company press release, Oct 12, 20]
Libertarian Spirit. But this time—unlike in the spring—public-health experts broadly and increasingly agree, with some worried that the general public won’t cooperate with another monthslong, generalized lockdown against a disease whose transmission is now much better understood. [Drew Hinshaw, Wall Street Journal, Oct 13, 20]
Wisconsin officials have denied a request by Foxconn Technology Group [China] for the first payments in what had been envisioned as $3 billion in state subsidies for a major technology complex. [Wall Street Journal, Oct 13, 20]
Disproof by contradiction. Researchers report first death from coronavirus reinfection. [Washington Post, Oct 13, 2020] While Trump claims immunity in his fantasy rallies.
“Half the world is redoing its kitchens, the other half is starving,” DeLillo wrote in “Zero K” (2016). [Dwight Garner, reviewing DeLillo's latest novel The Silence, NY Times, Oct 6, 20]
After helping Moderna push a respiratory syncytial virus (RSV) vaccine for adults into the clinic, Merck is calling it quits. The Big Pharma is doubling down on its in-house RSV antibody and will see Moderna’s jab through the phase 1 trial before handing back the rights to the program. Moderna welcomes the program, mRNA-1172, back into its prophylactic vaccine pipeline, where it joins mRNA-1345, an RSV vaccine for children that just began a phase 1 study. [Amirah Al Idru, Fiece Biotech, Oct 8, 20]
Walden Biosciences (Cambridge, MA; no SBIR), a biotechnology company focused on transforming the treatment of kidney disease, announced its launch with a $51 million Series A financing [to] develop breakthrough medicines that reverse the progression of both rare and common forms of kidney disease and restore renal function. [company press release, Oct 6, 20]
Avrobio has licensed a Hunter syndrome lentiviral gene therapy from the University of Manchester in the U.K. The deal positions Avrobio to join Regenxbio and Sangamo Therapeutics in the race to develop gene therapies for use in patients with the rare disorder. Hunter syndrome, also known as mucopolysaccharidosis Type II, is driven by a mutation that limits a patient’s ability to break down sugar molecules generated as a byproduct of cell activity. [Nick Paul Taylor, Fierce Biotech, Oct 5, 20]
Applied Technology Associates (Albuquerque, NM; $39M SBIR) wins $100M in Air Force contracts [Collin Krabbe, Albuquerque Business First,Oct 9, 20] Well, as long as it is paid for with R&D funds, the agency can fund any SBIR-qualified firm as much as it wants as often as it wants. And as long as the SBIR firms get the total annual mandated amounts, Congress will not intevene after three decades.
“Now we have tens of thousands of people getting convalescent plasma” — a Covid-19 treatment that was granted an E.U.A. in August — “and we still don’t know whether it works,” [Dr. Jesse Goodman, F.D.A.’s chief scientist from 2009 to 2014] said. [Robert P. Baird, NYTimes, Oct. 10, 20] Now we also have a politically desperate politician who got the treatment threatening a command directive to allow it widely, regardless of FDA legally required decision.
Cytokinetics down 42% [Oct 8, 20] announced topline results from GALACTIC-HF, a Phase 3 pivotal clinical trial of omecamtiv mecarbil in patients with heart failure with reduced ejection fraction (HFrEF). The results of GALACTIC-HF show that treatment with omecamtiv mecarbil achieved the primary composite efficacy endpoint and demonstrated a statistically significant effect to reduce cardiovascular (CV) death or heart failure events (heart failure hospitalization and other urgent treatment for heart failure) compared to placebo in patients treated with standard of care (HR: 0.92; 95% CI: 0.86, 0.99, p=0.0252). No reduction in the secondary endpoint of CV death was observed. [company press release, Oct 7, 20]
financial insecurity: By the time the Baby Boomers hit a median age of 35, their generation owned 21 percent of the nation’s wealth. As of last year, Millennials—who will hit an average age of 35 in three years—owned just 3.2 percent of the nation’s wealth. [David Brooks, NY Times, Oct 8, 20]
Ocular Therapeutix up 29% [Oct 7, 20]
Janpix (Cambridge,MA; no SBIR) a biotech company developing monovalent small molecule protein degraders of STAT proteins as novel therapeutics, closed a $10M Series B round [BostInno, Oct 7, 20]
While politicians spar. Economists are dialing back their forecasts for U.S. economic growth as prospects fade for a renewed round of government stimulus. [Jeffrey Sparshott, WSJ, Oct 8, 20] With enough stimulus, we could declare a semi-socialist government to guarantee jobs for all. Republican Senators are torn between helping low income constituents and undercutting their free market religion protecting corporate interests that support that senatorial religion. This problem might have been substantially lessened if the adminstration had taken a serious approach to controlling the pendemic.
Molecular engineering company Scribe Therapeutics ($300K SBIR) has entered into a research collaboration with Biogen for the development of CRISPR-based genetic medicines for neurological diseases. Scribe will secure $15m upfront payment and is eligible to receive over $400m in potential development and commercial milestone payments between on the two targets of interest. [Pharmaceutical Business Review Oct 7, 20]
The motto of England’s Royal Society, founded in 1660, is “Nullius in verba”: “Take nobody’s word for it.” [Jennifer Szalai reviewing The Knowledge Machine: How Irrationality Created Modern Science By Michael Strevens, New York Times, Oct 8, 20]
ChromaDex (Los Angeles, CA; $800K SBIR) up 28% [Oct 6, 20] announced that results from the study "Combined metabolic cofactor supplementation accelerates recovery in mild-to-moderate COVID-19" were published on the open access preprint publication server medRxiv.org. The Phase 2 study reported patients with mild-to-moderate COVID-19 experienced a 29% reduction in recovery time when receiving the standard of care in combination with a nutritional protocol including nicotinamide riboside (NR). [company press release, Oct 6, 20]
Celldex Therapeutics up 19% [Oct 6, 20]
Cytokinetics up 19% [Oct 5, 20]
coronavirus vaccine developer Moderna has now explicitly said that its vaccine will not be ready by the election. [BostInno, Oct 5, 20]
Scribe Therapeutics (Alameda, CA; $300K SBIR), focused on engineering the most advanced platform for CRISPR-based genetic medicine, unveiled its vision for highly efficient and specific in vivo genome modification. Since launching out of UC Berkeley’s Doudna Lab, Oakes Lab, and the Innovative Genomics Institute in late 2018, Scribe utilized an initial $20 million Series A round to further develop a custom platform of gene editing and delivery technologies that will revolutionize genetic medicine. [company press release, Oct 6, 20]
Walden Biosciences (Cambridge, MA; no SBIR), focused on transforming the treatment of kidney disease, announced its launch with a $51 million Series A financing [to] develop breakthrough medicines that reverse the progression of both rare and common forms of kidney disease and restore renal function. [company press release, Oct 6, 20]
If you can't stand the answer... The White House has decided not to trace the contacts of guests and staff members at the Rose Garden celebration 10 days ago, where at least eight people, including the president, may have become infected, according to a White House official familiar with the plans [New York Times, Oct 6, 20] ... don't ask the question.
C4 Therapeutics (Watertown, MA; no SBIR) up 34% [Oct 2, 20] priced its [IPO] for $182.4 million [to] to support the development of its multiple degrader drug candidates to human proof-of-concept [company press release, Oct 2, 20]
Solid Biosciences up 21% [Oct 2, 20]
Immunome (Exton, PA; $300K SBIR) a biopharmaceutical company utilizing a proprietary human memory B cell platform to discover and develop first-in-class antibody therapeutics designed to change the way diseases are currently being treated, announced the pricing of [IPO] to raise $39M. [company press release, Oct 1, 20]
Liberate liberty and help the hospital biz. The decisions [in several states] to end restrictions come as the number of new cases confirmed every day begins to rise once again. [Reid Wilson, The Hill, Oct 3, 20]
Synthetic Biologics (Rockville, MD; no SBIR), a diversified clinical-stage company leveraging the microbiome to develop therapeutics designed to prevent and treat gastrointestinal ("GI") diseases in areas of high unmet need, announced [that] it was concluded that although SYN-010 was well-tolerated, it is unlikely to meet its primary objective by the time enrollment is completed. As a result, CSMC has agreed to discontinue the trial and will conduct a comprehensive review of the final data set and publish its findings. [company press release, Oct 2, 20]
PhotoniCare (Champaign, IL; $4M prior SBIR) startup making ear imaging technology raised $5.2 million in a Series A round In addition to the funding, PhotoniCare also received a $2.1 million [NIH] Phase II SBIR [which] brings PhotoniCare’s total funding to more than $12 million, according to Crunchbase. [Chicago Inno, Oct 1, 20]
Presidential trials. There are no approved treatments for Covid-19, but the Regeneron [antibody cocktail] treatment is one of the most promising candidates, along with another antibody treatment developed by Eli Lilly. Both are being tested in patients around the country. ... Mr. Trump was also taking zinc, vitamin D, melatonin, a daily aspirin and famotidine, [none of which have yet proved effective]. During the pandemic, Mr. Trump has promoted a range of unproven or scientifically questionable treatments for the virus, and himself took the malaria drug hydroxychloroquine in the hopes that it could prevent infection .... Mr. Trump in 2018 signed the Right to Try law, which allows patients and their doctors to directly request an experimental treatment from a company, without first seeking approval from the F.D.A [Katie Thomas and Gina Kolata, NY Times, Oct 3, 20]
Political medicine. Senior White House officials have raised objections to [FDA]’s proposed standards for deciding whether a Covid-19 vaccine should be given widely and don’t appear likely to sign off on the agency’s guidelines, people familiar with the matter said. [Wall Street Journal, Oct 3, 20] Any electoral impact of a vaccine announcement has probably already come and gone.
Virus repugnant to command (Shakespeare). The French government will shut bars and impose other restrictions in the Paris region from tomorrow as authorities struggle to contain a spike there. New curbs are also expected to be announced in Ireland and Italy. U.K. Prime Minister warned of a "tough winter" as the country's test-and-trace system came under fire again after it failed to capture 15,000 positive tests last week. [Bloomberg, Oct 5, 20]
Solid Biosciences (Cambridge, MA; no SBIR) up 70% [Oct 1, 20] announced that [FDA] has lifted the clinical hold placed on the Company's IGNITE DMD Phase I/II clinical trial. [company press release, Oct 1, 20]
AMAG Pharma up 45% [Oct 1, 20] Covis Group (Belgium) and AMAG Pharmaceuticals announced that they have entered into a definitive agreement under which Covis will acquire AMAG for [$498 million] on a fully diluted basis and approximately $647 million on an enterprise basis, including debt obligations expected to be assumed or repaid net of cash. [joint companies press release, Oct 1, 20]
Logic Bio down 32% [Oct 1, 20] announced the pricing of its previously announced underwritten public offering
One study looked at the 210 drugs approved by the [FDA[ from 2010 to 2016 and found that “NIH funding contributed to every one.” For too long, governments have socialized risks but privatized rewards. [Mariana Mazzucato, Foreign Affairs, Oct 2, 20]
MIT Technology Review is launching the Outcome, a pop-up newsletter focused on the security and integrity of the election. It will cover topics such as misinformation, voting machines, and cybersecurity, but above all it will ask the same questions of the election that we ask of every technology: Is it working as intended? [MIT Tech Review, Oct 2, 20]
Debate watchers were confronted with a core truth: What Trump did to that debate Tuesday night is what he’ll do to America in a second term. ... Abraham Lincoln’s Secretary of State William Seward made the essential point: “There was always just enough virtue in this republic to save it; sometimes none to spare.” [David Brooks, NY Times, Oct 1, 20]
Ingenia Therapeutics (Cambridge, MA; no SBIR) raised $4.7M [SEC filing]
Tetragenetics (Arlington, MA; $4M SBIR in New York) which focuses on autoimmune disease and pain targets leveraging recombinant ion channel expression, raised $1M in debt in a $2M funding round, per an SEC filing. [Rowan Walrath, BostInno, Sep 29] 20]
AeroVironment (SIMI VALLEY, CA; $24M SBIR) a global leader in unmanned aircraft systems (UAS), announced a teaming agreement with Robotic Skies (Chicago, IL; no SBIR), a global maintenance, repair, and overhaul network for UAS, to provide field maintenance, inspection and repair support for AeroVironment customers. [joint companies press release, Sep 29, 20]
AXT (Fremont, CA; $2M SBIR as American Xtal in 1990s, founded 1986, 730 employees) up 20% [Sep 29, 20]
Adicet Bio up 19% [Sep 29, 20]
Dewpoint Therapeutics (Boston,MA; no SBIR), the biomolecular condensates company, announced it has raised $77 million in a Series B financing [to] further develop its platform and identify additional compounds that modulate these condensates. [company press release, Sep 29, 20]
Babson Diagnostics (Austin, TX), a transformative medical technology company, announced it closed $13.7 million in cumulative Series A funding. Originally incubated at Siemens Healthineers and developed in partnership with Becton Dickinson, Babson’s disruptive technology is designed to analyze capillary blood samples using only one-tenth the volume typically collected with venipuncture without sacrificing quality, accuracy, or menu breadth, all from a simple finger stick. [company press release, Sep 24, 20]
Optimism abounds: Moderna’s shares have more than tripled so far this year, while Novavax stock has surged more than twentyfold. The so-called “vaccine trade” has become very popular with retail investors. After all, the federal government has opened its checkbook to companies trying to develop vaccines. What’s more, the total addressable market includes all of humanity, at least in theory. [Charley Grant, Wall Street Journal, Sep 29, 20] Megamoney from Uncle Sam's enthusiasm for spending and borrowing to keep the economy pumped up in an election year. Classic spend, spend, elect, elect.
In the last week, leading epidemiologists from respected institutions have, through different methods, reached the same conclusion: About 85 to 90 percent of the American population is still susceptible to SARS-CoV-2, the virus causing the current pandemic. [Donald G. McNeil Jr., NY Times, Sept. 29, 2020]
Anavex Life Sciences up 20% [Sep 28, 20]
Celldex Therapeutics up 17% [Sep 28, 20]
Inovio Pharma (Plymouth Meeting, PA; $1.3M SBIR) down 28% [Sep 28, 20] placed its vaccine trial on hold as it announced that [FDA] notified the company it has additional questions about the company's planned Phase 2/3 trial of its COVID-19 vaccine candidate INO-4800, including its CELLECTRA(R) 2000 delivery device to be used in the trial. [company press release, Sep 28, 20]
Medical device startup Longeviti Neuro Solutions (Cockeyville, MD; no SBIR, founded 2016) secures $6M in new funding [Morgan Eichensehr, Baltimore Business Journal, Sep 23, 2020] collaborates closely with industry and academia to develop and commercialize implantable neurosurgical devices [company website]
ARCA Biopharma [Westminster, CO; no SBIR, 13 employees) Announces Submission of IND [FDA] Application [to] evaluate the use of one of Arca Biopharma's drugs, AB201, as a treatment for patients hospitalized with Covid-19. [company press release, Sep 23, 20]
PMV Pharmaceuticals (Cranbury, NJ; no SBIR) up 108% [Sep 25, 20], a precision oncology company pioneering the discovery and development of small molecule, tumor-agnostic therapies targeting p53 mutations, announced the pricing of its [IPO] to raise $212M [company press release, Sep 25, 20]
Cassava Sciences up 18% [Sep 25, 20]
Exact Sciences up 275 [Sep 24, 20] after the company’s" CEO offered" favorable early-stage results of a blood-based screening test for some major cancers at an industry conference [Barron's, Sep 24 20]
Vaxart down 18% [Sep 23 20]
Seattle Genetics and Astellas Pharma (Japan) announced that a phase 3 trial of PADCEV® (enfortumab vedotin-ejfv) met its primary endpoint of overall survival compared to chemotherapy [with] with a 30 percent reduction in risk of death (Hazard Ratio [HR] [joint companies press release, Sep 25, 20]
Prelude Therapeutics (Wilmington, DE; no SBIR) cancer drug developer, priced its IPO at $19 per share, raising $158.2 million. [xconomy.com, Sep 25, 20]
Conflict of Interest. Trump’s Vaccine Czar Refuses to Give Up Stock in Drug Company Involved in His Government Role. [Isaac Arnsdorf, ProPublica, govexec.com, Sep 25, 20] calls him a "contractor" who would therefore be a czar with no power to issue directions to government. Would you accept a small biz tech contractor in your field picking SBIR winners?
MediciNova down 22% [Sep 24, 20] announced positive clinical findings published in Cancer Chemotherapy and Pharmacology regarding MN-166 (ibudilast) as a treatment for prevention of chemotherapy-induced peripheral neuropathy (CIPN). [company press relese, Sep 24, 20]
Cedilla Therapeutics (Cambridge, MA; no SBIR), a startup focused on diseases caused by protein dysregulation, raised $30.4M in equity in a $60M funding round, per an SEC filing. [Rowan Walthrup, BostInno, Sep 24, 20] launched previously launched with $56.2 million in Series A funding [company website]
FluGen (Madison, WI; $4.4M SBIR) is developing M2SR, an influenza vaccine that is currently in human trials. FluGen Inc specializes in the fusion on intradermal delivery and vaccine biology. They are committed to forging a new and more effective weapon in the fight against influenza. [Wisconsin Inno, Sep 25, 20]
companies that seem to use SBIR awards as a primary revenue stream rather than a means to creating future revenue paths through new product and process innovations persist, based on SSTI’s review of award data. Known as “SBIR mills” many of these companies appear to be clustered geographically in specific metropolitan areas, many of which house major federal labs or research centers, the analysis of SBIR data reveals. This suggests, from a policy perspective, that the federal agencies could be doing much more to curtail the mills and redirect awards into companies more consistently focused on turning innovation into products, profits and jobs [SSTI, Sep 23, 20] The problem persists in "mission agencies" wherein the agency is doing R&D to fill its own technology needs, and therefore prefers reliable contractors and predictable results. In contrast, NIH has a long list of SBIR big successes as demonstrated by reports in the business press of companies being acquired for billions. Will it continue? Of course, as long as the small biz world gets its annual handout that Congresscritters can claim at election time.
Never so low. The Trump administration’s bungled response to the coronavirus pandemic and its subsequent efforts to meddle with recommendations from the Centers for Disease Control and Prevention (CDC) are taking a substantial toll on the nation’s foremost public health institution. In interviews with half a dozen current and former CDC officials, they described a workforce that has seen its expertise questioned, its findings overturned for political purposes and its effectiveness in combating the pandemic undermined by partisan actors in Washington. “I have never seen morale this low. [Reid Wilson, The Hill, 09/23/20] An irresponsible force feeding a gullible audience. Elections have consequences. But the administration may have so undercut public faith in the virus struggle that it will gain nothing when it announces total victory is a new vaccine.
Vaccinex (Rochester, HY; $4.4M SBIR) down 58% [Sep 22, 20] Although the study did not meet pre-specified co-primary endpoints, the results of each of the two cognitive assessments demonstrated a strong trend for beneficial change (OTS, p=0.028 and PTAP, p=0.06). These cognitive assessments reflect changes in planning ability and memory associated with disease progression. [company press release, Sep 22, 20]
Adicet Bio down 25% [Sep 22, 20] Determines Not to Proceed with Public Offering of Common Stock [company press release, Sep 22, 20]
Cardiff Oncology up 33% [Sep 21, 20]
Adicet Bio down 37% [Sep 21, 20] announced sale of oommon stock
Illumuina a leading maker of the machines that sequence genes, said it will pay $7.1 billion in cash and stock for a developer of a long-sought blood test that promises to detect cancer early. The deal for the part of Grail Inc. that Illumina doesn’t already own will move the company deeper into the application of its gene-sequencing technology to the diagnosis and treatment of patients, a potential multibillion-dollar market. Illumina founded Grail four years ago and owns a large stake in the company. [Jonathan D. Rockoff, Wall Street Journal, Sep 21, 20]
PhotoniCare (Champaign, IL; $4M SBIR) dedicated to revolutionizing healthcare by providing physicians with better diagnostic tools, announced an oversubscribed $5.2 million Series A financing [to] expand PhotoniCare’s executive team, ramp up manufacturing, execute on the company’s sales and marketing plan, fuel artificial intelligence development to enable real-time decision support for the TOMi Scope, and expand reimbursement activities and customer support [company press release, Sep 3, 20]
Triumvira Immunologics (Austin, TX and Germany; no SBIR) biopharmaceutical developing a novel platform for engineering T-cells to attack cancers, successfully completed a USD $55 million Series A financing [to] to advance multiple autologous and allogeneic programs into the clinic for solid tumors and hematologic malignancies. [company press release, Aug, 27, 20]
each of the top 11 states in per-capita [Covid-19] cases voted for Trump in 2016. [Jonathan Bernstein Bloomberg, Sep 22, 20]
Moderna said data should be reported by year-end or early next year, Moderna’s protocol also gave more color, saying its first analysis of early trial data might not be conducted until late December, although company officials now say they expect the initial analysis in November. In terms of how it’s measuring efficacy, a total of 151 COVID-19 cases “will provide 90% power to detect a 60% reduction in hazard rate (60% vaccine efficacy [VE]), rejecting the null hypothesis,” it said in its protocol. “This is a case-driven study,” Moderna’s protocol said. [Ben Adams, Fierce Biotech, Sep 18, 20] Meanwhile, Trump's tongue is hanging out for any table scrap of data that could be conceivably claimed as the decisive nation-saving vaccine.
Moderna has landed R&D deals with Vertex and Chiesi worth $100 million upfront. Vertex struck the larger of the two pacts, agreeing to pay Moderna $75 million to collaborate on gene editing cystic fibrosis therapies. Through the Vertex agreement, Moderna will discover and optimize lipid nanoparticles (LNPs) for the treatment of cystic fibrosis. Using the LNPs, the partners aim to get gene editing therapies to lung cells and, in doing so, enable the expression of functional cystic fibrosis transmembrane conductance regulator (CFTR) protein. [Nick Paul Taylor, Fierce Biotech, Sep 17, 20]
Synthekine (Menlo Park, CA; no SBIR) an engineered cytokine therapeutics company, announced the closing of an $82 million Series A financing [to] to leverage discoveries showing that cytokines can be tuned to enhance their therapeutic effects. [company press release, Sep 17, 20]
Some members of the Trump administration are already discussing the pandemic in the past tense. So if the president wins re-election, the federal response is unlikely to change. We’ll continue relying on individual states, cities, schools and businesses to manage the crisis on their own until a vaccine curbs the virus. Mistrust between the White House and the nation’s leading scientific institutions is likely to persist. [NYTimes, Sep 18, 20]
Cardiff Oncology (San Diego, CA; no SBIR) up 40% [Sep 17, 20], a clinical-stage oncology therapeutics company developing drugs to treat cancers with the greatest medical need for new treatment options, including KRAS-mutated colorectal cancer, castration-resistant prostate cancer and leukemia, today announced an electronic poster presentation of clinical data further demonstrating the safety, efficacy and durability of response of onvansertib in KRAS-mutated metastatic colorectal cancer (mCRC) patients [company press release, Sep 17, 20]
Free Form Fibers (Saratoga Springs, NY; $4.3M SBIR, founded 2009) says it is nearly ready to sell [CVD formed fiber] product a decade in the making [Justin Dawes, Albany Business Review, Sep 15, 20]
CoapTech (Baltimore, MD; $1.1M SBIR) a leading medical device start-up pioneering the world’s first and only ultrasound-based feeding tube placement system, announced the closing of a Series B investment of $7 million [to] commercialize the First FDA-cleared, Ultrasound-based system for Feeding Tube Placement. [company press release, Aug 28, 20]
We knew the world hates Donald Trump. We knew people outside the United States have been giving Americans side-eye since 2016. We just didn’t know it was this bad. [Kevin Baron, DefenseOne, Sep 17, 20] As we slink back into our fortress -- expect fewer exports, dearer imports, fewer jobs, and fewer smiles at your US passport.
Inovio Pharma
up 36% [Sep 16, 20]
AlloVir up 20% [Sep 16, 20]
Axogen up 20% [Sep 16, 20]
Inovio Pharma up 20% [Sep 15, 20]
Athira Pharma (formerly M3 Biotechnology, Seattle, WA; no SBIR, founded 2011) plans to raise up to $170 million [IPO] ... is in late-stage development for its lead therapeutic candidate called NDX-1017. The drug could halt or reverse the nerve damage that causes Alzheimer’s disease and other illnesses including Parkinson’s and ALS, or Lou Gehrig’s Disease. It uses regenerative technology that rebuilds connections between neurons. [Taylor Soper, GeekWire, Sep 14, 20]
Nanospectra Biociences (Houston, TX; $5M SBIR) a medical device company pioneering a novel use of nanomedicine for selective thermal ablation, announced that it has closed on an initial $3 million in a Series B-1 financing [to] to further develop AuroLase, including full completion of the ongoing pivotal study for prostate cancer tissue ablation, filing of a 510(k) with the U.S. Food and Drug Administration (FDA) for marketing clearance, and preparing for commercialization [company press release, Sep 8, 20]
Cassava Sciences (Austin, TX; no SBIR) up 133% [Sep 14, 20] announced final results of a Phase 2b study with its lead drug candidate, sumifilam, in Alzheimer's disease. [company press release, Sep 14, 20]
Immunomedics up 98% [Sep 14, 20]
Solarea Bio (Cambridge, MA; no SBIR), developing microbiome-based therapeutics, raised $11.3M in equity in a $14.8M funding round, per an SEC filing [Rowan Walrath, BostInno, Sep 14, 20]
biotech Vaxess Technologies (Cambridge, MA; $3.3M SBIR, founded 2011) has formed a partnership with Taiwanese pharmaceutical company, Medigen Vaccine Biologics Corp. (MVC) (TPEx: 6547.TWO), to develop a combined COVID-19 and quadrivalent seasonal influenza vaccine (QIV), delivered via the novel MIMIX patch system. [company press release, Sep 14, 20]
The first data detailing Russia’s COVID-19 vaccine—nicknamed Sputnik—was published last week (September 4) in The Lancet. Almost immediately, other scientists began to call attention to unlikely patterns in the data, asking for raw numbers to verify the study’s conclusions. [Amanda Heidt, The Scientist, Sep 14, 20] Never trust a fact spewed by an autocrat, especially one being advised by loyalists.
Gilead Sciences will pay $21 billion to buy biotech Immunomedics (Morris Plains, NJ; $16M SBIR) and its prized breast-cancer drug, the company said Sunday, a sign of the value of the cancer-drugs business. Immunomedics has a market value of roughly $10 billion following a recent surge in its stock, meaning that Gilead is paying up to secure ownership of the company. [Cara Lombardo and Jonathan D. Rockoff, Wall Street Journal, Sep 13, 20] No, Uncle Sam gets no piece of the reward.
Merck has struck a deal to develop Seattle Genetics’ antibody-drug conjugate (ADC) ladiratuzumab vedotin. The agreement will see Merck pay $600 million and make a $1 billion investment in Seattle Genetics in return for the chance to embark on a joint development program. [Nick Paul Taylor, Fierce Biotech, Sep 14, 20]
Prelude Therapeutics (Wilmington, DE; no SBIR) is going for a $100 million IPO, a pretty common goal for biotechs in 2020, as it looks to finish off early clinical work for its cancer candidate PRT543. [Ben Adams, Fierce Biotech, Sep 8, 20]
OncoImmune (Rockville, MD; $4.3M SBIR) announced the completion of a $56 million financing in Series B [to] support its novel therapeutic programs in late stage clinical trials and to expand its product pipeline. [company press release, Sep 9, 20]
Savara (West Lake Hills, TX; $4.5M SBIR, founded 1995) announced the decision to discontinue ENCORE, a 48-week, open-label, non-controlled Phase 2a exploratory clinical study of Molgradex for the treatment of nontuberculous mycobacterial (NTM) lung infection in people living with cystic fibrosis (CF). Molgradex, an inhaled formulation of recombinant human granulocyte-macrophage colony-stimulating factor (GM-CSF), was also evaluated for the treatment of NTM in non-CF patients in the Phase 2a OPTIMA study that completed in March 2020. [company press release, Sep 3, 20] While not mentioned by name, this is referring to Vertex’s Trikafta (elexacaftor/ivacaftor/tezacaftor), now FDA approved for patients 12 years and older with CF who have at least one F508del mutation in the cystic fibrosis transmembrane conductance regulator (CFTR) gene, which is estimated to represent 90% of the cystic fibrosis population. [Ben Adams, Fierce Biotech, Sep 4, 20]
Money, of course. Joe Biden [when primary candidate] rejecting the big-government plans of progressive rivals as unaffordable. In the general election campaign, he has rolled out his own multi-trillion-dollar platform that a new study finds would push long-term Washington spending to its highest level in decades. The former vice president has proposed a total of $5.4 trillion in new spending over the next 10 years, according to an analysis published by the Penn Wharton Budget Model [Wall Street Journal, Sep 14, 20] When zillions of people need a handout from a government with boundless borrowing power, what's a candidate to do? Where and when does the free money train end? Not soon if we have a blue wave election that removes conservatives from power.
Agenus (Lexington, MA; $1.3M SBIR) up 24% [Sep 10, 20] ahead of a planned oral presentation of clinical trial data at the European Society of Medical Oncology (ESMO) Conference on Sept. 18, 2020. An immuno-oncology biotech company developing compounds to help the immune system fight cancer, Agenus' most advanced drugs in development are the anti-PD-1 targeting therapy, balstilimab, and the anti-CTLA-4 antibody, zalifrelimab. [Motley Fool, Sep 10, 20]
Satsuma Pharma (South San Francisco, CA; no SBIR) down 76% [Sep 10, 20] announced that Topline data did not show statistically significant differences between either dosage strength of STS101 and placebo on co-primary endpoints of freedom from pain and most bothersome symptom at two hours post-administration [company press release, Sep 10, 20]
Casma Therapeutics (Cambridge, MA; no SBIR), completed a $50M Series B round. [BoInno, Sep 10]
Korro Bio (Cambridge, MA; no SBIR) biotech, raised more than $90M to advance its technology to repair genetic mutations that cause a variety of diseases.
No lies barred. POTUS has been spreading related disinformation about the U.S. election. "More than 100 times this year, President Trump has peddled false claims or imaginary threats about voting by mail," the Washington Post's fact checker Salvador Rizzo reported. [DefOne, Sep 11, 20]
Intra-Cellular Therapies (New York, NY; $6M SBIR) up 73% [Sep 9, 20] announced positive topline results from its Phase 3 clinical trial (Study 402) evaluating lumateperone as adjunctive therapy to lithium or valproate in the treatment of major depressive episodes associated with Bipolar I or Bipolar II disorder. ... also announced that it has commenced an underwritten public offering of $350 million of shares of its common stock. [compamy press releases, Sep 9, 20]
Recursion Pharmaceuticals (Salt Lake Ciy, UT; $3.3M SBIR, founded 2013) announced a $239 million oversubscribed Series D financing [to] apply our ever-growing integrated discovery and development technologies to the hardest problems in biology, and this fundraising round provides us with additional resources we need to continue to advance on our mission to decode biology to radically improve lives,” said [CEO] Chris Gibson. ... also announced that Bayer {Germany) and Recursion Pharmaceuticals have entered into a strategic collaboration agreement. [company press releases, Sep 9, 2020]
William Hartung of the Center for International Policy says,"[T]he process through which the new [ICBM] missiles are being developed — a 'sole source' contract without competition — is suspect, if not outright corrupt." [Defense One, Sep 9, 20] Sounds purely pre-elecTion political. Sole source is authorized only for extreme circumstances of no competition and urgent time-critical need. The only time pressure ends Nov 3. Eventually potential competitors will sue, and Congress will refuse to apprppriate the funds. By then the election will be over and the action shelved.
Spero Therapeutics (Cambridge, MA; $1M SBIR) up 46% [Sep 8, 20] announced positive topline results from ADAPT-PO, the pivotal Phase 3 clinical trial evaluating Spero's oral antibiotic candidate, tebipenem HBr, for the treatment of adults with complicated urinary tract infection (cUTI) and acute pyelonephritis (AP). Topline data from the trial demonstrate that oral tebipenem HBr was statistically non-inferior to intravenous (IV) ertapenem in the treatment of patients with cUTI and patients with AP. [company press release, Sep 8, 20]
Albireo Pharma (Boston, MA; no SBIR), a clinical-stage orphan pediatric liver disease company developing novel bile acid modulators, announced that topline results from the PEDFIC 1 Phase 3 clinical trial evaluating the efficacy and safety of lead candidate odevixibat for the treatment of progressive familial intrahepatic cholestasis (PFIC) will be announced September 8, 2020. [company press release, Sep 7, 20] also announced that it has commenced a proposed underwritten public offering of 3,000,000 shares of its common stock. [company press release, Sep 8, 20]
OraSure Technologies (Betkhlehem, PA; one SBIR in 2012} is expanding operations to support manufacturing of its rapid at-home antigen test. The company aims to have it on the market by year-end, [Brianna Abbott and Thomas M. Burton, Wall Street Journal, Sep 8, 20]
Athenen Therapeutics (Boston, MA; no SBIR) raised $7M in equity in a $15M funding round, according to an SEC filing. [BostInno, Sep 8, 20]
Fractyl (Lexington, MA; no SBIR), a life sciences company focused on metabolic diseases, raised $55M in a Series E round [company press release, Aug 6, 20]
Dyne Therapeutics (Waltham.MA; no SBIR) focused on developing life-transforming therapies for patients with serious muscle diseases, today announced the closing of a $115 million equity financing [company press release, Aug 10, 20]
Aerovate Therapeutics (Boston, MA; no SBIR), closed on $72.6 million in Series A funding to advance trials of AV-101, an inhaled, dry powder aerosol version of imatinib to treat pulmonary arterial hypertension (PAH). An oral version of imatinib showed significant efficacy in a phase 3 trial as a disease-modifying therapy for PAH, but it was poorly tolerated by PAH patients because of systemic side effects. [company press release, Aug 6, 20]
Albamunity (Boston, MA; no SBIR) raised $5M in equity in a $20M funding round, [SEC filing, Aug 5, 20].
Vaccine Trial Halted. After Patient Becomes Ill. The news about AstraZeneca’s drug came on the same day that the company and others pledged to thoroughly vet any vaccine. [NY Times, Sep 9, 20]
Science to rule. Novavax has joined with [eight] several other biopharmaceutical executives in a global pledge to prioritize safety over speed in the race to find a viable Covid-19 vaccine. [DCInno, Sep 8, 20] Don't bet against Trump's October surprise claiming his immunity success.
I can assure the American people that the senior leaders would only recommend sending our troops to combat when it’s required for national security and a last resort, Army ChofStaff McConville said during an interview with Defense One online. [Katie Bo Wlliams, DefOne, Sep 8, 20] The Army does not start wars, it only offers the lives of its soldiers to execute the political objective by force. As a desperate President, with little depth in the history of the subject, fills the air with accusations at all and sundry.
Biomerica up 18% [Sep 4, 20]
Aspinity (Pittsburgh, PA; no SBIR, founded 2015), a pioneer in ultra-low-power analog machine learning processors, today announced that it has raised $5.3 million in Series A funding [to] to dramatically improve battery life in smart electronic devices that are always on and always sensing the environment for acoustic, vibrational, or other ambient triggers. [company press release, Sep 2, 20]
Vuzix up 18% [Sep 3, 20] announce that the Company has signed an agreement with a new major international defense contractor to build a customized waveguide solution. [company press release, Sep 3, 20] also announce that Pixee Medical, a France-based medical company, in collaboration with Dr. Villeminot and his team from Clinique St Odile in Haguenau (France), have successfully validated a new milestone by using Knee+, the first total knee replacement AR navigation system, solely guided by the Vuzix M400 AR Smart Glasses. [company press release, Sep 2, 20] also announced the Company is developing next generation product line of smart glasses powered by micro-LED technology that are expected to become available in 2021. [company press release, Sep 1, 20]
Akebia Therapeutics down 74% [Sep 3, 20] announced Vadadustat did not meet the primary safety endpoint of the PRO(2) TECT program, defined as non-inferiority of vadadustat versus darbepoetin alfa in time to first occurrence of major adverse cardiovascular events (MACE), which is the composite of all-cause mortality, non-fatal myocardial infarction, and non-fatal stroke across both PRO(2) TECT studies. [company press release, Sep 3, 20]
Lumen Bioscience (Seattle, WA; $900K SBIR) a clinical-stage biopharmaceutical company developing biologic drugs for highly prevalent diseases, today announced the closing of a $16 million Series B financing [to] support continued advancement of Lumen’s three clinical programs for C. difficile, norovirus and traveler’s diarrhea. [company press release, Sep 1, 20]
“our [GAO] analysis also showed that the majority (67 percent) of IR&D projects completed between 2014 and 2018 focused on incremental, rather than disruptive, innovation.” In other words, while defense contractors are spending some of their money on big ambitious goals, they prefer to spend more on low-hanging fruit, in little improvements to existing technologies that they can sell to the government more easily. [Patrick Tucker, DefenseOne, Sep 3, 20] No surprise, the military has always sought a brand new idea that has been thoroughly tested. Its record in SBIR shows its R&D conservatism. The sole DOD agency wth an innovative spirit is DARPA which was invented to prevent technological surprise and has stuck with that mission for many decades.
The federal guidance to not test asymptomatic carriers "is like saying we won't fight the fire until it reaches the second floor." [Caroline Chen, DefenseOne.com, Sep 3, 20]
2020 national voting starts today, mailing the first ballots in North Carolina, where Trump suggests early and often. The two major parties have nominated 296 women to run for 259 U.S. House seats [Reid Wilson, The Hill, Sep 3, 20], who alone would make a majority with better common sense.
Nanoviricides up 42% [Sep 2, 20] said Our current COVID-19 drug development candidates have shown efficacy against multiple different coronaviruses in our BSL2 virology lab. The Company believes this research provides scientific support that the virus would not be able to escape our drug candidate despite mutations, unlike many other drugs, antibodies and vaccines. [company press release, Sep 2, 20]
GI Windows Medical (West Bridgewater, MA; no SBIR) medical device company announced a $16.4million Series A-1financing [to] support further product development and clinical studies for GI Windows patented technology [company press release, Aug 19, 20]
Gilead Sciences committing $120 million to Jounce Therapeutics (Cambridge, MA; no SBIR) for rights to an antibody drug approaching clinical testing [to] selectively deplete regulatory T cells—the type of immune cells that suppress the immune response. Jounce has said that therapies targeting regulatory T cells may help address cancers that don’t respond to currently approved immunotherapies. [Frank Vinluan, xconomy.com, Sep 1, 20]
Top White House officials rang the alarm bell during a call with the nation’s governor, pleading with them to advise college presidents in their states to keep COVID-infected students on campus or risk another major outbreak. [Sam Stein, Matt Taylor, The Daily Beast, Sep 1, 20] After demanding re-opening, Trump now wants colleges to eat the ensuing problem. As usual, no help offered.
Akcea Therapeutics up 61% [Aug 31, 20] Ionis Pharmaceuticals and its affiliate Akcea Therapeutics announced that they have entered into a definitive agreement under which Ionis will acquire all of the outstanding shares of Akcea common stock it does not already own, approximately 24%, for $18.15 per share in cash. ... a total transaction value of approximately $500 million on a fully diluted basis. [joint companies press release, Aug 31, 20]
Pyramid Biosciences (Waltham, MA; no SBIR) developing new precision therapies focused on the modulation of cell surface receptors, announced the close of $28 million USD in funding [to]accelerate the growth of Pyramid Biosciences’ programs focused on novel tropomyosin receptor kinase (TRK) modulators in oncology and dermatology disorders. [company press release, Aug 31, 20]
Proudly free. the number one reason given by Americans who are not wearing a mask is that it is their right as an American to not have to do so. [Edward D. Vargas and Gabriel R. Sanchez, Brookings, Aug 31, 20] Which explains voting for a Trump and having the civilized world's highest rate of Covid infection. They are also risking a long life of post-Covid health complications yet to be quantified.
“In the past few years,” Subramanian writes, “as we’ve witnessed deliberate assaults on fact and truth and as we’ve realized the failures of the calm weight of scientific evidence to influence government policy, the need for scientists to find their voice has grown even more urgent.” [A DOMINANT CHARACTER The Radical Science and Restless Politics of J.B.S. Haldane, by Samanth Subramanian].
Triumvira Immunologics (Austin, TX & Germany; no SBIR) biopharmaceutical developing a novel platform for engineering T-cells to attack cancers, successfully completed a $55 million Series A financing round [to] advance multiple autologous and allogeneic programs into the clinic for solid tumors and hematologic malignancies. [company press release, Aug 26, 20]
Clene Nanomedicine (Salt Lake City, UT; no SBIR), a clinical-stage biopharmaceutical announced that it has secured $42.5 million in a Series D financing [to] advance Clene's clinical pipeline— particularly the lead nanocatalyst, CNM-Au8—through its ongoing Phase 3 study for the treatment of amyotrophic lateral sclerosis (ALS), and multiple Phase 2 clinical trials for the treatment of progressive neurologic impairment seen in people suffering from multiple sclerosis, Parkinson's disease, and ALS. [company press release, Aug 26, 20]
Onconova Therapeutics (Newtown, PA; $2.2M SBIR), a biopharmaceutical focused on discovering and developing novel products to treat cancer, announced that INSPIRE, the company’s pivotal Phase 3 study assessing the efficacy and safety of IV rigosertib in higher-risk MDS (HR-MDS) patients, did not meet its primary endpoint of improved survival. [company press release, Aug 24, 20]
From best to least prepared. In October 2019, a global study found the United States to be the best-prepared nation in the world for “high-consequence and globally catastrophic biological events.” Less than a year later, however, the United States leads the world in both infections and deaths from COVID-19, with close to 300,000 people projected to die by the end of 2020. [Joshua M. Sharfstein and Georges C. Benjamin, Foreign Affairs, Aug 26, 20]
Dim prospects. Economists say the new layoffs reflect a shift in corporate thinking toward a more protracted crisis. “Companies that thought they could either cut wages temporarily or cut costs temporarily or hold on are now finding out that the weakness of the pandemic is now longer than they hoped,” said Diane Swonk, chief economist at Grant Thornton. [Jeffrey Sparshott, Wall Street Journal, Aug 30, 20]
Until it's not. “Ultimately, capitalism is the best economic model. It will always yield the most efficient outcome. But there are times where the most efficient outcome is not the best outcome for America,” Sen. Marco Rubio (Fla.), one of the Republican sponsors of the semiconductor legislation, said in an interview. [Jeanne Whalen, Washington Post, Aug 29, 20] Ultimately, best, always, but. Conservatives support returning manufacturing to America (as Trump like all his GOP predecessors since Reagan have lost manufacturing jobs), so long as U.S. workers agree to accept China level wages - and corporations get another tax deduction for it. [public commenter]
Three Great Premises. 1. “Any theory is valid if it sells books, soaks up ratings or otherwise moves units. 2. “Anything can be true if someone says it loudly enough. 3. “Fact is that which enough people believe. Truth is determined by how fervently they believe it.” [Charles P. Pierce, Idiot America: How Stupidity Became a Virtue in the Land of the Free, 2009]
VBI Vaccines (Cambridge, MA; no SBIR) up 30% {Aug 27, 20], a commercial-stage biopharmaceutical developing next-generation infectious disease and immuno-oncology vaccines, announced data from three preclinical mouse studies conducted to enable selection of optimized clinical candidates for the company's coronavirus program, VBI-2900. As a result of these studies, VBI has selected two vaccine candidates, with the potential to be one-dose vaccines, to take into an adaptive Phase 1/2 human clinical study, expected to begin around year-end 2020, [company press release, Aug 26, 20]
Fluidigm down 27% [Aug 27, 20]
Evelo Biosciences down 24% [Aug 27, 20]
REGENXBIO (Rockville MD; $1.1M SBIR), a leading clinical-stage biotechnology company seeking to improve lives through the curative potential of gene therapy based on its proprietary NAV® Technology Platform, announced the [FDA] clearance of the Investigational New Drug (IND) application to evaluate the suprachoroidal delivery of RGX-314 in patients with diabetic retinopathy (DR). The IND is active, and REGENXBIO plans to begin dosing patients in a Phase II trial, ALTITUDE, in the second half of 2020. [company press release, Aug 25, 20]
Johnson & Johnson and the U.S. Biomedical Advanced Research and Development Authority (BARDA) are teaming up ... to boost innovation and “amplify” scientific and technological advancements to prepare for potential health threats—starting with COVID-19. They've picked seven startups from J&J’s global JLABS network [to] receive up to $500,000 in support, as well as mentorship from BARDA and J&J to help them navigate R&D challenges and regulatory pathways and get medicines and tools to patients and healthcare workers as soon as possible. Startups are: Houston-based 7 Hills Pharma and San Diego’s Persephone Biosciences, New York’s Autonomous Therapeutics ($1.5M SBIR), South San Francisco-based Epic Bio, Specific Biologics out of Toronto, Beerse, Belgium-based Genome Biologics, GabiSmartCare, also based in Beerse. [Amirah Al Idrus, Fierce Biotech. Aug 26, 20] A USG entity and supporting three foreign companies.
Vaccine public input. Starting September 1, the National Academies will invite public comments on a Discussion Draft of the Preliminary Framework for Equitable Allocation of COVID-19 Vaccine, part of a study commissioned by NIH and CDC. The study will recommend priorities to inform allocation of a limited initial supply of COVID-19 vaccine, taking into account factors such as racial/ethnic inequities and groups at higher risk due to health status, occupation, or living conditions. Public Listening Session Sept. 2 | 12 to 5 pm ET Register Now.
Fluidigm (South San Francisco, CA; $2M SBIR) up 30% [Aug 26, 20] announced that it has received [FDA] Emergency Use Authorization (EUA) for the Advanta Dx SARS-CoV-2 RT-PCR Assay, an extraction-free saliva-based test to detect nucleic acid from the SARS‑CoV‑2 virus. The Covid-19 test is designed to be run on the company’s Biomark HD microfluidics platform. [company press release, Aug 25, 20]
Kinnate Biopharma (San Diego, CA; no SBIR, founded 2018) focused on the discovery and development of small molecule kinase inhibitors for difficult-to-treat, genomically-defined cancers, announced that it has raised $98 million in a Series C financing [company press release, Aug 26, 20] total funding $172M [crunchbase.com]
Central Intelligence Agency’s venture capital firm InQTel is among a half-dozen investors in Morpheus Space, a German startup whose novel electric thrusters enable tiny satellites to maneuver and big ones to reduce complexity. [Marcus Weisgerber, DefenseOne, Aug 26, 20]
AXT down 20% [Aug 25, 20]
ACADIA Pharmaceuticals (San Diego, CA; $1.6M SBIR) announced the acquisition of CerSci Therapeutics (Ft Worth, TX; $2.2M SBIR), a clinical-stage biotechnology company with worldwide rights to a portfolio of novel compounds for neurological conditions, including non-opioid therapies for acute and chronic pain. ... ACADIA acquired all of the outstanding shares of CerSci for $52.5 million, primarily in ACADIA stock. CerSci shareholders may also receive up to $887 million in development, commercialization, and sales milestones in addition to tiered royalties in the mid-single digits based on annual net sales. [joint companies press release, Aug 25, 20]
Vascugen (Madison, WI; no SBIR, founded 2017) is applying $10 million in recently raised capital to build out its manufacturing capacity for its product – therapeutics that repair human tissue. ... is developing regenerative medicines technology being licensed from Indiana University [that]repairs human tissue damaged by reduced blood flow due to disease or injury. The Yoder lab at IU was the first to discover rare cells that are responsible for the formation of new blood vessels in the body and to then develop methods for manufacturing those cells, according to the university. [Nick Williams, WisconsinInno, August 25, 2020]
RNAimmune (Gaithersburg, MD; no SBIR) raised $2.35M in a seed round [to] advance the company’s Covid-19 vaccine program and cancer vaccine programs, RNAimmune spun out of local biopharmaceutical company Sirnaomics ($1.2M SBIR), which develops antifibrosis and anticancer RNAi therapeutics — a process that shuts down disease-causing genes using what’s called RNA interference technology. [DCInno, Aug 25, 20]
Tricida (South San Francisco, CA: no SBIR) pharmaceutical company focused on the development and commercialization of its drug candidate, veverimer (TRC101), a non-absorbed, orally-administered polymer designed to treat metabolic acidosis in patients with chronic kidney disease (CKD), announced that it received a [FDA] Complete Response Letter (CRL) for its New Drug Application (NDA) for veverimer on August 21, 2020. the FDA is seeking additional data beyond the TRCA-301 and TRCA-301E trials regarding the magnitude and durability of the treatment effect of veverimer on the surrogate marker of serum bicarbonate and the applicability of the treatment effect to the U.S. population. FDA also expressed concern as to whether the demonstrated effect size would be reasonably likely to predict clinical benefit. [company press release, Aug 24, 20]
news and views about government programs, politics, attitudes ...1996-1997; 1998; 1999; Y2K; 2001 , 2002-2003 ; 2004-5; 2006; 2007-08 2009-2010; 2011-2012; 2013-14 ; 2015; 2016; 2017-18; 2019-20
BMDO/ MDA including SBIR the doings of star wars
Miscellaneous Stories 1996-1997; 1998-1999; 2000-2001; 2002-2003 ; 2004-5 ; 2006; 2007 2009-2010 ; 2011-2012; 2013-2014; 2015; 2016; 2017
IPO and Venture Markets 1996-1998 .... 1999-2005 ... 2006-present
Quotes steal them if you like
Note: in these old stories, many links are dead, obsolete, or missing
Stories about companies; 1-Al .. Am-Az .. B .. C ... D-E .. F .. G-H .. I-J .. K-L .. M ... N-O ... P ... Q-R .. S1-Se .. ... Sf-Sz .. T-U .... V-Z
10 Kardiac Devices .... 10X Genomics ..... 1366
Technologies ... 1st Detect ...
21-Century Silicon ... 21st Century
Systems .... 23andMe ... 24M Technologies
... 30
Second Software ... 360fly ..... 3Bar Biologics .... 3C Semiconductor
... 3DEO .... 3D Glass Solutions ..... 3Dnamics ..... 3D
Robotics .... 3D Systems
..... 3D Technology
Laboratories
.... 3F ... 3iNanotech .... 3PrimiR ...
3Scan ..... 3-V
Biosciences
.... 3VR ... 410 Medical Innovation .... 454 Life Sciences .... 4C
Medical Technologies .... 4D Molecular Therapeutics ..... 4s3
Bioscience ... 5D Robotics
..... 65Bio ... 7AC
Technologies ... 89Bio ... 908Devices ... 9Mile Labs
A10 Networks ... A123Systems ... A4 Pharma .... A&G
Pharmaceutical ... Aastrom
Bioscience
.. Abacus Technology ... ... Abaxis .... Abcombi Sciences
.....
Abeona Therapeutics
..... AbGenomicsInternational ..... Abilitech
Medical ... Abiomed ... Ablative Solutions ....
Ablexis
...... ABL
Technologies .... Abpro
Therapeutics ..... AbSci .... Absorbent
Materials ... Abundant Robotics ..... AbVitro ...
Acadia Pharma ... Acambis
.. Accel Diagnostics ..... Acceleron Pharma
... Accelrys
... Accentia
BioPharmaceuticals ... Accent Therapeutics ..... Accera ....
Access Pharmaceuticals
...
Access
Scientific .... Access Vascular ... Accion Systems .....
Accumetrics
... AccuraGen ..... Accurate
Automation
.. Accuray ... Accuri Cytometers
... Acelerox ....
Acelity .... AcelRx
Pharmaceuticals ...
Acera Surgical .... Acer Thrapeutics .... Acetylon
Pharmaceuticals ... Achaogen ... Achates
Power .....
Achillion
Pharmaceuticals ... ACIST Medical Systems .... Acorda
Therapeutics
... Acorn
Cardiovascular ... Acquia .... AcroMetrix
... AcryMed ...
ActaCell ... Actasys .... ACT Biotech ... Active
Power ...
ActivBiotics
... ActivMedia Robotics .... actnano .... Acton
Pharmaceuticals
...
Actuality... Actuate
Therapeutics .... Acucela ... AcuFocus ....
Aculight
...
Acumentrics ... AcuraStem .... Acutus Medical .... Adagio
Therapeutics .... Adamas Pharmaceuticals ......
Adamis Pharmaceuticals
... Adapteva .... Adaptimmune Therapeutics .... Adaptive
Biotechnologies ..... Adaptive
Computing
... Adaptive
Phage Therapeutics ..... Adaptive TCR ... Adarza BioSystems
.....
Addiction
Therapeutix
...
Addrenex Pharmaceuticals ... Adelor ... Adenosine
Therapeutics
... Adesto Technologies .... Adeza Technologies ... Adherex
Technologies ... Adhesys Medical .... Adial Pharmaceuticals .... Adicet
Bio .... AdiMab
... ADispell ... Adlyfe .... ADMA
Biologics .... Admittance
Technologies
.... Admune Therapeutics ..... Adnexus
Therapeutics ... Adrenergics .... Advanced
BioHealing ... ADS Biotechnology ... Aduro BioTech
.... Advanced Animal Diagnostics .... Advanced Biologics ..... Advanced
Bionics
... Advanced Cell Diagnostics ... Advanced Cell
Technology (now sub to Bio-Techne) ... Advanced Ceramics
.... Advanced
Circulatory .....
Advanced Countermeasures
Systems ... Advanced Diamond
Technologies .... Advanced Electron Beams ...
Advanced Fuel
Research ...Advanced Life Sciences ... Advanced Lighting
Technologies ... Advanced Liquid Logic
...
Advanced Magnetics ... Advanced Photonix ....
Advanced
Programming Concepts ... Advanced Receiver
Technologies .... Advanced Scanners .... Advanced Scientific Concepts
..... Advanced Targeting
Systems
.... Advanced
Technology
Materials.(ATMI) ... Advanced Uro-Solutions ..... AdvanDx ...
Advantic ..... Advaxis ..... Adventrx
... Adverum Biotechnologies ..... Advion BioSciences
...
Adynxx ...... Aegea
Medical ... Aegerion Pharmaceuticals .... Aeglea
BioTherapeutics
Holdings ..... Aerial BioPharma .... Aerie
Pharmaceuticals
... Aerin Medical ..... AerisPhotonics ...... Aerius
Photonics
... Aerodyne Research ... Aero Farms System
... Aerovate Therapeutics .... Aerovel .....
AeroVironment ... Aerpio
Therapeutics .... AesRX
...
AETC ... Aethlon Medical
... Aethon .... Aevi Genomic Medicine .....
Affectiva
.... Afferent
Pharmaceuticals ..... Affigen .... Affinia Therapeutics< .....
Affinimark
Technologies
... Affinity BioReagents ... Affinium
Pharmaceuticals ..... Affinivax .... Affomix ....
Affymax ....Affymetrix ... aFraxis ... AgBiome ..... AgeneBio
....
Agennix ... Agenovir ..... Agenus .... Agere
Pharmaceuticals ..... Agile
Materials
... Agile
Planet ... AgileSwitch .... Agile Therapeutics ....
Agility
Robotics ..... Agilis Biotherapeutics .... Agiltron...Agilvax ....
Agilyx ....
Aagios
Pharmaceuticals... AgraQuest .... Agritope... Agrivida
... Agro Biosciences .... Aguila
Technologies.....Ahura Scientific.... Aiko Biotechnology
... Aileron Therapeutics .... Aimmune Therapeutics
(formerly
Allergen Research) ..... airtricity... Airware .... Airxpanders ....
Airway Therapeutics .... ait laboratories... Akadeum Life Sciences ....
Akamai
Physics
Akarna
Therapeutics
..... Akashi Therapeutics ..... Akcea Therapeutics ..... Akebia ....
Akero Therapeutics ... Akermin ..... Akers BioScience ..... Akita
Innovations
... Akouos ....
Akrevia Thera {now Xilio Thera) .... Akron
Polymer Systems ..... Akron Surface
Technologies ..... Akros Medical ....
Alabama
Cryogenics ... Alafair Biosciences ....Albamunity .... Albany Molecular
(AMRI) ...A?
nanotech .... Alcon .... Alcresta
.... Aldagen
... Aldatu Biosciences ..... Aldea
Pharmaceuticals
... .
Alder biopharma Aldevon ..... Aldeyra Therapeutics (formerly
Aldexa Therapeutics) .... Alector .... Alexar Therapeutics .....
Alexion
... ....Alexza ....
Alfalight.... Algaeventure Systems ... Algenetix .... Algeternal
.... Algorithmia ..... Alien Technology
.... Alimera sciences.... Alios BioPharma ....Aliva
biopharmaceuticals ..... AliveGen .... Alivio Therapeutics .....
Alkermes...
Alkeus Pharmaceuticals ...
Allakos ... Allcast ....
Allegro Diagnostics ....
Allegro
microsystems ... Allena Pharmaceuticals .... Allergy Amulet
.....
Allerquest
.... Alleviant Medical .... Allied BioScience ..... Allied Minds ....
Alliqua .... Allos .... AlloVirs (formerly VeraCyte) .... Alloy
Polymers .... Alloy
Surfaces .....
Allurion Technologies ... Allylix ... Ally Therapeutics ....
Alnara Pharmaceutical
...
Alnylam... Alper Biotech ... Alphabet Energy .... AlphaCore Pharma ...
Alphamed.... Alphatec
Holdings .....
Alphavax ... Alpine Biosciences .... Alpine Data
Labs .... Alpine Immune Sciences ..... Alseres ..... Algeternal
.... Alta Devices ... AltAir Fuels ... Altair
Therapeutics
... Altamira Technologies .... AltaRock
... AltheaDX .... Althea
Technologies ... Altimmune .....Altis Biosystems
.... Altor ...
Altra ...
Altura Medical ... Altus Pharmaceuticals ...
ALung
Technologies
... Alvine Pharmaceuticals .... ALX
Oncology .... Alycone
Lifesciences .... Alzeca ..... AMAG Pharmaceuticals
... Alzheon ..... Amaranth Medical .... Ambarella .....
Amberwave
... Ambiq
Micro ....
Ambit
Biosciences .... AMBP
Technology ... Ambri .... Ambrx ...
Ambry .... Ambys Medicines .... Amendia .... American Bionics .....
American
Gene Technologies International .... American Lithium Energy ....
American Medical Systems ....
American Science and Engineering
... America Stem Cell, now Targagyme .... American
Superconductor
... American XTAL .. Ames
Technology ... Amgen ... Amicus Therapeutics .... Amionx ..... Amnis
...
AMO
Pharma ..... Amphivena Therapeutics .... Ampio Pharmaceuticals .....
Ampla
Pharmaceuticals ... Amplimmune .... Amplyx Pharmaceuticals
.....
Amprius .... ARMO
BioSciences .... Amunix Pharmaceuticals .... Amylin
Pharmaceuticals ... Amylyx ..... Amyris
Biotechnologies ... AN2 Therapeutics .... Anacor
Pharmaceuticals ...
Anadys
Pharmaceuticals ... Anakim Biologics ....
Analog Computing
Solutions .... Analytical Space ..... AnaptysBio
... Anavex Life Sciences .... Anchor Therapeutics ...
Ancora Pharmaceuticals
... AnDAPT ..... Anexon .... Anew Optics ... Angeion ...
AngioDynamics
... Angiologix ... Angstrom Medica .... Angstron
Materials
... Animalgesic Labs .... ANI Pharmaceuticals ...
Animetrics .... Anivax .... Anivive Therapeutics ..... Annexon
Bioscience ..... Annovis Bio .... ANP Technologies
..... Ansoft
... Ansun Biopharma (formerly NexBio) .... Antegrin
Therapeutics
..... Anthera
Pharmaceuticals .... Anthos Therapeutics .....
Antibody
Biopharm .... Antigenics ... Anue Systems ... Anulex
Technologies
... Anybots ... AOBiome Therapeutics
(formerly
Nitrocell) .... AOptix Technologies
... Aortica ..... APA
Optics (Enterprises) ... Apellis Pharmaceuticals
.....
Apexigen ... Aperiomics .... Aperion Biologics .... Aphios
... Apic Bio .... Apieron ... Apnex Medical
... ApniCure .....
ApoCell ....
ApoGen Biotechnologies .... Apollo
Diamond
... Apollo Endosurgery ... Apollomics
(previously CBT
Pharmaceuticals) .... Apoplogic Pharmaceuticals
... Applied Biomolecular Technologies .... Applied Biosystems
.... Applied Defense Solutions ..... Applied DNA
Sciences .... Applied Genetic Technology ... Applied Molecular
Transport
.... Applied Nanotech
....
Applied
NanoWorks ... Applied Optimization ..... Applied
Optoelectronics ... Applied Physical Electronics ...
Applied Physical Sciences ... Applied Precision ..... Applied
Proteomics ..... Applied Quantum Technologies .... Applied Quantum
Technology
.... Applied Research Associates
... Applied
Science and Technology ... Applied Signal
Technology
... Applied Therapeutics ...... AppThwack ....
Aprea Therapeutics .... Aprecia Pharmaceuticals ....
Apricus
Biosciences
... APS BioGroup .... Apse .... Aptalis Pharma .... Aptevo
Therapeutics .....
Aptima ... AptamiR
Therapeutics .... Aptinyx .... Aptose
Biosciences .... Aptus
Endosystems ... Aquaback Technologies ...
Aqua Bounty
... Aquacue .... AquaHarmonics ..... Aqua Metals .... AquaMost
...
Aquarius
Technologies ... Aquestive Therapeutics ....
AqueSys
... Aqueti .... Aquion .... Aradigm ....
AragonPharmaceuticals
...
Aratana
Therapeutics ..... Arbor Biosciences< ..... Arbor Biotechnologie
..... Arbor Pharmaceuticals
...
Arbovax
... Arbutus BioPharma (formerly OnCore) ..... Arca Biopharma ....
Arcadia Biosciences ..... Arcadia Pharma ..... Arcantatura...
Archemix
... Arcellx .... ArcherDX ......Arch Innotek ..... Arch
Oncology ..... Arch
Therapeutics
... Arctic Sand Technologies .... Arcturus Therapeutics ....
Arcus Biosciences ..... Arcutis Biotherapeutics .... Ardea Biosciences
...
Ardelyx .... Ardian .... Arena Pharmaceuticals
... Argentum ..... Arginetix
... Argo AI ..... ArgonST ... Argos Therapeutics ... Aria CV
...
Ariad Pharmaceuticals .. Aria Insights (previously CyPhy
Works) .... Ariosa Diagnostics ..... Arista MD
....
Arista Networks .... ARIZ Precision
Medicine .... Arkansas Power Electronics ..... Arkuda Therapeutics ...
Armadillo Aerospace
... Armata
Pharmaceuticals .... Armetheon .... ARMO BioSciences .... Armonica
Technologies .... Armorworks
... Armune BioScience ..... Aro Biotherapeutics
.... Aronora ..... Arpeggi
.... ArQule ... Arrakis Therapeutics .....
Array ... Arranta Bio .... Array Information
Technology ..... Arresto
Biosciences .... Arrien Pharmaceuticals ... Arrivo
BioVentures ..... Arrowhead Pharmaceuticals ..... Arrowhead
Research .... Arsanis ... ArsenalBio ...
Arsenal Medical
.... Arstasis ... Artel .... Arteriocyte
... Arterys
..... ArthroCare
...
Arthrosurface ... Artisan Pharma ... Artiva Biotherapeutics
.... Artizan .... Artrility
Medical ..... ArunA Bio .... Arvegenix ..... Arvinas .... Arxan
Technologies .... Aryx
Therapeutics ..... Aryx
... Arzeda
... Asana Medical (now Regentsys) .... Asante Solutions .....
Ascelegen
Therapeutics .... Ascension
Orthopedics ... Ascent
Solar Technologies ....
Ascent
Therapeutics .... AsclepiX Therapeutics .... Aseptia .... Ash
Access Technology .... Asklepios
Biopharmaceutical .... AstroWatt .... Aspen Aerogels
.... AspenBio
Pharma .... Aspen
Neuroscience .... Aspen Products Group ....
Aspen Technology
... Aspyrian Therapeutics .... Assembly Biosciences
Assurex Health ..... Astex
Therapeutics ...
Asthmapolis .... Astralux
... Astrobotic Technology ....
Astronautics Corp. of
America ... AstroPower... AstroTerra ..
Astrum Solar ... Astute
Medical ....
Astute Medicales ... Asuragen
... Atacama ..... Atara Biotherapeutics ..... Ataxion ....
Athenex
(formerly
Kinex) ..... Atea Pharmaceuticals .... Athenen
Therapeutics ... Athenex .... Athenix
... Athens Research ..... AtheroGenics ... AtheroMed ....
Athersys .... ATI Industrial
Automation
... Atlantia ... Atmocean .....
Atmospheric Glow
Technologies ...
Atomate ... Atomic Medical Innovations .....
Atomometrics
... Atomwise ..... Atoptix .... Atossa
Genetics
... Atreaon ....
Atreca .... Atreon Orthopedics
..... AtriCure ... Atrium
Medical ... ATRP Solutions ... aTyr Pharma .....
Audentes
Therapeutics ..... Audience
... Augmenix
.... AUM
Cardiovascular ... Aura Biosciences ....
Auris Health .... Auris Medical .... Auris Surgical Robotics
..... Aurora
Algae ... Aurora Flight
Sciences ....
Aurora
Imaging Technology ...
Aurora Spectral Technologies
... Auspex
Pharmaceuticals ... Ausra ... Auterra
.... AuthenTec .... Autolus Therapeutics .... Automated Dynamics ...
Automated
Medical Instruments .... Autonet ... Aushon
Biosystems ... AutoGenomics .... Autonomic Materials
.... Autonomic Technologies ..... Autonomous Technologies
....
Auxilium
Pharmaceuticals ... Avalanche
Biotechnologies .... Avalyn Pharmaceuticals .... Avanir Pharmaceuticals
... Avant Immunotherapeutics ... Avanti Metal ...
Avaxia
Biologics ... Avedro ... Avelas Biosciences ....
Aveo
Pharmaceuticals
... Avery Therapeutics ..... AveXis .... Aviation Resources
Delaware .... AVI
BioPharma ... Avici Systems ... AvidBiotics
.....Avidity
Biosciences .... Avid
Radiopharmaceuticals
... Avila Therapeutics ... Avinger ....
... Aviragen Therapeutics (formerly Biota
Pharmaceuticals)
..... Aviron ..... Avisa Pharma .... Avita Medical Americas .....
Avitude .... Avrobio
..... AVT Simulation .... Aware ... Axcella Health (was Pronutria)
.....
Axelo .... Axerion Therapeutics
... Axial
Biotech .... Axial Biotherapeutics ..... Axion BioSystems
.....
Axion Power
... Axis Clinicals .... Axis
Semiconductor
... Axium Nanofibers ...... Axium Pharmaceuticals .... Axogen
.... Axonia Medical ....Axonics Modulation Technologies
Axsome Therapeutics ..... Axsun Technologies ... Ayasdi
..... Azaya
Therapeutics ... Azelon Pharmaceutical ... Azimuth
.... Azitra ..... Aziyo Biologics ..... Azure Biotech ..... AzurRx
BioPharma
Baby Genes .... Bacterial Robotics .... BacterioScan ....
Baebies
..... Bagaveev
.... Ballard
Power ... Bamboo Therapeutics ..... Bandgap ... Banner Life
Sciences ..... Banyan Biomarkers ... Bardy
Diagnostics .... BarioSurg ..... Baryonyx .... Barrier
Therapeutics ... Baseload Renewables .... Basis
Science
.... Bastion
Technologies
.... Batu Biologics ..... Bauhaus Software ..... Baxano ...
Baxano Surgical .... BayoTech ..... Beacon Biomedical ..... Beacon
Power ... Beam Therapeutics ..... Beat
Biotherapeutics .... Beeco
... Beeken Biomedical .... Behavioral Recognition
Systems .... Bellerephoon
Tera .... Bellicum
Pharmaceuticals .... Belmont Instrument ....
Benchmark
Automation ... BeneChill
... Benefuel ... BeneVir Biopharm ....
Bennett
Aerospace .... Benson Hill
Biosystems ..... Benvenue
Medical .... Berg .... BerrieHill
Research
... BESS Technologies .... BetaBatt
...
BetaLED ....
LEDBG Medicine
... Bettergy .... Bexion Pharmaceuticals .... Bina
Technologies .... Bind
Bioscience ... Bind Therapeutics .... BinOptics ..... BiO2
Medical
... BiO2
Technologies
...
BioAmber ... BioAdvanTek ... BioAffinity
Technologies .....
Bioanalytical Systems
... BioBehavioral Diagnostics ... BioBridge
Global
..... BioCardia .....
BioCentra Molecular Innovations ..... Biocept
...
BioChemics ..... BioClin Therapeutics .... Bicycle Therapeutics .....
Bien-Etre
Labs ..... BioCold Genesys .... Bioconnect Systems .... BioConsortia
..... BioCritica
... BioCryst Pharmaceuticals ...
BioDelivery Sciences ... Biodesix .... BioDirection ..... BioDtech ...
BioFactura ... ..... BioE ...
BioFire .... BioFluidica ..... Biogenic
Reagents
.... BioGreenChoice ... BioHaven Pharmaceuticals ..... Bioheart
...
Biohelix ... Bio-Imaging Technologies
...
Bioincept .... Biointervene .... BioIQ .... BioKier ..... Biolex
Therapeutics
... BioLife4D ..... BioLink Life
Sciences
... Biolinq (formerly Electrozyme) .... Biologics
...
BioMagnetic Solutions ....
BioMarin
Pharmaceutical
... BioMarck
Pharmaceuticals .... bioMASON ..... Biomatrica ...
BioMedical
Enterprises
... Biomedical Sciences ..... Biomedical
Structures ...
BioMedix .... Biomeme .... Biomerica .... Biometric
Signature
... BioMimetic Therapeutics
... BioMotiv .... BioNano
Genomics ... BioNanomatrix ... Bionostics
Holdings
... Bio-Path Holdings ..... Biophan Technologies
... Biophysical ... BioProcessors ...
Bioptigen
... Bioptix .... BiOptix Diagnostics ..... BioPulping
International
...
Biopure ... Biorasis ..... BioRelix ... BioResource
International
...
BioRestorative Therapies (formerly Stem Cell Assurance) ....
BioSante Pharmaceuticals ... BioScale
.... BioSense
Technologies ... BioSensics .... BioSentinel
Pharmaceuticals
... BioSig Technologies ..... Biosortia Pharmaceuticals ....
BioSphere Medical
.... Biostage (formerly Harvard Apparatus
Regenerative
Technology) ..... BioStructures .... Biosurfaces .... Biosym
Technologies later Accelrys
....
BioSystem
...
Biota Pharmaceuticals .... Bio-Techne ..... BioTechnique ....
BioTechPlex .....
Biotectix
....
Biotel
.... BioTelemetry (formerly CardioNet) ..... BioTex
....
Biothera
... BioTheranostics ... Bio Time ...
Biotix
... Biotronic NeuroNetwork ..... Biotronik ....
BioTrove
... BioVaxys .... Bioventus ..... Biovest International ....
BioVex
... BioVirtua ..... Bird Rock Bio (formerly RuiYi) .....
Birich
Technologies .... Biscayne Neurotherapeutics ..... Bitstream
... Black
Diamond Therapeutics .... Black-I Robotics
... Black Sand ... BlackThorn
..... BladeLogic
... Blasch Precision Ceramics .... Blaze
Bioscience ... Blend
Therapeutics ....
BL Healthcare ... Block Engineering ...
Bloom Energy
... Bloo Solar ..... BluDiagnostics ..... Blue Belt
Technologies
...
Bluebird
bio ...
BluDiagnostics .... Bluefin Robotics ... Bluegrass
Proteins
.... Bluegrass
Vascular
Technologies .... Blueprint
Medicines ...
BlueRock Therapeutics ..... Blue
Sky Batteries ... Bluewater Bio International ... Blue Water
Vaccines .... Bolder Surgical ... Bolt
Biotherapeutics .... Bolt Threads ....
Boom Supersonic ..... Boragen .... Boston Biochem
... Boston Biomedical ... Boston Dynamics
...
Boston Engineering ... Boston Micromachines ... Boston
Micromachines (formally Boston
Electrometallurgical .... Boston-Power
...
Boston
Therapeutics ... Bot Dolly .... Boundless
... Boundless Bio ... BoXZY
..... Braeburn Pharmaceuticals ..... BrainCells
... BrainScope .... Brain Sentry ....
Brain Tunnelgenix
Technologies .... BrainXell ..... Bra-Ket Science ... Branch Medical
Group ..... Brayton
Energy
.... Breathe
Technologies ... Breethe .... Breonics ...
BreviTest
Technologies
..... Brewer
Science ... Brickell Biotech .... Bridger Photonics .... Bridgelux
... Brightsource Energy ... Bright View
...
Brimrose Corp of America ... Briteseed .... Brock Rogers Surgical
...
Bromium
.... Brooks
Automation ...
Bruker Daltonics .... Buffalo BioLabs ..... Burl
Concepts
..... Burr Oak
C12 Energy ... C2Sense .... C3Nano
... C4 Therapeutics .... C8
Sciences ....
C9 ... Cabaletta Bio .... CABG Medical ....
Cadence Pharma ....
CadheRx
Therapeutics
.....
Caisson Biotech .... Calabazas
Creek
Research .... Caladrius
Bioscience ... Cala Health ..... Calando
Pharmaceuticals
... Calbiotech .... Calera ... Caliber Biotherapeutics ....
Calibra
Medical ... Calient ... California Wave Power
Technologies ..... Calimmune ..... Caliper Life Sciences
....
CaliSolar ... Calistoga Pharmaceuticals ...
Calithera
BioSciences .... Calixa
Therapeutics ... Callidus Biopharma ... Calporta
Therapeutics
.... Calspan .... Caltech Metals ... Calysta .... Calyxt ..... Cambrian
Innovation ... Cambridge
Endoscopic Devices ... Cambridge Heart
.... Cambridge
Research & Instrumentation ... Cambrios
Technologies .... CAMX ..... Candela Laser ....
Cancer
Genetics .... Cancer Prevention
Pharmaceuticals .... CanDiag .... Canopy Biosciences ..... Capesym
... Capillary
Biomedical ..... Capio Biosciences .... Capnia
... CAPP Medical ..... Capricor Therapeutics .... Cara
Therapeutics .... Carbon .....
Carbon
Design
Systems ... Carbon Engineering .... Carbtex Technology
.... Carbylan Therapeutics ..... Cardeas
Pharma ....
CardiacAssist ..... Cardiac Concepts ...
Cardiac
Dimensions
... Cardiac Science ..... Cardialen ..... CardiAQ Valve
Technologies ... Cardica
... CardioDx
... Cardio Flow ..... CardioFocus ... CardioInsight
Technologies .....
Cardiokinetix ..... CardioMag ... CardioMEMS .... Cardionomic ....
CardioNXT ..... Cardiorobotics
...
Cardiosolutions ... Cardiosolv .... CardioSpectra ... CardioTech
... Cardiovate ..... CardiOx ...
Cardioxyl
Pharmaceuticals
.... CareDx (formerly XDx) .... Caribou Biosciences
.....
Carigent Therapeutics .... Carisma Thera (formerly CARMA Therapeutics)
..... Carlsme .... Carmot Therapeutics
..... Carnegie Robotics
.... Carnegie Spee .... ... .... Carnot BioSciences ....
CaroGen .... Carter Aviation Technologies .... Carticept
Medical ... Cartiva ..... Cascade Designs ...
Cascade
Microtech
... Cascadian Therapeutics (formerly Oncothyreon) ..... Casma
Therapeutics .... Castle Pharmaceuticals .... Castle Creek
Pharmaceuticals
Catabasis Pharmaceuticals ... Catadon
Systems ... Catalyst Biosciences ... Catalyst Pharma
.... Catalytic Innovations ..... Catalyze ..... Catelectric
.... Cebix .... Cedarburg Pharmaceuticals .... Cedilla
Therapeutics ..... CeeTox
... Celadon ... Celator Pharmaceuticals
... CelcuityCeldara Medical ..... Celladon .... Cellara .... Cell Care
Therapeutics ..... Cellceutix
.... CellCyte
Genetics ... Cell Design Labs ..... Celldex Therapeutics
... ..... Cellectar ... Cellerant
Therapeutics
... Celleration .... Cell Genesys ... CellRight
Technologies
..... Cellular
Bioengineering
...
... Cellular Bioengineering ..... Cellular Biomedicine Group
.....
Cellular Dynamics International .... Cell>Point
.... CellSavers ..... Cellscape .... Cellscript
..... Cell
Signaling Technology ...Cell
Therapeutics (now CTI
BioPharma)
... CellTraffix ... CeloNova Biosciences
..... Cel-Sci
.... Celsion ...
Celtaxsys ..... Celula..... Celularity ..... CellzDirect ...
Cempra Pharmaceuticals.
.... CeNeRx
BioPharma ... Censa Pharmaceuticals .... Centocor ....
Centrexion Therapeutics .....
Centrose ... Centice .. Century Therapeutics .... Centritec
Seals ... Cephalon
... Cepheid
... Cephalon ... Ception Therapeutics
... Cequent
Pharmaceuticals ... Cerebras Systems ..... Ceradyne ...
Ceramic
Tubular Products .... Ceramitron ... Cerapedics
.... Ceramatec
... Cerevast Therapeutics .... Cerealus Holdings
... Cerebral
Therapeutics .... Cerecor .... Ceregene ...
Cerahelix
.. Ceres Nanosciences ..... Cerevance .... CereVasc .....
Cerexa
.... Cerion
Enterprises ...
Cermet ... Cernostics ..... Cerulean Pharma
... Cerus ... Cervel Neurotech .... Cesca
Therapeutics .... Ceterix .... Orthopaedics ... CFD Research ..
CFX Battery
.... CGI Pharmaceuticals ... ChaCha
... Chantilly BioPharma .... Chapman
Innovations ... Charles River Analytics .... Charles
River Lab ... Charter Medical ..... Chase Therapeutics ....
CHASM
.... Chatham
Therapeutics ..... Checkerspot ..... Chemat ... Chembio Diagnostic
Systems .... ChemImage ... Chemir Analytical
Services ...
ChemoCentryx
... Chemtura ....
Chesapeake Sciences
...Chesson Labs ... Chiasma .... Chimera
Bioengineering ..... Chimerix
... Chlorogen ... Choice Therapeutics
... Chondrogenics
... Chordia
Therapeutics .... Chorum Technologies
.... ChromaCode
..... ChromaDex
..... Chronix
Biomedical
... Chrysalis BioTherapeutics .... Cibus
Global
... Cidara Therapeutics .... Ciena
....Ciencia ...
Cilion .... CimaBay Thera ..... CinCor Pharma .... CinRx ....
Ciranova
... Circle
Technologies ..... Cirius Therapeutics ..... CivaTech
Oncology ... Civetta Therapeutics .... .... CiVi Biopharma .....
Civitas Therapeutics
..... Claret Medical .... Clarassance ..... Claresta
Solutions
.... Clark-MXR ...Claros
Diagnostics
.... Clean Diesel
Technologies ... Clear Catheter Systems .... ClearCount
Medical
Solutions .... ClearEdge
Power .... Clear Guide Medical .... Clearside
Biomedical ... Cleave Biosciences ... Cleveland BioLabs ...
Cleveland
Polymer Technologies ..... CleverSet ... Clinical Data
... Cloudant ... CloudMade ... Cloud
Pharmaceuticals
(formerly Teradiscoveries) .... Clovis
Oncology ... Clovis Tech ..... CMC Biologics .... C-Motive Technologies
.... CoAdna,Holdings ..... CoAxia ....
Cobalt Biofuels ... Cocoon Biotech .... Cocrystal
Discovery ... Coda
Biotherapeutics .... Codexis
... Co-Diagnostics< ... Codiak
BioSciences ..... Codon
Devices ... Co-D Therapeutics .... Cofactor
Genomics ....
Cogenra .... Cogentix Medical ..... Cognex
...Cognition
Therapeutics .... Cognitive Code
... Cohera
Medical .... Coherus Biosciences .... Cohesive
Technologies ... ColdQuanta .... ColdWatt ... Collagenex
Pharmaceuticals ...
Collegium Pharmaceutical ... CoLucid Pharmaceuticals
... Columbia Labs ..... CombiMatrix ...
CombinatoRx
..... Combined Energies .... Combinent
BioMedical Systems ... Comet Therapeutics .... Comfort Motion
Technologies
...
Commonwealth Biotechnologies ... Commonwealth
Fusion Systems ..... Compact Membrane Systems ...Compass
Therapeutics .... Compellent Technologies ... Compendia
Bioscience
.....
Complete
Genomics ....
Complexa
..... Conatus
Pharmaceuticals ... Concert
Pharmaceuticals
.... Concordia Fibers ...Concurrent Technologies ...
Conductus
.. Confluence Life Sciences ..... ConforMIS ...
Cognigen
.... Conispire
.... ConjuGon .. Connecticut
Valley Bindery ... Consonus Technologies
... Constant Therapeutics .... Constellation
Pharmaceuticals .... Context Therapeutics ..... Contour Energy
Systems ControlRadSystems ..... Convelo
Therapeutics ....
Conventus
Orthopaedics ..... Convergen
... ConverGene .... Convio .... Convoy
Therapeutics
.... Cool-Bio
.... CoolCAD Electronics .... CoolChip Technologies
....
Cool Earth
Solar
.... Cooligy ... CoolTech .... Corbus
Pharmaceuticals
..... Corcept
Therapeutics
...
Cordex Systems .... CoreStreet ... CoreTek ...
.Corgenix
Medical
... Corindus ....Corinthian
Ophthalmic ... Corium International .... Corixa
....
CorMatrix
Cardiovascular
.... Cormedix ... Cornami ..... Cornerstone Research
... Cornerstone BioPharma then Cornerstone
Therapeutics
..... Cornerstone Therapeutics .... Coronado
Biosciences ... CorQuest Medical ..... Correx ... Corridor
Pharmaceuticals
... Cortana ..... Cortendo AB ..... Cortexyme ....
Corvidia
Therapeutics ..... Corvus
Pharmaceuticals
..... CosmosID ..... CoStim Pharmaceuticals
.... Cougar
Biotechnology ...
Coulbourn
Instruments .... Coulter Pharmaceuticals ... Cour
Pharmaceutical
Development .... Coverity ..... Creare ...
Creative
Hybrid Solutions .... Creatv MicroTech .... Cree
Research ... Crescendo Bioscience .... Crinetics
Pharmaceuticals
....
CrispTek .... Critical Therapeutics .... CritiTech
... Crossbar .... Cross Current ..... CrossFire
... Cruise Automation .... Crux Biomedical
...
CryoCor ...
CryoLife ... Cryomedical Sciences ..... Cryosa ....
Cryptonite .....
Crystal
IS
...
Crystal Systems ... Crystallume ... CSA
Engineering ... CS-Keys ... CTD Holdings
..... CTI
BioPharma (formerly
Cell Therapeutics) .... Cubist
Pharmaceuticals
... Cue Biopharma .... Cullinan Oncology ..... Cumberland Pharma ....
CuraGen ... Curamir Therapeutics ... Curative .... Current Motor
...
Curtana Pharmaceuticals .... Custom Electronics .... CVD
Equipment ..... CVRx
... CV
Therapeutics ... Cyanotech ..... Cyberdyne .... CyberKey Solutions
... Cyberkinetics Neurotechnology ... Cybernet Systems
... CyberOptics ... Cyclerion
Therapeutics .... Cydan ....
Cygnal
Therapeutics .... Cykloburn
Technologies ..... CymaBay
Therapeutics
.... Cymbet ... CyMedica Orthopedics ..... Cymer
...
Cynosure ... Cyntellect ... Cypher Genomics ... CyPhy Works
... Cypress Bioscience ... Cyrus Biotechnology .....
Cyteir
Therapeutics ..... Cyterix
Pharmaceuticals ...
CytImmune .... CytoBioScience ..... Cytocentrics ..... CytoCore
(formerly Molecular
Diagnostics) ..... Cytocybernetics ..... CytoDyn
.... Cytogel Pharma
.... Cytokinetics
... Cytometix ....CytomX ...
Cytonome
....
Cytori Therapeutics ... Cytophil CytoSolv
... Cytosorbents ..... Cytovas ... CytRx ..... Cytyc
...
CyVek
E25 Bio .... E3 Clean .... Eagle
Optoelectronics ... Earl Energy .... EarLens .... Earth Networks ....
Earthrise
Nutritionals ... eASIC ..... Eboo Pharmaceuticals .... EBR
Systems ..... Ebullient
....
Echelon .... Echodyne
..... Echogen Power Systems .... Echometrix ... EchoPixel
..... Echo Therapeutics (was
Sontra)... ECI Biotech
... ECM Technologies ..... Ecocurrent
... EcoPesticides .... EcoPro Polymers .....
Eccrine Systems ..... Ecovative
Design ... Edaptive
Computing .... Eden
Bioscience
... Edenspace
Systems ... Edge Therapeutics ..... Edico Genome .... Edison
Agrosciences ..... Editas
Medicine .... EEStor
... Effector
Therapeutics .... Egalet .... eGenesis .... Eiger BioPharmaceuticals
..... Eikos ... E-Ink
... EIS .... Eko Devices .... Ekos ... EKR
Therapeutics .... Ekso
...
Elcelyx Therapeutics ... Electrical
Geodesics ..... Electric Power Systems .... ElectroCell
Technologies
... ElectroChemical Systems ... Electro Energy
...Electromed ... Electro Optical Sciences ...
Electro
Scientific ... Electrozyme ....
Elementary Robotics ....
Elemetric Instruments
... ElevateBio .... Elevation Pharmaceuticals
... Eleven
Biotherapeutics ... Elicio Therapeutics
.... Elira Therapeutics
..... Elixir Biopharm ... Elixirgen Therapeutics ..... Elixir
Pharmaceuticals ...
Ellipse Technologies ..... Elon ... Eloxx Pharma ... Elstar
Therapeutics ..... eMagin .. Embera
NeuroTherapeutics .... Embodied ....
EmboMedics
.....
Embrex ..
EMCORE
... Emendo Biotherapeutics .... Emerald BioStructures
.... Emergent BioSolutions ...
Emergent
Technologies ... EM Photonics .... Empire Genomics
.... Empire
Robotics ....
EMRes Technologies
... Emtora Biosciences (formerly Rapamycin Holdings) .... Emulate ....
Enable
Injections ...... Enanta Pharmaceuticals ..... EnChroma ..... Encite
...
Encoded Genomics .... Encoded Therapeutics .... Encompass Bioscience
..... Encore
Vision .... Encysive
Pharmaceuticals ... Endeavor Robotics ..... Endece
...
Endgame Technologies
... EndoChoice .... Endocyte ... EndoGastric
Solutions
... Endo International ..... Endoscopic
Technologies ... Endosee ..... EndoStim
.... Endotherapeutics ..... Ener1
... EnerG2 ... Energen
... Energesis Pharmaceuticals .... Energetiq
Technology ... Energid Technologies ... Energous
..... Ener-G-Rotors
... Energy Control ... Energy Conversion
Devices .
.. Energy Focus ..... Energy Materials .... Energy Recovery
... Energy
Solutions
... Energy Storage Systems ..... EnerMat Technologies .....
EnerMed ..... Enertech
Environmental ... EnerVault ... Engineered
BioPharmaceuticals
.... Engineered Propulsion ...Engineous
Software
... Enlibrium ..... Enlight
Bioscience ... EnSync Energy Systems (formerly ZBB Energy)
.....
Ensysce Biosciences ... Entasis
Therapeutics ..... Entech
... Entegrion ... Entellus Medical .....
Entera
Biotech .... Entergem Ventures .... EnteroMedics
... Entia Biosciences ..... Entira Bio .... Entopica
Therapeutics
...
EntreMed
... Entrada Therapeutics ..... Entra Pharmaceuticals
... ENTrigue Surgical ...
Envia
Systems .. Entrotech Life Sciences ..... Entvantage
Diagnostics
..... EnviroFlight ..... Envisia Therapeutics
..... Envistacom .... EnVivo
Pharma ... Enzenia ... Enzium
... Enzo Biochem ... Enzymatics ... EnzyMed ..... Enzyvant
.....
EO2
Concepts
.... EOIR
... Eonix ....
EpiBiome ....
EpiBone .... Epicentre
Biotechnologies .... Epic Sciences .... Epic Systems ..... Epicypher
.... EpiEP ...
Epion
... Epiphany Solar Water Systems .... Epitomics
...
Epiva Biosciences ..... EpiVax ... EpiWorks .... Epix
Pharmaceuticals ... Epizyme
...
Eppin Pharma .... EQRx ... EqualLogic ... Equex
... Equillium .... Equipment
Concepts ...
EraGen Biosciences ... Erallo Technologies
... Erasca .... Ercole
Biotech ... ERT ..... Escalier Biosciences BV ..... Escalon
Medical
.... E-Scape
Bio ..... Escient Pharmaceuticals ..... Escoublac
....
eScription
... eSolar ... Eso-Technologies
... Esperance Pharmaceuticals ..... Esperion
Therapeutics
..... Essential Biotechnology
..... Essential Medical .... Essentient ....
Essex... Eta Devices ..... Eta-Gen .... Etegent
Technologies
... E-Tek
Dynamics ... Eton Pharma ..... Euclid
Labs .... Euclises Pharmaceuticals ..... Eureka
Therapeutics ..... Euthymics
Bioscience ... EVapt .... Evelo
Therapeutics ....
Evena Medical ..... Ever Cat Fuels
...
Evergen Biotechnologies ... Evergreen Solar ... Everspin
Technologies .... Evestra ....
Evident
Technologies ... Evofem Biosciences ....
Evoke Pharma .....
Evolution
Robotics ... Evolv .... Evolve BioSystems ....Evolved By Nature .....
Evozyne .... EWI .... Exact
Sciences .... Exagen
Diagnostics ... Excelimmune ... Excel
Technology .... Excision BioTherapeutics ..... Exelixis .....
Exelixis
Plant Sciences ... Exemplar Genetics .... Exicure .... Exo
.....
Exogenesis
..... Exone .... Exonics Therapeutics .... Exosome
Diagnostics ..... Exovita .... Biosciences .... ExploraMed
NC4 ...
Expression
Analysis .... Exquadrum .... Exsulin
....Extreme Molding ... Extremity Innovations ... EyeGate
Pharmaceuticals ... EyeNetra .... EyeTel
Fallbrook
Technologies
... Famigo ... Faraday Pharmaceuticals .... Farodox
Energy
Storage
...
FarSounder ... Far-Tech.... FastCAP Systems ...
Fate
Therapeutics
... Fathom .... Fe3 Medical .... FEI ... Femasys
.... Femta
Pharmaceuticals
.... Ferrate
Treatment Technologies ... Ferric Contrast ...... FerroKin
BioSciences ....
Fervo Energy .... Feuz Manufacturing ... FGC Plasma Solutions
..... Fiber and Sensor ....
Fiberight ...
Fiber Materials ... Fibersense ... Fiberstar ....
Bio-Ingredient
Technologies ... Fibertek .... Fibrocell Science
... FibroGen ... Filter
Sensing Technologies ...
Finally Light
Bulb ..... Finch Therapeutics Group ..... FineLine Prototyping ....
Finisar
... Fire Alarm
Specialty Design .....
Firefly
BioWorks ... Firefly Energy .... Firefly LED
...
First Solar ... Fisker Automotive ... Five Prime
Therapeutics .... Flex Biomedical
... Flexion Therapeutics ... Flex Pharma
.... Flextronics
America ....
Flexus Biosciences .... FLIR Systems
.. FloDesign
Wind Turbine ... FlowCardia
...
FlowMedica .... FlowMetric .... Flow Metrix
...
FluGen
... Fluidic Energy ... Fluidigm ... Fluid Innovation
Group
... Fluidnet ... Fluidnet
FluoroPharma
... Fog Pharma ..... Foghorn
Therapeutics .... FokusLabs .... FoldRx Pharmaceuticals
...
Follica ...
Footnote .... Foresight Biotherapeutics .... Forest Devices .... Forge
Therapeutics .....
F-Origin
... Forma
Therapeutics ...
Formlabs
.... For-Robin ..... ForSight Vision5 .... Fortis Therapeutics .....
Forty Seven ..... Forum Pharmaceuticals ..... Forus
Health ... Foster-Miller .... Foundation Medicine
... Fox Chase Chemical Diversity Center ....
Fractal
Antenna Systems ... Fractyl Labs ..... Freedom Meditech
... Free
Flow Power ... Free Form Fibers .... Freenome ..... Froedtert
Health ..... Frontier
NanoSystems ..... Frontier Technology ..... Front Range Biosciences
.... FTL Solar
...
FuelCell Energy
... Fuel Tech
.. Fulcrum Therapeutics ..... Fulgent Therapeutics ..... Full
Spectrum Genetics .... Furiex
.... Fused
Innocation.
...
Fusion
Coolant Systems ... Future Technologies
G1 Therapeutics ..... G3
.... Gadusol Laboratories (aka
Seaceuticals) ..... Galderma .... Galectin Thera ..... Galenea ...
Galena
Biopharma
.... Galera
Therapeutics ..... Galil Medical ..... Galleon
Pharmaceuticals ... GAM Enterprises .... GameSalad
... Gamma Medica Ideas ... Garland
Technology .....
Garwood Medical Devices ..... GATR Technologies ..... Gateway
Biotechnology .... G-Con .... Gecko
Biomedical .... Gecko Robotics .... Gel Combs .... Gelesis ... GelSight
.... Geltech ...
Gema Diagnostics .... GEMFIRE .. Gemin X Pharmaceuticals
... Gemmus
Pharma ... Gemneo Bioscience ..... Gemphire Therapeutics
...... Gemstone Biotherapeutics
..... Gen9 ...
Genaera ...
Genalyte
... Genapsys .... GenAudio .... Gene by Gene .... GeneCentric
Diagnostics
... Genelabs Technologies ... Gene
Logic ... Geneoscopy ..... General Compression
...
General
Pneumatics
..... Generation Bio ..... Generex
Biotechnology ... Gene Security Network .... GeneSegues
Therapeutics ..... GenesisLabs ....
GeneSystems ... Genetesis .... Genetic Networks ..... Genetix
Pharmaceuticals
... GeneTx Biotherapeutics ..... Geneu .... Genia
Technologies
.... GenMark Diagnostics
.... Genoa Pharmaceuticals ..... Genocea
Biosciences
... Genomatica
... Genome Profiling ... GenomeQuest ... Genomic Health
...
Genomind ....
Genoptix
Medical
Laboratory ... Genor ... Genprex .... Gen-Probe
...
GenSpera
.... GenTel BioSciences ... GentiBio .... Gentris
... GenturaDx
...nbsp; GenVec ... GenWay Biotech ..... Genzyme .... Geocent
.... Geocove ..... Geomagic
... GeoMed
Analytical ... GeoVax Labs ...
Geospiza
... Germfalcon ..... Geron ...
Gevo
..... GI Dynamics
... GigaGen ..... GigOptix
... Gilead Sciences .... Giner . ..
Ginkgo BioWorks
.... Glauconix ..... Glaukos
.... GlideLine
Systems ... Gliknik ... Global Blood
Therapeutics
...... Global Cancer Diagnostics ..... Global Positions ...
Global Blood Therapeutics ....
GlobeImmune ....
Gloucester Pharmaceuticals ... Glowforge ..... GlucaGo ...
GlycoFi
... GlycoMimetics .... GlyGenix ... Glympse Bio
.... Glyscend .....
GlySens
... GMZ
Energy
... GnuBio
.... Goddard Labs .... Goldfinch Bio .....Goodman
Technologies< ..... Good Start Genetics
.... Gore
Photonics ... Gossamer Bio ..... Gotham Biotech .... Gotham
Therapeutics ..... GPC-Rx
... gRadiant Research ... Gradiant ....
GraftWorx
..... Grail ..... Graphene
Energy
... Graphenix Development .... Graphic
Surgery ... GraphLab (now Dato) .... Grassroots Biotechnology
...
Greatbatch
... GrayBug ..... Graybug Vision ..... Great Basin Scientific .....
GreatGrow Maryland ....Great North Lab .... GreatPoint Energy
... Green & Grow .... GreenFuel
Technologies .... Greenlight Biosciences .... GreenMark Biomedical
..... Green Mountain Radio
Research .... GreenSight Agronomics ..... Green Sulfcrete
.....
GreenTech America
... Greenwich Geriatrics .... GridBridge .... Grid
Therapeutics
..... Gritstone
Oncology
..... GRO Biosciences ..... Group14 Technologies ..... Grove
Instruments
... Grow Home Organics
.... GSI Technology ... GT Advanced
Technologies ...
GTC Biotherapeutics ... G-Tech Medical .... GT
Equipment .... GTI
Diagnostics
... GT Medical
Technologies ..... GTx .... Guardant Health .... Guided Surgery
Solutions
....
Guided
Therapeutics
.... .... Guided Therapy Systems ..... Gynesonics .....
G-Zero
Therapeutics
Energy Now ...... H2O
Score ..... H2Pump ...
H2Sonics
.... H3
Biomedicine ... HNC Software ... Halozyme ...
Hana
Biosciences .... Hansen Energy and Environmental
....
Hansen Medical ... Haplogen Genomics ..... Harbor
Technologies .. Harbour BioMed ....Hardcore Computer ...
HarkerBio .... Harmony
Enterprises ....
Harpoon Medical .... Harpoon Therapeutics .... Harvard Apparatus
Regenerative Technology .... Harrisvaccines .... Harvard Bioscience
... Harvest Automation .... Harvest Power ...
Harvest Technologies .... HDL Therapeutics .... Healionics
.. Health Diagnostics
Laboratories .... HealthMyne ....
Healthtronics
.... Hearforward
... Heartland Robotics .... HeartWare International
... Heat
Biologics .... ... HeatGenie ... Helicos
BioSciences
... Helion Energy .... Heliovolt ...
Helius Medical
Technologies ..... Helix .... HelixBind .... Helix
Therapeutics
... Helomics (formerly Precision Therapeutics)
.....
Hemadvance ..... HemaQuest Pharmaceuticals ... Hemarrest ... Hememics
Biotechnologies< .... Hemera
Biosciences .... Hemispherx Biopharma .... HemoGenyx .... Hemoshear
Therapeutics ..... HemoSonics..... Hemostasis
... Hennepin Life Sciences .... Hepion
Pharmaceuticals .... Hepregen ... Heraeus Medical
Components .... Herley Industries
... Hermemics
Biotechnologies .... Hermes Biosciences ... HexaTech
.... Hexfuel .... Hibernaid .... Highbury Defense
Group .... High Impact
Environmental
.... HighPassBio .... High Performance
Technologies ... High Point Pharmaceuticals .....
Histogen
.... HighRes Biosolutions .... Histogenics
... HistoRx
... HistoSonics .... HJM
Precision .....
HocusLocus ..... Hoku
Scientific
... Holaira .... Hollingsworth & Vose .... Hollis-Eden
Pharmaceuticals ... Holomni .... Holos .... Homology
Medicine
.....
Honeycomb Batteries .... Hontek
... Hookipa Pharma .... Hoopers Island
Oyster Aquaculture ...
Hoppe Tool
.... Hoth Therapeutics ..... HotSpot Therapeutics .... Howe
Industries .... Hsiri Therapeutics ..... HTG
Molecular ..... HTSS ... Humacyte
...
Humanetics ..... Human
Genome
Sciences ...
Human
Metabolome Technologies .... HuTerra .... Huya Bioscience International
.... Hybritech ..... Hybrivet .... HYCOR
Biomedical ...
Hydra Biosciences ...
HydroCision ... Hydrogen
Safety ... HydroLogic Industries .... Hygeia
Therapeutics
... HyperBranch Medical
Technologies ... Hyperion Therapeutics ... HyperMed
... HYPRES .. Hy-SyEnce
... HyTrust
i20 Therapeutics .... IAP ... IBC Advanced
.... iBio .... iBiquity Digital ..... Ibis
....
Iblogix
.... IBT
Laboratories
... Icagen .... Icardiac.... Ichor Medical Systems .... Iconic
Therapeutics ..... Icos.... Icosavax ... ICX....
Idaho.... Ideal
Converters ... Ideapaint.... Ideaya Biosciences ..... Idera
Pharmaceuticals ..... ID Genomics ....
Idevices
... IDx ..... iFirst Medical Technologies ...... IFM
Therapeutics
..... Igenica
Biotherapeutics .... IGM Biosciences ..... Ignyta.... Ii-IV
.... Ikaria... Ikonisys... Illinois Superconductor.... Illumigen....
Illumina.... Illuminating Diagnostics ..... Illuminoss....
Illumitex.... Imagen Energy .... Imagevision.... Imaging
Biometrics... Imagineoptix ... Imago Instruments... Imanis
Life... Imara .... Imbed Biosciences... Imetalx... Immco...
Immersion... Immtech...
Immucell .... Immucor .... Immunai .... Immune...
... Immune... Immune Pharma .... Immunetics...
Immunex...
Immunexcite...
Immuneworks... Immunexpress ..... Immunic ..... Immunicon... Immunitas
Therapeutics ..... ImmunoCellular Thera .... ImmunoChemistry
Technologies ..... Immunocore...
Immunogen... Immunome ..... Immunomedics..... ImmunoMolecular
Therapeutics .... Immunomic Therapeutics
.....
Immunophotonics ... Immurx... .... Immusant...
Immusoft ..... Impact Biomedicines .... Impact Proteomics
.... Impact Science...
Impel
Neuropharma... Imperium Renewables... Impinj... Implant
Sciences... Impossible Foods .... Imprimis Pharmaceuticals .... Imprint
Energy .... Impulse
Monitoring ... Imricor Medical Systems ..... Imris .....
Imthera... ImvaxA .... I-nalysis ... Inari Agriculture ....
InCarda Therapeutics ....
INCELL .... Incelldx
..... Incitor (now XF
Technologies) .... Incodema3D ..... Incontrol
Research... InCube Labs ..... Incyte ....Incytu... Indalo
Therapeutics ..... Indiana
Nanotech... Indi Molecular ... Industrial Heat ..... Industrial
Perception...
Inentec ... InfaCare Pharmaceutical .... Infarct Reduction
Technologies .... Infinera...
... Infinia... Infinite Electronics .... Infinity... Infinium
.... Inflammatix .... Inform
Genomics... Infoscitex... Inframat... Infraredx... Infrascan... Inf
Robotics ... Infusion Medical ... Ingeneus... Ingeneron .....
Inhibitex... Inhibkase
Therapeutics .... Inhibrx< .... INI
Power... Inland Labs ..... Inmobly .... INmune Bio .... InnAVasc
Medical ....
Inneroptic...
Innerpulse... Innocrin Pharmaceuticals ..... Innography...
... Innopad... Innotec ..... Innovalight...
Innovari Energy Design Microplate Scientific...
pulmonary solutions.... silicon... Innovate Biopharmaceuticals .....
Innovative Spinal...
Innovative... Innoventiontech ... Innovention (now
Ccardiorobotics) ... Innovative Trauma or...
Innovolt ...
Innowave... ... ... Innoviva ...
Innov-x... Inocucor ..... Inorganic Specialists... Inotek...
Ino
.... Inova
Labs
Biomedical... Inovio... Inovise Medical ..... Inozyme Pharmaceuticals
..... Inphase...
... Inphi... Inpria ..... Inscripta ..... Insert MRI...
Insight...
..Insite Vision...... Insitu... InSitu
Biologics ..... Insmed... Inspired Solar Systems ...
Inspire...
Insulet
Labs
... Intact Vascular... Intaglio... Intalio ... Intarcia
Therapeutics ...
Integenx... Integra Group Diagnostics... Integral Molecular .....
Integrated BioTherapeutics
.... Integrated
Diagnostics .... Integrated
Diagnostics InDi .... Integrated DNA Technologies ..... Integrated
Fuel...
... Integration Associates... Intelect
Medical
Intelleflex ... Intellia Therapeutics .....
Intellicyt
Automation Bio-systems ...
Intelligent Devices .... Intelligent Epitaxy Technology .....
Intellimedix ..... Intelliphage.... Intellirad
Control...
.Intellisense .... Intelomed ....Inter-4... Interactive Supercomputing
... Interdigital
Interlace ....
Intermagnetics General ...Intermolecular ... Intermune....
International Stem Cell ... Interpace
Biosciences ..... Interrad Medical ..... IntersectENT ....
Intersense... Intersystems ...
Intervalve.... InterVene .... Intevac.... Intra-Cellular Therapies
.....
Intralase ...... Intralytix .... Intrepida Bio .... Intrexon .....
Intrinsic Therapeutics
.... Intrinsity....
Introgen....
... Intuitive Biosciences .... Intuitive Genomics ..... Intuitive
Surgical.... Invenra ....
Invensense .... Inventev ..... Inverness
Innovations.... Invirsa ..... Invertix.... Invictus.... Inview
Technology....
Inviragen.... Invisage Technologies ....
....InvisionHeart .... Invision Medical ....
Invitae....
Invitrogen.... ...Invivosciences.... Invivo Therapeutics=
Holdings .... Invuity....
Inx Medical.... IoGyn .... Iomai.... ... Iomed....
IOmet
Pharma ..... Ion America Optics..... Ionic Materials ..... IonQ ....
Ion
Torrent.... Iovance Biotherapeutics ..... Iovation.... Iowa Thin
Film.... IgGenix .... Ipierian.... IPG Photonics....
... Iquum
...Irhythm...
iRobot... Iroko...Ironbridge.... ... Ironwood....
... .... Irvine Sensors... .... biopolymer
. .... Ischemia Care.... iSee ..... iSIGHT
Partners
.....
Isis.... Island Ddata....
Isogenis.... Isomark.... IsoPlexis .... Isoray....
Isothermal....
Isthmus Biosciences ..... IstoTechnologies....
itaconix....
I-Therapeutix..... Itherxm Pharmaceuticals.... Itraumacare... .. Itseez
..... Itzbig ..... Iveric bio .... Iwalk
Jade Therapeutics ..... J&Y ... Janssen Biotech .... Janus Biotherapuetics ... Javelin Pharmaceuticals ... Javelin Semiconductor ... JDP Therapeutics ..... Jennerex ... Jnana Therapeutics ..... Joule Biotechnologies .... Jounce Therapeutics .... Joyent .... Joylux .... Joyn Bio .... Juno Therapeutics ..... Just Biotherapeutics
K2M .... K2 Therapeutics
.... KAER
Biotherapeutics .... Kala
Pharmaceuticals ... Kalion .... Kaleido
Biosciences .....
Kallyope ..... KaloBios Pharmaceuticals ..... Kalocyte .... Kalon
Biotherapeutics ..... KalVista Pharmaceuticals .... Karius ..... Karuna
Therapeutics ...
Karyopharm Therapeutics ... Kateeva
..... Kayo
Technology ..... KaZaK
... KC BioMediX ... KCI .... KDH Defense Systems
... Kebotix .... Keithley Instrument ...
Kelyniam ...
Kenall
Manufacturing
..... Kensey-Nash
... Kent Displays ... Kentucky
BioProcessing ....
KeraNetics .... Keros Therapeutics ..... Kezar Life Sciences ..... KeyW
.... Kilawatt
Technologies ... Kinaset Therapeutics .... Kindara .... KinDex ...
KindHeart ..... KineMed ....
Kinestral Technologies ..... Kineta ...
Kinetic
Concepts .... Kinex
Pharmaceuticals .... Kingbright .... Kior .....
Kips Bay
Medical ... Kite Pharma ..... Kitware ...
Kiva Systems ... KLD
Energy Technologies .... Klotho Therapeutics .... KMel
Robotics .... Knightscope
.....
Knome ...
Knopp
Neurosciences .... KNOW Bio ..... Know Labs .... KnuEdge ....
Koam
Engineering Systems .... Kodiak Sciences
.... Kolltan
Pharmaceuticals
...
Komoku ... Kona Medical .... Konarka ... Koning ...
Kopin
.. KOR
Electronics ...
Koronis Pharmaceuticals ... Kosan Biosciences ... Kosmetikos
....
Kovio ... KPI
Therapeutics (from Kineta)... Kraig Biocraft ..... Kratos Defense
& Security
Solutions
.... Kronos Advanced
Technologies ... Krystal Biotech .... KSE
... KSQ Therapeutics ..... Kultevat ..... Kura Oncology ....
Kumu Networks .... KVH
.. Kylin
Therapeutics
...
Kyma ....Kymera Therapeutics ..... Kymeta
... Kyn Therapeutics .... Kyocera
Solar .... Kypha ..... Kyras Therapeutics ..... Kyron Clinical Imaging
.... Kytopen
LAAMScience
... LaBelle
Associates .....
LabNow
...Laborie Medical Technologies ... Labrys Biologics ... Lacerta
Therapeutics ..... Lactic
Solutions ..... Laguna
Pharmaceuticals (formerly ChanRx) ..... La Jolla
Pharmaceutical
... Lake Shore Cryotronics .... Landec
.... Landos Biopharma .... Lantern
Pharma ..... Lantheus
...
Lantos
Technologies ... Lariat Biosciences .... Laser
Design .... Lasergen ..... LaserMax ..... LaserMotive
... Laser Tissue
Welding .... Lassen Therapeutics .... Lattice
Biologics ..... Lattice
Biotech .... LaunchPad Medical .... Lawrie ... Lazarus Effect
..... LDR
Holding
..... Leading Edge Crystal Technologies ..... Lead Therapeutics
... LeafBio .... LeCroy ... LED Lighting
Fixtures
... Lehigh
Technologies .... Leica Microsystems
.....
LetoSolutions .... Lexicon
Genetics
... LexaGene ..... Lexicon Pharmaceuticals ... Lexington
Medical .... Leuko .... Leyden Energy ... Libra
BioSciences .... LifeCell ... LifeGen
Technologies ...
Life Image ... LifeMine Therapeutics .... LifeSprout ....
Life Technologies
....
Ligand
Pharmaceuticals ....Ligon Discovery ... Lightpointe
... Light Sciences Oncology ... LightWorks Optics
....
Lilliputian Systems
.... Lily Robotics ..... Linares Management
Associates
.. Lingotek
... Linnaeus Therapeutics .... LinQuest .... Lionano .... Lion
Biotechnologies ..... Lipocine ....
LipoScience
...
Liquid Biotech ..... Liquidia
Technologies ...
Liquid Light ...
Liquid Metal
Battery ...
LiquidPiston ... Liquid Robotics ... Liquid X Printed Metals
....
LiQuifix ...
Lithium Technology
... LiveData ... . LiveLeaf
Bioscience .... LKC Technologies ... Locana.... Locus Biosciences ....
Lodo
Therapeutics .... Logical
Therapeutics
... LogicBio Therapeutics ..... Logos
Tech
... Lohocla Research
.....
Lombard Medical ..... Longeveron ..... Longeviti .... LonoCloud .....
Lookingglass ..... Loon Medical
..... Lotus Tissue
Repair
...
Loxo Oncology ... LPath Thera .... Lq3 Pharmaceuticals ....
LS9
...
Luca
Technologies .... Lucerno Dynamics .... Lucidux ...
Lucigen
.... LumaSense Technologies .... Lumena
Pharmaceuticals .... Lumen Bioscience .... Lumencor
... Lumense .... Lumera ... Lumicell Diagnostics
... Luminar Technologies ..... Luminary Micro ...
Luminex .... Luminus Devices ... Lumisyn
..... Lumitex
... LumiThera .... Lumos Pharma .... Luna Innovations
... Luna Technologies
... Lung Therapeutics .... Lutonix
... Luxtera
... Lycera ... LyGenesis ..... Lyncean ..... Lyndra
Therapeutic ... Lynntech ... Lynx Biosciences ... Lyra Therapeutics
..... Lysosomal Therapeutics ....
Lytro Therapeutics
M3 Biotechnology ....
MabVax .... MacAulay-Brown
..... Macrochem ...
MacroFab ..... Macrogenics
... Macrolide Pharma ..... Macrophage Therapeutics ....
Madison
Vaccines .... Madrigal Pharmaceuticals ..... MagBioSense ..... Magenta
Therapeutics ..... Magic Leap
..... MagneMotion ...
Magnesium Development ..... Magnetek ... Magnolia
Medical
Technologies .... Magnolia Optical
Technologies
... Magnolia Solar ... Mainstay Medical International ......
Mainstream Engineering ... Major
Pharmaceuticals .... Mako Surgical
... Mammoth
Biosciences .... Manhattan Scientifics ..... Manifold Bio .... Mantra
Bio .....
>Manufcturing Techniques ..... MapInfo
...MAP
Pharmaceuticals
... Mapp
Biopharmaceuticals .... Marathon Pharmaceuticals ..... Marcadia
Biotech
... Marina Biotech ... Marinus
Pharmaceuticals
... Maritime Applied Physics ....Marker Therapeutics ....
Marrone Bio Innovations
....
Martek Biosciences ...
MarvelBiome .... Mascoma ... Mashery
... Mason Box ... Masten Space Systems
... Masterson Industries .... Mast Therapeutics
(formerly
ADVENTRX) .... Material Sciences ... Material
Technologies ... MathStar ... Mati
Therapeutics .... Matouk
Textiles ... Matritech ... Matrix Product Development
.....Matrix
Research ....
Matrix Sensors ... Maverick Therapeutics .... MAX
BioPharma
...
MaxCyte ...... Maxdem
... Maxpower ... Maxygen ....
Maze Therapeutics .... MBio Diagnostics
.... MC10 .... MCube .... M
Cubed Technologies .... MD Biosciences ..... MDSolarSciences
... Mebias Discovery ..... Mechanical
Technology
...
Mechanology ... Medafor ...
Medarex ...
MediBeacon .... Medicago USA .... Medical21 ..... Medical Cyberworlds
.... Medical
Device Logistics ...
MedicaMetrix... Medgenics ..... MediciNova .....
Medicool
Technologies .... MedImmune ..
Medina Medical .... Mediomics .... Medior Therapeutics .... Medis
... MEDITE Group .... Medivation ... Mednology Solutions ....
Medrobotics ...
MedShape .... MedSocket (formerly 1CDS) ...... Medsphere Systems .....
MedTel ..... MEI Pharma
..... Meka .... MELA
Sciences .... Melinta Therapeutics .... Melior Discovery .... Memjet
...Memry ...
Memsic ... MEMS Optical... Mendel Health .... Menlo Therapeutics .....
MER
...
Mercator Therapeutics ... Mercury Computer
Systems .... Merganser Biotech ....
Merge
Technologies ... MeriaGTx ..... Meridian Bioscience
... Meritage Pharma ..... Merkatum ... Merrimack
Pharmaceuticals
... Meryx .... Mersana Therapeutics ... Mesa
Photonics ... Mesocopic
Devices ... Metabasis ... Metabiota .... Metabolic Solutions
Development .... Metabolex .... Metabolix
... MetaCarta ... Metacrine .... Metactive Medical
.....
Metal Oxygen
Separation Technologies ... Metamark Genetics ...
MetaModix
... Metavention ..... Metompkin Seafood .... MetroLaser ...
MGC
Diagnostics
...
MIACH Orthopaedics ..... Misaole .... Micell
Technologies
... Michelman ... Micracor .... Micrel ... Microbiotix ....
MicroCoating ...
Microbe Detectives
... Microbia ... Microbot Medical ... Microfluidics International
(Microbia)
... MicroGreen
Polymers .... MicroIslet ...
Microlin Bio ....
MicroMask ...
Micronics ... MicroOptical (New
Mexico)... MicroOptical
(Massachusetts) ... MicroOptx ..... MicroPower Technologies
...
MICROrganic Technologies .... MicrowSat
Systems .... Microscopy Innovations ..... Microstaq
... MicroTransponder ..... Microvision ... MicuRx
Pharmaceuticals
.... Midori Renewables
..... Mid Valley
Industries
... Milestone Pharma ..... Millendo
Therapeutics (born as
Attercor) ..... Million Concepts ..... Miltec .... MiMedx Group ....
MimiVax ....
Minerva
Biotechnologies
... Minerva Neurosciences .... Minerva Surgical
.... Minimally Invasive Devices .... Minnesota
Thermal Science ..... Minnetronix ... MIOX ..... Mirador Biomedical
... Mira Dx ... MiRagen
Therapeutics .....
Miramar Labs .... Mirati Therapeutics ..... miRecule .... Mirimus ...
Mirina ... Mirna
Therapeutics.... Miromatrix Medical ...
Mirus Bio ....Mirum Pharmaceuticals ..... Mission Bio ..... Mission
Research ...
Mississippi Polymer ... Mithridion ...
Mitochon Pharmaceuticals ..... Mnemosyne
Pharmaceuticals ...
Mobile Robots ... Mobius Therapeutics ..... Moderna Therapeutics ....
Modern Meadow .... Modern Technology Solutions
.... Modis Therapeutics ..... Moduline Systems .... Modumetal .....
MOgene Green Chemicals ....
Molecular
Biometrics
... Mohawk
Innovative Technology ..... Molecular Assemblies .... Molecular
Detection ... Molecular Diagnostics .... Molecular Imprints
... Molecular Insight
Pharmaceuticals ... MolecularMD ... Molecular
Sensing ... Molecular Templates
.... Moleculin Biotech ..... Molten
Metal .. >Moma Therapeutics ..... MoMelan
Technologies ... Momenta
Pharmaceuticals ... Monebo ... Monogram Biosciences
.... Monopar Therapeutics ..... Monteris Medical
..... Morphic Therapeutics
.....
Morphormics
... Morphotek
...
Morris
Innovative Research ... Mortara Instrument ...
MortaSecurity .... Motif ... Motricity
... Motus Therapeutics .... Mound Laser
& Photonics Center ..... Movia Robotics ..... Moximed ....
mPower Technology .... MPP
Group ... MPSP ...
MSNW ....
Mudawar Thermal
Systems
.....
Munksjo Paper ... Muons ... Muse bio .... Myco
Technology
....
Myocor
... MyoKardia
...
Myomo
... Myonexus Therapeutic ..... Myovant Sciences
.....
Myriad Genetics
...
Myriant
Technologies
... Mystic Pharmaceuticals
N12 Technologies
... (N30 Pharmaceuticals) now Nivalis Thera .... NABsys
... Nalas
Engineering ....
Nammi Therapeutics ..... NanOasis Technologies
... NanoBio
...
Nanobiosym ... Nano-C ... NanoCellect (formerly NanoSort)
.....
Nanocomp Technologies ...
NanoCoolers ... Nanocopoeia ... NanoCor Therapeutics
...Nanodynamics (Buffalo) ... Nano DX ..... Nanodynamics
(NYC)...
NanoeXa
.... Nanofiber Solutions ... Nanogen ... NanoGraf (formery SiNode)
..... NanoGram .... nanoGriptech
..... NanoGuard Technologies .... NanoH2O ...
Nanohmics ... NanoLab
... NanoLite Systems ... NanoLogix ...
NanoLumens
..... Nanomaterials
Research
... NanoMatrix ... NanoMedex ... NanoMedicalSystems
...
NanoMedical Systems .. Nanomix ... nanoMR ..... Nanophase
Technologies
... NanoPhotonica ... Nanopore Diagnostics ..... Nanoptek
... Nanoramic
Laboratories (formerly FastCap Systems) ..... nanoRETE .... Nanoscale
Components ...
Nanoscale
Materials
... Nanoscope Technologies .... Nanosolar ...
Nanosonic ... Nanospectra Biosciences .... Nanosphere ... NanoSteel
...
Nanostim .... NanoString
Technologies .... Nanosys ...
NanoSystems ... Nano Tailor ... Nanotech Energy
..... Nanotek Instruments
.....
Nano-Terra ... Nanotherapeutics ..... NanoTune Technologies
... Nanova
....
Nanovation
Technologies ... NanoVault Medical .... NanoVibronix ... NanoViricides
... NanoVision Diagnostics .... NantCell
..... Nantero .... NantHealth ... NantKwest ..... Napo
Pharmaceuticals ... Narus
Biotechnologies ..... Nascentric
... Nastech
Pharmaceutical ... Natera .... National Technical Systems
..... Natural Molecular Testing ..... NaturalNano ...
Nature's
First .....
Natus Medical ... Naverus ... Navidea
Biopharmaceuticals ... Navini Networks
... Navire Pharmaceuticals .... Navitor Pharmaceuticals ....
Navmar Applied Sciences
... NBD Nanotechnologies ....NCD Technologies
.... nContact
Surgical ...
Neah Power ... Near Infinity .... Neato Robotics ... Necci
.... Nektar
Therapeutics ... Nekton
Research
.... NemaMetrix .... NeoChord ... Neogen
.... NeoGenomics ..... Neograft
..... Neoleukin Therapeutics ..... NeoLight .....
Neon Therapeutics ....
NeoPhotonics ... Neoprobe
...
Neos Therapeutics ..... NeoSync ..... Neothetics .... Neotron
...
NephroGenex .... Nereus
Pharmaceuticals ... Nest .... Netcentric .... Netezza ...
NetLogics
Microsystems... Netspeed Systems ...... Net Watch
Solutions
..... NetworkFab
...
NeurAccel
Biosciences ...
Neurala .... Neural Analytics .... Neuralstem .... Neuraly
..... Neuraptive
Therapeutics .....
Neuro
Amp .... Neurobiological
Technologies
...
NeuroChaos Solutions .... Neurocrine Biosciences
...
NeuroDx Development ... NeuroEM .... Neurodyne Medical ...
Neurofluidics ....Neurogastrx .... Neurogen
... NeurogesX ...
Neurognostics .. NeuroHabilitation .... NeuroLogica
.... NeuroLutions ..... NeuroMap
... Neuro Kinetics ....
NeuroMetrix... Neurona Therapeutics .... Neuronetics .
Neuronex .. NeuroOne ..... NeuroPace
...
NeuroPhage
Pharmaceuticals
... Neuron Systems ... NeuroPointDX
..... Neuroptix
... NeuroRecovery
Technologies .... Neuroscience .... NeuroSigma .... NeuroTek ....
Neurotrack ....
NeuroTronik .... Neurotrope ..... Neurovance
... NeuroVigil ...
Neurovascular
Diagnostics ..... NeuroVision Imaging .... NeuroVista ....
NeuroVive
.... NeuWave
Medical ...Nevro ... New Dominion Enterprises ..... NewLeaf
Symbiotics .... NewLink Genetics
.... Newlink genetics england ... biolabs ...
new
era technology ... New Haven Pharmaceuticals ... Nexant
...Nexbio
... NexImmune .... NexPlanar .... NextCODE Health ....
NextCure ..... Nextio ....
NEXTracker
....Nextreme Thermal Solutions ... NextStep Robotics .....
Nexus
Biosystems ..... NFlection Therapeutics ..... NG1 Technologies .... NGM
Biopharmaceuticals .... Nico
..... Night Vision ... Nido Biosciences ....
Nimblegen Systems ... Nimble Storage .... Nimble Therapeutics
.... Nimbus Discovery ... Nimbus
Therapeutic
.....
Ninepoint
...Niowave ... NIRvana Sciences .... Nitero....
Nitric Biotherapeutics
....Nitricgen ... Nitride Solutions .... Nitrogenics ..... Nitrome
Biosciences ..... Nitromed ...Nitronex
... Nivalis Therapeutics formerly N30 Thera ..... NKT
Therapeutics ...
Nlight ... NMT Medical .... Noah
Technologies ....
Noble Fiber
... Nocion Therapeutics .... Nohla Therapeutics
.... Noivatone .... Nok Nok
Labs .... Nomadics .... NONA Composites .... Noninvasix ....
Nonvolatile
Electronics .... Nora Therapeutics .... Norian ... NorMedix
.....
Normoxys
.... Norse .... Northeast Photosciences
... Northstar Medical
Radioisotopes .... Northstar Photonics...
Northwest Biotherapeutics .. Norwich Technologies ....
Nostopharma .... Notice
Ttechnologies ... .Novacea
... Novalar Pharmaceuticals ... Novalux
... Novan
Therapeutics .... NovaScan
... Nova Synthetix .... Novatek ... NovaTorque
... NovaTract
Surgical
... Novavax .... Novazyme Pharmaceuticals ..... Novecon
Technologies ... Novella
Clinical
.... Novelos
Pharmaceuticals
... Novelos Therapeutics ... Noveome Biotherapeutic
.....
Novian Health .... Novira
Therapeutics ...
Novocell ... Novogy
... Novome Biotechnologies .... Novomer
...
Novophage ... Novo Sol-u-tions MD .... Novosource ...
Novozymes .... Novus Biologicals ....
Noxilizer
... Nox Technologies ... NP Photonics ...
NPS Pharma ..... NRGindependence ..... NSS Labs
..... Nucelis
.... Nuclea
Bioechnologies ... Nufern .... NuGEN Technologies ..... NuMat
Technologies ..... NuMedii
.... NumereX .... NUMiX Materials ..... NuPathe .... Nurel
(now PeriphaGen) .... Nurix Therapeutics ... Nuron
Biotech ... Nutrabiotix
... Nutrient Recovery and Upcycling .... NuVant
... Nuvaira .... NuVascular Technologies ....Nuvation Bio ....
Nuve .....
Nuventix ...
Nuvera Biosciences ... Nuvera Fuel Cells.. . Nuvotronics
.....
Nuvox
Pharma ..... Nu Waves ..... NxThera ... Nvision
Biomedical
Technologies ..... NZ
Applied Technologies
Oak-Mitsui .... Oasys
...
ObjectVideo
... Obsidian Therapeutics ..... OBS
Medical ... Ocarina Networks ... Ocata Thera ...
Occipital .... Ocean Bio-Chem .... Ocean Power
Technologies
... Ocean Renewable Power .... Ocera Thera .... OCI ...
Ocugen ..... Ocular
Therapeutix
....
Oculeve
... Oculogica ..... Oculus ... Oddpost
... Odyssey Systems
Consulting Group ... Oil Chem
Technologies ... OLEDWorks .... Olema Oncology .... Omega Therapeutics
.... Omeros
... OmniGene Bioproducts ... OmniGuide ...
OmniLytics
... Omniox ..... OmniSonics Medical Technologies
... Omnis
PharmaRebiotix .... Omni
Water Solutions ... Onboard Dynamics .... ONCE Innovations
.....
OnChip
Power .... Oncobiologics ..... OncoCyte
.... Oncogenex
... Oncolmmune ..... Oncolinx .... Oncolix ..... Oncolytics
Biotech
...
OncoMed
Pharmaceuticals .... OncoNano Medicine .... Onconova
Therapeutics
...Oncoscope
...
OnCore Biopharma ..... OncoResponse ..... Oncorus .....
OncoSec
Medical
.... OncoTartis ...... Oncothyreon
... Oncovista Innovative Therapies ..... Oncternal
Therapeutics ... Onduo ..... One
Resonance Sensors .... Onexio Biosystems .... Onko Solutions ....
OnKure Therapeutics ..... ONL
Therapeutics .... OnLume ....
On-Q-ity .... Onspira Therapeutics .... On Target
Laboratories
.... Ontela ..... On-X
Life
Technologies ....
Onyx
Pharmaceuticals ... Oorja
Protonics .... Open Algae ... Open Monoclonal Technology
.....
Open Silicon
... OpenWater
Power .... Opertech Bio ..... Opexa
Therapeutics
... OpGen ... OPNET Technologies
... Opsonix .... OptTek
Systems ... Optelecom ...Optelecom-NKF ... Optherion ...
Optical
Concepts .. Optigain .. Optimal Technologies ... Optimus
Technologies .... OptiNose .... Optivision
...
Optofluidics ... OptoLum ..... Optonicus .... Opto Technology
...
Optomec
....
OPX
Biotech
... Oragenics .... OraMerix
... Orasi Medical ... OraSure
Technologies .... Orbital Insight .... Orbital Sidekick ... Orbital
Technologies
... Orbotix .... Orca Bio .... Orchard Therapeutics
.....
Orchestra BioMed .... Orchid
Cellmark
... Oregon Iron
Works .... Orexigen
Therapeutics
... Organic Research .... Organogenesis ...
Organovo
..
ORIC Pharmaceuticals ..... Oricula Therapeutics .... Origin
Medsystems ..... OriginOil
... Orion Energy Systems ... Orion Genomics ...
Ormet
Circuits ... Oroboros Bio .... Orologic...
OrphoMed ..... Ortel ...
OrthoAccel
Technologies ... Ortho Kinematics
.... Oryx Technology ... Osazda Energy ... Oscient
Pharamceuticals ...Oscilla
Power
.... Osiris
Therapeutics ... OSI Pharmaceuticals ... Oso Biopharmaceuticals
Manufacturing .... Osprey Medical ....
Ossianix
... OSSIO ..... Ostendo Technologies ...
Osteotech ... Osterhout Design Group .... OtoNexus Medical
Technologies .... Otonomy .... OtoSense
.... Ottomatika .... Outset Medical .... OvaScience ...
>Ovid Therapeutics ..... Oxalo Therapeutics .... Oxford
Performance Materials ... Oxis International .... Oxygen
Biotherapeutics ... Oyster Point Pharma
P3I ... Pace Packaging
.... Pacific Biosciences
.... Padlock Therapeutics .... Pain Therapeutics ...
PaizaBio .... Palvella Therapeutics ... Palantir Technologies ....
Palleon Pharmaceuticals ....
Palmaz Scientific ..... Palmer
Labs
...
Paloma Pharmaceuticals ... Panacea Solutions ....
Panacos
... Pandion ..... Pandromics ..... Pan Genome Systems .... Panomics
..... PanTheryx .... Paper
Battery ....
PapGene .... Parabricks .... Paradigm Diagnostics
.... Paradigm Sensors
... Paradromics ..... ParaGen Technologies ..... Paragon
Bioservices ..... Paragon Dynamics .... Paragon Space
Development ...
Paragonix Technologies .... Parasol Therapeutics
... Paratek
Pharmaceuticals .... Parexel International .... Parhelion .... Parion
Sciences
... ParkerVision .... Partner Therapeutics ..... Partpic ....
Passage Bio ... Passport
Systems ... Pasteuria Bioscience ... Pathfinder ...
PathoGenetix
... PathoVax ..... Pathway Genomics .... PatientStream ...
PatientWise ...
Patton Medical Devices ... Patton Surgical .... Pavilion
Technologies ... Pax Streamline ... PaxVax ...
PDI Therapeutics ..... PDL
BioPharma ... PDS Biotechnology ..... Pearl
Therapeutics
... Pear Therapeutics ..... PECA Labs
.... Pediatric Bioscience .... Peerless Technologies .... Pegasus
Sustainability Solutions ....
Pelican
Products ..... PellePharm .... Pellion
Tech ... Peloton Therapeutics ..... Peninsula
Pharmaceuticals ..... PennAlt Organics ..... Penumbra .....
PeproMene Bio .... Peptimed
... Peptilogics .... Peptimmune
... Perceptive Navigation ..... Perceptive Sciences
... Perceptron ....
PercipEnz
Technologies
... Peregrine Semiconductor .... PeriphaGen .... Permeon
Biologics
...
Perosphere .... Perscitus Biosciences ... Perseon .....
Persimmon
Technologies ....
PersonalBee ... Personalis ...... Personal Genome
Diagnostics
.... Pervasis Therapeutics
... Pervasive
.... Petra Pharma ..... Pfenex ...
Pharmacyclics
.... PharmaJet .... PharmAkea Therapeutics ....
Pharmasset
... PharmAthene
... PharmatrophiX .... PhaseBio
Pharmaceuticals .... Phase Bioscience ... PhaseRx ....
Phigenix
..... Phoenix (formerly Phoenix Nuclear Labs) ..... Phoenix Analysis
and Design Technologies ..... Phoenix
Biotechnology .... Phoenix Molecular Designs .... Phoenix
Nuclear Labs ...
Phio Pharmaceuticals .... Phoenix Science
.. Phononic
Devices
... Photobit ... Photolitec .....
PhotoMedex
... Photonics
Innovations ... Photon-X ....
PhotoSonix Medical .... PhotoThera
...
Photronics ... Phoundry Pharmaceuticals .... Phraxis
.... Phrixus
Pharmaceuticals ..... Phurnace
Software ... PhylloTech ..... Phylonix
.... Phylos Bioscience ..... Physcient .... Physical
Optics... Physical
Sciences
... PhysioGenix
... PhysioSonics ... PhytoTech ... Picolight ....
Picometrix
... PIC Therapeutics .... Piedmont Biofuels .... Pieris
Pharmaceuticals ..... Pika
Energy ... Pilus
Energy ....
Pinger
...
Pinnacle Technology ... Pioneer Surgical
Technology .... Pionyr Immunotherapeutics ..... Pivot
Bio ..... Pixelligent .... Pixel
Optics .. Pixim ... Pixtronix ... Plakous Therapeutics .....
Planar Energy
...
Planar Systems ... Planet Labs .... Plano Microwave ..... Plasan ...
PlasmaTech Biopharmaceuticals .... Platelet
BioGenesis .... Platypus
... Play-i
.... PLC
Medical Systems
... Plextronics ... Plexxikon
... Pliant Therapeutics .... Plug
Power ... Pluromed ... Plus Therapeutics .... PLx Pharma
..... PLX Technology ....
PMT
.... PMV Pharmaceuticals .... PneumRx .....
Point Source .... Polarean ..... Polatis
.... Polychromix
...
Polyera ... PolyMedica ... PolyMedix ... Polymer
Technology
Systems ... Polynoma ..... PolyNova .... PolyPlus ... PolyRemedy ...
Polysciences ... Polystor ...POP
Biotechnologies .... Portola
Pharmaceuticals ... Poseida Therapeutics .... Possis
Medical ... Pothole Pros ... PowerGenix ...
Powerlight
... Power
Precise Solutions ... PowerVision ... Pozen ... PQ
Bypass .... Prairie
Technologies ..... Pranalytica ... Praxis Biotechnology .....
Precipio ... Precision Biopsy
... Precision BioSciences
.... Precision for Medicine .... Precision Genome
Engineering .... Precision Ocular Metrology ..... Precision Optics
...
Precision
Therapeutics (now Helomics) .... Precision Virologics .... Precisive
Surgical .... Predictive
Biosciences
... Pregmama ..... Prellis Biologics .... Presage
Biosciences
... Presidio
Pharmaceuticals
.... Pressure BioSciences
... PreTalen ..... Prevail Therapeutics ..... Preventice .....
Prevention
Pharmaceuticals ....
Prieto Battery ..... Primary Data ..... Primera
Biosciences ... Primordial .... Primorigen Biosciences
... Primus Power .... Princeton Satellite
Systems ..... Principia Biopharma ....
Prism
Solar Technologies .... Procept BioRobotics ..... ProCertus
BioPharm
... Processa Pharmaceuticals .....
Proclara
Biosciences (formerly
NeuroPhage
Pharmaceuticals) .... Procyrion .... Profectus BioSciences .
.. Progenics
Pharmaceuticals
... Progenity .... Progeny Systems ..... Prologic
...
Promedior
...
Promega ..... Promentis .... Prometheus Laboratories
.... PROMISS
Diagnostics ...... Pronutria ..... Propagenix ..... Propeller
Health .... Propulsive Wing .... ProstaGene ....
Protagonist
Therapeutics .... Protein Foundry ..... Protein Sciences
... ProteinSimple (formerly Cell
Biosciences) .... Proteon Therapeutics
...
Proteostasis
Therapeutics
... Proteotech ... Proteus
Biomedical
... Proteus Digital Health .... Protez Pharmaceuticals
.... Prothena .... ProThera Biologics ...
Proto Labs ... Proton Energy Systems ...Protonex ..
Prototype
Productions .Provagen ... Provenance Biopharmaceuticals
... Provention Bio .... Proventys
... Provista Diagnostics .... Pryor Medical Devices .....
PsiKick
..... pSivida
... PTC Therapeutics
.... Pulmatrix ... Pulmonx .... Pulmotect ..... Pulse
Aerospace .... Pulse
Electronics ....
PulseTherapeutics .... Puma Biotechnology ..... PUR
Biologics ..... Pure Bioscience .... Purfresh
... Purillume ..... Purinomia Biotech .... Pursuit
Vascular ... PurThread
.... PvP
Biologics ..... Pylum Biosciences ... Pyramid .... Pyran ... Pyxis
Oncology
Q32 Bio .... Qcept Technologies ....
Qcue .... QD Vision
... QED ... qFuzion ..... Qioptiq
... QM Power
... Qpex .... QPixel ... QR
Pharma
... QSpex .... Qteros
... QuaDPharma .... Quadra-Aerrow International ...
Quadraspec
...
Quad Technologies .... Qualcomm ... QualityMetric
...
Qualtech Systems ....
Qualtré ... Quanterix
... QuantRx Biomedical
.... Quanttus .... QuantTera .... Quantum Circuits ..... Quantum
Epitaxial
Designs ... Quantum Fuel Systems... Quantum Logic
Devices
... Quantum Materials .... QuantumSphere
.... Quantum Xchange .... Quark
Biotech ... Quark
Pharmaceuticals ... Qubitekk ..... QQuench Bio .... Quentis
Therapeutics .....
Quick–Med
Technologies .... Quid ..... Quidel
... Quincy
Bioscience
... Quintessence Biosciences ... Quorum
Systems QurAlis
Radant Technologies ... Radiabeam Technologies
... Radiance Technologies .... Radiant Photonics...Radiation
Monitoring Devices
... RadioMedix ... Radius
Health ....
Rafagen ... Rainbow Organic Farms ... RainDance
Technologies
...
RainStorm ...
Rain Water Solutions ... Rallybio ..... Raland Therapeutics .... RaNA
Therapeutic ...
RAN Biotechnologies .... Range Fuels
... Rapamycin Holdings ..... RaPharmaceuticals
... Rapid Diagnostek ... Rapid
Micro Biosystems
... Rapiscan ... Rapt Therapeutics ... RareCyte
..... Raser Technologies
.... Raydiance ... Raydiant Oximetry .... Raymond
.... Raze
Therapeutics
.... RE2
.... ReadCoor ..... Ready Robotics ..... ReAlta Life
Sciences .... Reata Pharmaceuticals ....
Rebellion
Photonics .... Rebion ..... Rebiotix ....
Receptor Logic ...
Receptos
..... Recodagen ... ReCode
Therapeutics .... Recombinetics
... ReconRobotics
.. Recovery Engineering ..... Recro Pharma ....
Recursion
.... Redox Power
Systems .... Redpin Therapeutics .... Red Rock Biofuels .... RedShift
BioAnalytics .... Redwood Robotics .... RedZone
Robotics .... RefleXion
Medical .... Refuge Biotechnologies .... Regado
Biosciences
... ReGear Life Sciences ..... ReGen
Biologics ... Regenerative
Medical Solutions ..... Regenerative Sciences ... Regentys
(formerly Asana Medical) .... Regenxbio
....
Regulus Therapeutics ... Rehabtics .... Relativity Space ....
Relay Therapeutics
..... ReliantHeart ....
ReliefBand Technologies ..... Relievant Medsystems
..... Relypsa .... Remedy Plan Therapeutics .... Remedium
Technologies ... RemoteReality .... Rempex
Pharmaceuticals .... Renaissance Services ..... Renegade
Materials .... Reneo
Pharmaceuticals ..... Renerva ..... ReNeuroGen .... Renewable
Alternatives
... Renewable Energy Group .... Renmatix .....
Renovacor
..... RenovoDerm ..... Renovia .... Renovion .... Renovis ...
Rentech ... Repare Therapeutics .... Replidyne
...
Repligen .. Replimune Group .... Reprieve
Cardiovascular .... Research Frontiers
.. Research Innovations ..... Resolve
Therapeutics
... Resolvyx
Pharmaceuticals ... Resonetics ..... Respicardia
... Respira
Therapeutics .... Response Genetics
...
Restoration Robotics ..... resTORbio ..... Restore Medical ... Retectix
..... Retek
...Rethink
Robotics ... Retia Medical .... Retriever
Technology
.... Retrophin< ... RetroSense Therapeutics .....
Revacom ... Reva
Medical
... Revance Therapeutics Pharmaceutical ....
Revegen
... ReVision Optics ....
ReVision
Therapeutics .... Revitope Oncology ..... ReVivo Medical
....
RevMedx .... ReVolt Tech
... Revolution
Medicines .... ReWalk
Robotics (Israel) .... Rexahn
Pharmaceuticals
... Rex Computing ..... RF Code ...
RFMicron
.. RFS Pharma ..... RF Surgical.
.... Rgenix .... Rgenta Therapeutics .... Rhenium
Alloys .. Rheos Medicines ..... Rheostat
Therapeutics ..... Rheumco .... Rhevision
... Rho ... Rhythm Pharmaceuticals ... Rhythmia
Medical
... Ribometrix ....
RiboNova .... Ribon Therapeutics ..... Rib-X
Pharmaceuticals ... Rice Technology ..... Ridgeback BioTherapeutics
.... Ridgetop
Group ... Rigel Pharmaceuticals .... RightEye ..... RightHand
Robotics .... Rinat
Pharmaceuticals
.... Rinovum Women’s Health ..... Rio Grande Neurosciences .....
RipCode ... Rite
Solutions .... Ritter
Pharmaceuticals ..... River Vision Development ..... Rive Technology
... RJA Dispersions ... R.L. Phillips ...
RMH
Sciences ...
Robb Surgical Devices .... Robopsy ...
Robotic FX ... Robotics VISION
Technologies ..... Robotic Research .... Robotic Technology
... Rocket Pharmaceuticals .... Rockwell Medical
..... Rocky Research .... Rodeo Therapeutics ..... Rodin
Therapeutics ... Roka
Bioscience
.....
RoosterBio .... RootPath .... Rosina Food Products ....
Ross Valve ..... Rotational
Medical .... RotoMetrics ..... RoverMed Biosciences ..... Rowbot
Systems .... Royole ..... RQx
Pharmaceuticals .... RRE
Solar ....
Rubicon Tech ...
Rubigo Therapeutics .... Rubitection ..... Rubius Therapeutics ....
RubrYc Therapeutics ..... Rules-Based
Medicine
... Rushford Hypersonic ... Ruud Lighting ..... RxFunction
...
RXi Pharmaceuticals
...
RxMedic .... Rypos
S2 ... Sadasis
.... SafeShot .... Saffron
Technology
.... Sage
Electrochromics ... SADAR 3D .... SafeLi .... Sage Science
... Sage
Therapeutics ... Sakti3 ... Salarius
Pharmaceuticals .....
Salient Surgical
Technologies
... Salix
Pharmaceuticals ... Salutaris Medical Devices ..... SAM Medical ....
Sancilio
Pharmaceuticals .... Sand 9 .
.. Sandia Biotech .... Sangamo
Biosciences
... Sangart
... Santalis Pharmaceuticals ..... Santarus .... Sanuwave
Health
.... Sapheon .... Sapphire
Energy ....
SARbarcode .... Sarda
Technologies ...
Sarepta Therapeutics .... SatCon
Technology ...
Satori Pharmaceuticals
.... Savara Pharmaceuticals .... Savi ...
SBH
Sciences ...
Scanadu ..... Scholar Rock .... Sciaderm ..... SciClone
Pharmaceuticals
... Sciencescape ..... Scientific
Conservation .... Scientific Research ...
Scientific
Solutions ... Scientific Systems ... SciFluor Life Sciences ... Scilex
Pharmaceuticals .... Scinovia ..... Scioderm .... Scion Plasma ....
SciQuest ...
Scopic Software
... Scout Bio .... scPharmaceuticals ..... Scynexis ...
SD Catalyst
Group ... SDL .. SeaChange ...
Seacoast Science
... Seahawk Biosystems ... Seahorse
Bioscience
... Seaside Therapeutics .... Seattle BioMed .....
Seattle
Genetics
...
Seattle Medical Tech .... Sebacia .... Second Genome ....
Second
Sight Medical
Products ... Securboration ..... Secure
Computing ... Sedia Biosciences ..... Seeo
....Segetis ... S.E.G-WAY Orthopaedics .... Seldon
Labs ... Selecta Biosciences
... SELLAS Life Sciences Group .... SeLux
Diagnostics .... Sema4
Natalis
..... Semiconductor
Laser ... SemiProbe ... Semler
Scientific
.... Semma Therapeutics .... Semnur
Pharmaceuticals .... Semprius ... Semprus
BioSciences .... Sencera International ...
SenesTech .....
SenGenix ....
Senior Scientific ..... Seno Medical
Instruments .... Senomyx
... SensAble Technologies ... Sense .... Sense
Diagnostics
....
Senseonics ..... Sensintel .... Sensiotec ...
Sensors
Unlimited
... SensorTran ... Sentelligence
... Senti Biosciences ..... Sentient
Technologies ..... SentreHEART ..... Sepracor
... SeprOx .... SeQual Technologies ... Sequella ...
Sequel
Pharmaceuticals .... Sequenom ... Sequenta ...
Sequent
Medical
.... SeraCare Life Sciences ... Seragon
Pharmaceuticals .... Seraxis ..... Seres Therapeutics (formerly Seres
Health) .... Serenex
... Serionix .... Sermonix
Pharmaceuticals .... Servergy .....
SetPoint Medical .... Seurat Therapeutics ..... Seventh Sense
Biosystems ...
SGB
Biofuels ..... SGX
Pharmaceuticals ...
Shamrock Energy ... Shape Pharmaceuticals ..... Shape Security ....
Shapeways .... Sharklet
Technologies ..... Sharp Edge Labs ..... Sherlock Biosciences
Shift Labs ..... Shift Pharmaceuticals ..... Shiloh
Labs ....Shine
Medical Technologies
... ShiraTronics ... Shore
Thing Shellfish .... Shuttle
Pharmaceuticals ..... Siamab Therapeutics .... Si-Bone ....
Sicel Technologies ...
SiCortex
... Sideris Pharmaceuticals ..... SI
Diamond Technology .... Sienna Biopharmaceuticals ..... Sierra Energy
..... Sierra Monolithics
... Sierra Nevada ...
Siga Technologies ...
SiGe Semiconductor ... Sigilon Therapeutics ....
Sigma Labs
(NM) .... Sigma
Technologies .... SignalFX (formerly Signal Fuse) ..... Signal Genetics
.... Signature
Genomic Laboratories
... Sila Nanotechnologies .... Silarus Therapeutics
.... Silatronix ..
Silent
Power ... Silicon Biosystems Menarini ..... SiliconBlue
....
Silicon Laboratories ...
Silicon
Mountain
Design .. Silicon Space Technology .... Silk .... SilkTech
Biopharmaceuticals ..... Silk Tech .... Siluria
... Silverbrook
... Silverback ..... Silvergate Pharmaceuticals .... Silver
Spring Networks
... Simbol Materials ... Simcha Therapeutics ... Simply
Incredible Foods ... SiMPore
...
Simulation
Technology and Applied Research ... Simulution
... Singlera Genomics ..... Singulex ... Sinmat
... SiNode Systems .....
Sintact Medical Systems
..... Sion
Power
... SiOnyx ... Sioux Manufacturing ...
Sirga Advanced
Biopharma .... Sirion Therapeutics ...
Sirnaomics ..... Sirna
Therapeutics ... Sirtris Pharmaceuticals ... Sisu Global
Health
..... Sitari Pharma .....
Skybox Imaging .... Skyhawk Therapeutics ..... Skyline Medical
....
Skyonic
... SLI .. SLIPS Technologies .....
SmartCells
... Smart Modular
Technologies ... SmartSpark Energy Systems ...
Smart
Structures .... Smart Wires ..... SmartZyme BioPharma ....
Smisson-Cartledge Biomedical ...
Smooth-Stone
...
SNP Bio ..... Socrates Health Solutions .... Sofregen ....
Soft Machines
....
Soft Robotics ..... SoftSwitching
Technologies
... Soft Tissue
Regeneration ... Soladigm (now View) ..... SolAero
Technologies ..... Solaicx ....
Solais Lighting
....
Solana Surgical ..... SolaranRx ..... SolarBridge
Technologies ... Solar Connection ....
Solarea .....
Solaria ...
Solarmer
Energy ...
Solar Power Technologies ... SolarWinds
... Solazyme
... Solexant ... Solexel ... SolFocus ... Soliant
... Solid Biosciences .... Solid Concepts ..... SolidEnergy
....
Solidus Biosciences
..... SolidWorks
... Soliris .... Soliton ..... Solixia
... Solix
Biofuels
... SolMap
Pharmaceuticals ... SoloHealth ... Solomon
Technologies
... Solo Power .... Solstice Biologics .... Soluble Therapeutics ....
Solx ....
Solyndra ... Soma .... SomaDetect .... SomaLogic
.... Somatic Labs ..... Somatus ..... Somaxon
Pharmaceuticals .... Somerset Therapeutics .... Somna Therapeutics ...
Sonalysts ....Sonavex .... Soneter .... Sonex Aircraft ... Sonitus
Medical
... Sonivate ..... SonoSite
... Sonovex .... Sontra Medical ... Sonus
Pharmaceuticals
...
Sophiris
Bio .... Sophono ..... Soraa .... Sorrento Therapeutics ....
Soteira
... Sostena .... Sotera Wireless ... Sound Pharmaceuticals
.....
Sourcefire
... Source MDx
... Southwall Technologies ... Southwest Windpower
...
Space Dev ...
Spaltudaq ... Spansion .... Sparkbuy ..... SparkCharge .... Spark
Therapeutics ....
Sparo Labs .....
Spatial Photonics
...
SPEC ..... Spectra254 .... Spectragenetics .... Spectral Energies .....
Spectral
Systems .....
Spectranetics ...
SpectraWatt ... Spectro Coating ... SpectrumS4 ....
Speech
Tails ... Speer Medical .... Spero Therapeutics ..... Spinal
Modulation ..... Spinal
Restoration
... Spinal Simplicity ..... Spinal
Stabilization Technologies ..... SpineEX .... SpineGuard ...
Spineology
... Spine Wave .. Spintech .... Spin
Transfer
Technologies ....
SpiralGenetics .... Spiral Therapeutics .... Spiration
... Spire
... Spirox (formerly Nasoform) ..... Spoonflower .... Spotfire ... Spot
On Sciences ...
Spredfast
... Spring Bank Pharmaceuticals ... SpringLeaf Therapeutics
... SpringWorks .... SpringWorks Therapeutics ....
SPR Therapeutics
.... Spyrix ....SQZ
Biotech ..... SRL ... Staktek Holdings ... Standard
Bariatrics .... STAR Cryoelectronics
... Starfire ... Startech Environmental
... Startup Circle Pharma .... StarVision
Technologies .... Stasys Medical ..... SteadyMed Therapeutics
..... Stealth BioTherapeutics ..... Stealth
Therapeutics ... Steel City Optronics ....
Stellaray
.... Stellar Biotech .... Stellar Science ....
Stellent .... Stemagen ... StemBioSys .... Stem Cell Assurance (Now
BioRestorative Therapies) .... StemCells
... Stemcentrx ..... StemCo
Biomedical ... Stemgent ...
StemImmune ....
Stemina Biomarker
Discovery ... Stemonix ..... Stem Pharm .... Stereotaxis ...
Sterilmed ...... Sterling
Semiconductor ..... StimMed ..... Stirling Energy .... Stoke
Therapeutics ..... Stottler
Henke ... Straight Flight .... Stratagene ... Strata Oncology
..... Stratasys
... Stratatech
... Strategic Response Initiatives .... Stratos
Genomics
... Strella Biotechnology ..... StrideBio ....
Stromedix ....
Strongbridge
Biopharma .....
Sucampo Pharmaceuticals ..... Summit
Technology
.... Sun BioPharma ..... Sun Catalytix
.... Sunesis
Pharmaceuticals
.... SunHealth Solutions ... Suniva ....
Sunovion
Pharmaceuticals
... SunPower ... Sun Power Biodiesel ...
Sunrise
Ridge Algae ....Sunshine Heart .... Suntech ...
Sunvapor .... Suono ..... Superconductive
Components ... Superconductor Technologies ... SuperDimension ...
SuperFlex ..... Superior
Organoid Technologies ..... Supernus
Pharmaceuticals .... SuperPower ... Superprotonic
.... SupraSensor .....
Surefire
Medical
.... Surface
Logix
... Surface Oncology ..... Surgient ...
SurgiQuest
.... Surmet
... SurModics ... Suro Biopharma .....
Suros Surgical Systems
..... Surrozen .... SURVICE Engineering ..... Sustainable
Bioproducts .... Sustainable Oils ....
SustainX ... Sutro Biopharma ..... Sutron .....
SutroVax ..... SuturePro
Technologies (now Ceterix) .... SuviCA .... SuVolta ... Suzlon Rotor
... SVS
... SPEC ... Swallow Solutions .... SweetSpot Diabetes Care
... Swift Biosciences .... Swift Coat ..... Syagen Technology
... Symbiomix Therapeutics ..... Symbiont Web
...
Symbotic ...
Symetrix .... Symic Biomedical ..... Symyx
Technologies
... Synack .... Synageva BioPharma ... SynAm Vaccine
....
SynapDx
....
Synaptics ... SynCardia Systems ..,.. Synchroneuron ....
SynchroPET .... Syndax
Pharmaceuticals
... Syndexa Pharmaceuticals .... Synedgen ....
Synergy
Biomedical
....
Synergy Pharma ..... SynGen .... Synlogic ..... Synopsys .... SynSonix
.... Synta
Pharmaceuticals ... Syntax-Brillian ... SyntheMed
... Synthetic Biologics ..... Synthetic Genomics
.... SyntheZyme .....
Synthorx ....
Syntimmune ..... Syntrix
Biosystems .... Syntronics .... Synvitrobio ..... Syros
Pharmaceuticals .... Sysgain .... Syslogic .... Systagenix Wound
Management .....
Systems and Processes Engineering
SPEC ... Systima Technologies ..... Sytera
T2
Biosystems ... T3D Therapeutics ..... Tabula ... Taconic
BioSciences ..... Tactical Engineering and Analysis ..... Tactile
Systems
Technology .... Tactiva Therapeutics ..... TAI Diagnostics .....
Talaris Therapeutics .... Talecris Biotherapeutics
... Talee Bio ..... Taligen Therapeutics
...
Talima Therapeutics ... Tal Medical ... Talon Therapeutics
... Tandem Diabetes Care ...
Tangen Biosciences
..... Tango
Therapeutics ..... Tanox ..Tantaline
.... TapImmune .... Tarari ...
.Targacept ...
TargeGen
... Targ-Anox ... Targanta
... Targazyme (formerly)America Stem Cell....
Targeson
... Targeted Genetics ... Targeted Growth
... Taris Biomedical .... Tarveda Therapeutics
..... Tascent .... Tauriga
Sciences
.... Taxa Biotechnologies ..... Taxon
Biosciences .... Taxus
Cardium (formerly Cardium Therapeutics) ... Taylor
Devices .....Taysha Gene Therapies .... TCR² Therapeutics ..... TDA
Research .... Tealium ..... TearScience
... TearSolutions .... Tech-X ....
Techniscan Medical Systems
... Technology
and Devices Int'l ... TechTol Imaging ... Tectus ..... TELA
Bio .....
Telecardia ...
TeleContinuity ... Telefactor ..... Telemedicine
Up Close operates as DxUpClose ...... Telik ... Tempest
Therapeutics ..... Templex
Technology... Tempus ..... Tenax Therapeutics .... Tenaya
Therapeutics ..... Tendril
...
Tendyne
Holdings ..... Tensha Therapeutics ...
Tepha
... TeraDiode .... TeraDiscoveries (now Cloud
Pharma) ....
Terapio ... TeraStor ...
Terrabon ...
Terrajoule ... TerraMetrics ... Terumo BCT .... Terus
Technologies .... TESARO ....
TeselaGen
Biotechnology .... Tessera
Technologies ... Tethys BioScience .... Tetra
Discovery
Partners .... Tetragenetics
... TetraLogic Pharmaceuticals ...
Tetraphase
Pharmaceuticals ... TetraVue ... Tezzaron
Semiconductor .... TFF Pharmaceuticals .... TGS Knee Innovations
... TG Therapeutics .... Thar Pharma .... Thalchemy ..... The
ExOne .... The Medicines ..... Therabron Therapeutics ..... Theraclone
Sciences
...
Theragenics
.... Therametric Technologies ... Theranos
....
Therion
Biologics ... Thermacore ... Thermage
...
Thermal Gradiant .... Thermal Spray Technologies
....
ThermalTherapeutic Systems
... Thermedical ...
ThermoAura ....
ThermoCeramiX .... ThermoGenesis .... Thermon ... TherOx ....
Thesan
Pharmaceuticals .... Theseus...
Thetis Pharmaceuticals ...
ThingMagic... Third Wave Technologies .. Thoratech
Tech
... Thorley Industries .... ThreeRivers 3D ..... Threshold
Pharmaceuticals .... Thrive Earlier Detection .....
ThromboVision .... Thyritope Biosciences
.... Tiax ... Tibbetts Industries
... Tibion ..... Tiburio
Therapeutics ..... Tilera ... Tillges
Technologies ... Tilos Therapeutics .... Tioma Therapeutics .....
TissueGene ..... TissueLink
... Tissue Regeneration Systems .... Titan
Pharmaceuticals .... Titan Spine ..... TJ Technologies .... TLC
Precision Wafer
... Tmunity Therapeutics .... Tobira Therapeutics ....
Tocagen
...
Tokai Pharmaceuticals .... Tolerx .... TomoTherapy
... Tone Tree ..... Topia Technology .... TopicalRemedy ....
Topokine Therapeutics
.... Torax
Medical ... Torque Therapeutics ..... Total Immersion
...
TotipotentRx .... Totus Solutions .... Toyon Research ..... TP
Therapeutics ..... Trace
Genomics ..... Tracon
Pharmaceuticals
... Tranquis
Therapeutics .... TranS1
.... TransAstra .... Transatomic Power .... Transcend Medical
...Transcept Pharmaceuticals .... TransCorp
..... Transcriptic ..... TransEnterix ... Transgenomic
... Translattice ..... TransMedics
... Transmeta ... TransMolecular
... Transphorm .....
TransTech
.... TransTech Pharma (now vTv Therapeutics) ... Transzyme
Transzyme Pharma ... Travecta Therapeutics .... Traverse
Biosciences ... Traycer
Diagnostic Systems ..... Trefoil Thera .... Trellis
Bioscience
... Trellis Earth Products ... Trethera
.... Trevena
... Trevi Therapeutics ..... Trex Enterprises ... Triad
Semiconductor .... Tri Alpha
Energy ..... Triangle
BioSystems .... Tribogenics
....
Tribologix
.... Trice Medical .... Trice
Orthopedics .... Tricida ..... Trident Systems ... Trilumina ....
Trimble Navigation
.... Trimeris
... Triplet Therapeutics .... Triquint Semiconductor ...
Triton Systems ... Trius Therapeutics ...
TriVascular
Technologies .... Trovagene ..... Trubion
Pharmaceuticals ... Trucode
Gene Repair .... Tru-D SmartUVC ..... True Bearing Diagnostics ....
True Diagnostics
....
True Health Diagnostics
.... True North Therapeutics .... Truestone ..... TruTouch Technologies
..... Try Eco ..... Tryton
Medical
... TScan Therapeutics ..... Tularik .... Turtle Mountain
Communications .... TVA Medical
... Tvardi Therapeutics .... Twelve .... Twentyeight-Seven
Therapeutics ...... Twin Star Medical ... Twist
Bioscience
..... TwoXAR ..... Tyme Technologies .... TypeZero Technologies
....Tyra Biosciences .... Tyrosine Pharmaceuticals .... Tyrx
uBiome .... UCAN
... UES
... Ulthera .... UltraCell ... Ultragenyx
....
Ultralife Batteries
...
Ultramet... Ultradian
Diagnostics ..... Ultraviolet Sciences ... Unbounded Robotics
.... Unchained Labs .... UNIAX
... Unica
... Unidym ... UniEnergy Technologies ..... Unified
Nexsys
.... Unilife ..... Uni-Pixel .... Uniqure
.... United
Devices ... United
Therapeutics
... United Therapies ..... Unity Biotechnology .... Universal
Cells ...... Universal
Display ... Universal
Robots ..... Universal
Technical Resources .... Universal
Technology .... Unleash Immuno
Oncolytics ..... Unum Therapeutics .... Unwired
Nation ... Uptake Medical
... UQM Technologies ... Urbix Resources ....
Urigen
Pharmaceuticals
.... UroGene Pharma ..... US
Nanocorp ... Uroplasty ..... US Bioscience ..... US
Silicones ... UTC Power .... Utilidata ... Utron
.....
UVision360
Vaccinex .....
Vaccinogen .... Vader Systems ..... VakSea ....
Vala Sciences
....Valencell ... Valence Technology .... Validity
Sensors
... Valmont Industries .... Valulytics .... Vanda
Pharmaceuticals
... Vanguard Space Technologies ..... Vapogenix ..... Variant
Pharmaceuticals ..... Vascudyne ..... Vascular
Biogenics (also VBL Therapeutics) ..... Vascular
Designs ... Vascular Genesis ..... Vascular Pathways
...
Vascular Pharmaceuticals ....
Vascular Solutions .....
Vasculox .... VasoGenix
Pharmaceuticals ... Vasoptic Medical ..... Vast Therapeutics
.... Vativ
Technologies ... Vaxart ... Vaxcyte
(formerly Sutrovax) .... Vaxess
Technologies ....
VaxGen
... VaxNewMo ..... VaxInnate ... VBI
Vaccines .... vCalc
.... Vecna Tech ...
Vectorlogics
....
Vedanta
Biosciences
.... Veeva Systems .... Veezyon
... VeinAid ... Velano Vascular .... Velicept
Therapeutic
..... Velocimed ...
Velomedix
... VelosBio ..... VenatoRx Pharmaceuticals ..... Venaxis
..... Vendormate
....
Veniti ... Vensun
Pharmaceuticals ....
VentiRx
...
Ventria Bioscience
... Ventrix ..... Ventrus
Biosciences ... Ventus Therapeutics .....
Veracode
... Veracyte (now AlloVir) ... Veralox
Therapeutics .... Veran Medical Technologies
..... Verastem
... VeraSun Energy
... VerAvanti .... Verax
Biomedical ... Verdezyne ... Vergent Bioscience .....
VerinataHealth ...
Verenium ... Vericel (formerly Aastrom Bio) .... Verifica-BG
... Veritas Genetics .....
Vermillion .... Vermont
Composites ...Veros Systems ... Verrica Pharmaceuticals .... Versar
.... Versartis ... Versatope ..... Verseau
Therapeutics ... Vesigen Therapeutics .... Vestagen Technical
Textiles .... Vestaron .... VerteCore ..... VerteraSpine ..... Vertex
Pharmaceuticals ... VeruTEK Technologies ... Verve
Therapeutic .... Vesper
Medical
..... Vextec
... VGBioCogCubed .... V-Glass .... VGo
Communications ... VGX Pharmaceuticals ..... ViaCell
... ViaCyte
.... Viacor
.... Viamet Pharmaceuticals
... ViaSat
... Via Separations .... Vical . .. Vicarious .... Vicus Technologies
.... Vidacare VIDA Diagnostics ..... ... View .....
Vigene Biosciences .... Viking
Therapeutics .... Vion
Pharmaceuticals
... ViraCor Laboratories ... Viracta Therapeutics ..... Viral
Genetics ....
Vir Biotech .... Virdante Pharmaceuticals
...
Virdia
.... Virent Energy Systems ... Viresco Energy
... Virna
Therapeutics .... Virobay .... ViroPharma . .. ViroXis ...
Virtify ... Virtualitics .... VirtualScopics
.... Virtusa
... Viscardia ..... VisEn Medical ... VisiGen
Biotechnologies
... VisionGate ..... VisionQuest ..... Vision-Sciences
... Vistagen
Therapeutics ... Vistec
Lithography ... Visterra ...
Visualase .... Vitae Pharmaceuticals ..... VitalMedix
... Vital Therapies ...... Vital Vio .... VitaPath Genetics
... Vitriflex .... Vium ..... Vivex Biomedical
.... Vividion Therapeutics ..... Vivisimo .... Vixar
... Vixel ... Vixiar Medical ..... Vizgen ... Vizzario ....
Vlingo
... VLST ..... VMware ... Voci Technologies .... Volcano ....
Voltron
Therapeutics .... VoltServer ... VORAGO Technologies
(previously Silicon
Space Technology) ..... Vorbeck Materials
... Vor BioPharma ..... Vortex Biosciences ..... Vortex
Medical
... Voxel
.. voxeljet ..... Voyager Therapeutics
.... Vtesse ....
VT
Silicon
.... vTv Therapeutics (formerly TransTech Pharma) ..... VUV Analytics
.... Vuzix .... Vyriad .... Vyrx
Pharmaceuticals ..... VytronUS
WaferGen
Biosystems ...
Wakonda Technologies ... Walker Magnetics Group ...
Waste2Watergy
.... Waveband
..... Wave Computing ..... Waveguide ..... WaveRx ... Weinberg Medical
Physics .... WellStat
Therapeutics .... Werewolf Therapeutics ..... Whole Biome ..... Whole
Trees
.....
WiBotic .... Wicab ..... Wickr ... WildcatDiscovery ....
Wiliot .....
Willow Garage
... Wildcat ... Wilder Systems .... Wilocity
.... Wilson.... Greatbatch
.. Wilson Tool International .... Wilson Wolf Manufacturing
...
WiMax.com ...
Windlift ... Windtree
Therapeutics ..... WinSanTor .... Wintegra ... WISErg .... Wizbe
Innovations ...
WMR
Biomedical (now Arsenal Medical) ... Wolf Technical
Services ... WoundZoom .... Woven Orthopedic Technologies
....
Wright Materials Research
... Wright Therapy Products ..... W Solar
Group
X4 Pharmaceuticals .....
Xanofi ... Xanthus
Pharmaceuticals
... XBiotech USA ..... X-Biotix Therapeutics .... X-Body
Biosciences
... Xcede Technologies ..... XCELL BIOLOGIX .....
Xcell Biosciences
....
Xcellerex ... XChanger
Companies .... Xencor .... X-energy ..... Xenetic Biosciences ....
Xenex
Disinfection Services .... Xenex
Healthcare Services ... XenoGen Biosystems .... Xenomics
... Xenoport ... Xeris
Pharmaceuticals ... Xetrios Therapeutics .... XF
Technologies .... xG Technology .... Xidex ... Xilio Therapeutics
(formerly Akrevia Thera) .... Xitronix
... XL
Hybrids ... Xlumena .... Xoc Pharmaceuticals ..... Xollai ...
Xolve
(formerly
Graphene Solutions)
... Xoma
... XProSciences (now Icagen) ..... X-Ray Optical .... X-Spine
.... XSunX
...
Xtalic .. Xtant Medical
Holdings ..... Xtent ...Xtreme Power
... XTuit Pharmaceuticals ....
Xunlight .... XyloCor Therapeutics .... Xynomic
Pharma
Yan Engines ... Yardney Technical Products .... Y-Carbon ... Yulex .... Yumanity Therapeutics .... Yurie